{
  "meta": {
    "id": "test4",
    "title": "Medicine E&D - Mission 2.0, Lap 2 - 19-03-2025 - 2025-03-19",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Anil, a 58-year-old man with a history of hypertension, is admitted to the hospital with complaints of chest pain and shortness of breath. He is started on anticoagulants as part of his management. Laboratory monitoring is performed to assess the efficacy and safety of the anticoagulation therapy. Match the following anticoagulants with their corresponding properties: Column A: Unfractionated heparin (UFH) Low-molecular-weight heparin (LMWH) Bivalirudin LMWH and bivalirudin Column B: High bioavailability Dose should be adjusted if creatinine clearance is <30 mL/min Degree of anticoagulation can be monitored using the activated partial thromboplastin time Least likely to trigger type II heparin-induced thrombocytopenia",
      "options": [
        {
          "label": "A",
          "text": "A-i, B-ii, C-iii, D-iv",
          "correct": false
        },
        {
          "label": "B",
          "text": "A-iii, B-i, C-iv, D-ii",
          "correct": true
        },
        {
          "label": "C",
          "text": "A-iii, B-i, C-ii, D-iv",
          "correct": false
        },
        {
          "label": "D",
          "text": "A-ii, B-iii, C-iv, D-i",
          "correct": false
        }
      ],
      "correct_answer": "B. A-iii, B-i, C-iv, D-ii",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) A-iii, B-i, C-iv, D-ii</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 A-iii. Unfractionated heparin (UFH): Its anticoagulant effect is monitored using activated partial thromboplastin time (aPTT), as UFH primarily inhibits thrombin and activated factor Xa.</li><li>\u2022 A-iii. Unfractionated heparin (UFH):</li><li>\u2022 B-i. Low-molecular-weight heparin (LMWH): LMWH has high bioavailability and acts predominantly on factor Xa through antithrombin activation.</li><li>\u2022 B-i. Low-molecular-weight heparin (LMWH):</li><li>\u2022 C-iv. Bivalirudin: A direct thrombin inhibitor, bivalirudin has a low risk of type II heparin-induced thrombocytopenia (HIT).</li><li>\u2022 C-iv. Bivalirudin:</li><li>\u2022 D-ii. LMWH and bivalirudin: Both require dose adjustments in the presence of renal dysfunction, especially when creatinine clearance (CrCl) is <30 mL/min.</li><li>\u2022 D-ii. LMWH and bivalirudin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Understanding the properties of anticoagulants, including their mechanisms of action, monitoring requirements, and side-effect profiles, is critical for optimizing patient care, particularly in renal dysfunction or risk of thrombocytopenia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8f67c3ed",
      "audio": ""
    },
    {
      "text": "Suresh, a 52-year-old man from Chennai, presents with progressive exertional dyspnea and lower limb edema. An echocardiogram reveals restrictive cardiomyopathy, and cardiac MRI is shown. Which of the following conditions is most likely?",
      "options": [
        {
          "label": "A",
          "text": "Amyloidosis",
          "correct": true
        },
        {
          "label": "B",
          "text": "Sarcoidosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Myocarditis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ischemic heart disease (IHD)",
          "correct": false
        }
      ],
      "correct_answer": "A. Amyloidosis",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20140917.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Amyloidosis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Amyloidosis is a systemic infiltrative disease where amyloid deposits disrupt normal myocardial architecture. On cardiac MRI, circumferential subendocardial LGE is pathognomonic of amyloidosis. This pattern reflects the diffuse infiltration of the myocardium, leading to restrictive physiology. Amyloidosis also commonly presents with signs of heart failure and may be associated with extracardiac manifestations.</li><li>\u2022 circumferential subendocardial LGE</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Sarcoidosis: Sarcoidosis typically produces patchy myocardial LGE with subendocardial sparing, not circumferential enhancement.</li><li>\u2022 Option B. Sarcoidosis:</li><li>\u2022 Option C. Myocarditis: Myocarditis usually shows focal or patchy LGE in a mid-wall or epicardial distribution, sparing the subendocardium.</li><li>\u2022 Option C. Myocarditis:</li><li>\u2022 Option D. Ischemic heart disease (IHD): IHD produces LGE in a vascular distribution, often as a transmural or subendocardial patchy scar, not circumferential enhancement.</li><li>\u2022 Option D. Ischemic heart disease (IHD):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Circumferential subendocardial LGE on cardiac MRI is highly specific for amyloidosis and helps differentiate it from other conditions like sarcoidosis, myocarditis, and ischemic heart disease.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3ba8ee48",
      "audio": ""
    },
    {
      "text": "Ravi, a 62-year-old man from Pune, has a history of chronic stable angina and underwent coronary angiography. The angiogram revealed significant coronary artery disease. Which of the following is not an indication for revascularization with coronary artery bypass grafting (CABG) in chronic stable angina?",
      "options": [
        {
          "label": "A",
          "text": "LMCA >50% stenosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Triple vessel disease (>70% stenosis)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Double vessel disease (DVD) with proximal LAD involvement",
          "correct": false
        },
        {
          "label": "D",
          "text": "Controlled angina",
          "correct": true
        }
      ],
      "correct_answer": "D. Controlled angina",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Controlled angina</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 CABG is indicated in chronic stable angina when there is:</li><li>\u2022 Left main coronary artery (LMCA) stenosis >50%. Triple vessel disease (TVD) with >70% stenosis. Double vessel disease (DVD) involving the proximal left anterior descending (LAD) artery. Persistent angina despite optimal medical management or high-risk findings on non-invasive tests.</li><li>\u2022 Left main coronary artery (LMCA) stenosis >50%.</li><li>\u2022 Triple vessel disease (TVD) with >70% stenosis.</li><li>\u2022 Double vessel disease (DVD) involving the proximal left anterior descending (LAD) artery.</li><li>\u2022 Persistent angina despite optimal medical management or high-risk findings on non-invasive tests.</li><li>\u2022 Controlled angina, where symptoms are managed effectively with medications, does not warrant invasive revascularization.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. LMCA >50% stenosis: LMCA disease significantly impairs coronary perfusion and is a class I indication for CABG.</li><li>\u2022 Option A. LMCA >50% stenosis:</li><li>\u2022 Option B. Triple vessel disease (>70% stenosis): Revascularization is critical in TVD to reduce mortality and improve symptoms.</li><li>\u2022 Option B. Triple vessel disease (>70% stenosis):</li><li>\u2022 Option C. DVD with proximal LAD involvement: Proximal LAD lesions in DVD compromise significant myocardial territory, making CABG necessary.</li><li>\u2022 Option C. DVD with proximal LAD involvement:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 CABG is reserved for patients with severe coronary artery disease or refractory angina. Controlled angina does not require invasive interventions if symptoms are adequately managed with medications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "57cd6597",
      "audio": ""
    },
    {
      "text": "A 48-year-old woman presents to the emergency room with chest pain. An ECG is performed to evaluate her symptoms. Which of the following conditions is not associated with ST-elevation on ECG?",
      "options": [
        {
          "label": "A",
          "text": "Acute STEMI",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prinzmetal angina",
          "correct": false
        },
        {
          "label": "C",
          "text": "Takotsubo cardiomyopathy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Unstable angina",
          "correct": true
        }
      ],
      "correct_answer": "D. Unstable angina",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Unstable angina</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Unstable angina does not cause significant or persistent ECG changes such as ST-elevation. It is primarily diagnosed based on clinical history, including chest pain at rest or with minimal exertion, and the absence of biomarkers or ECG findings indicating infarction.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Acute STEMI: ST-elevation myocardial infarction (STEMI) is defined by ST-elevation on ECG, reflecting transmural myocardial injury.</li><li>\u2022 Option A. Acute STEMI:</li><li>\u2022 Option B. Prinzmetal angina: This condition is caused by coronary vasospasm, leading to transient ST-elevation during episodes of chest pain.</li><li>\u2022 Option B. Prinzmetal angina:</li><li>\u2022 Option C. Takotsubo cardiomyopathy: Also known as \"stress-induced cardiomyopathy,\" it can mimic STEMI with transient ST-elevation due to apical ballooning and myocardial stunning.</li><li>\u2022 Option C. Takotsubo cardiomyopathy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 ST-elevation is a hallmark of several conditions, including STEMI, Prinzmetal angina, and Takotsubo cardiomyopathy. However, unstable angina does not typically present with ST-elevation on ECG and is diagnosed based on clinical features.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4af7d87a",
      "audio": ""
    },
    {
      "text": "A 60-year-old man from Bengaluru presents to the emergency department with acute chest pain and is diagnosed with STEMI. The decision is made to administer thrombolytic therapy. Which of the following drugs is the easiest to administer in this scenario?",
      "options": [
        {
          "label": "A",
          "text": "Reteplase",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tenecteplase",
          "correct": true
        },
        {
          "label": "C",
          "text": "Alteplase",
          "correct": false
        },
        {
          "label": "D",
          "text": "Streptokinase",
          "correct": false
        }
      ],
      "correct_answer": "B. Tenecteplase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Tenecteplase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Tenecteplase is the easiest thrombolytic agent to administer because it is given as a single intravenous bolus over 5 seconds. The dosage (30\u201350 mg) is weight-based, and its simplicity in administration makes it suitable for rapid use in emergency settings without requiring specialized training. Tenecteplase also has minimal adverse reactions and high efficacy.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Reteplase: Administered as two boluses 30 minutes apart, making it less convenient than Tenecteplase.</li><li>\u2022 Option A. Reteplase:</li><li>\u2022 Option C. Alteplase: Requires a bolus followed by an infusion, increasing complexity and time for administration.</li><li>\u2022 Option C. Alteplase:</li><li>\u2022 Option D. Streptokinase: Administered as an infusion over 60 minutes, requiring more time and monitoring.</li><li>\u2022 Option D. Streptokinase:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tenecteplase is the thrombolytic agent of choice for ease of administration in acute STEMI, as it is delivered as a single bolus, ensuring rapid treatment initiation in emergency situations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "93082fc8",
      "audio": ""
    },
    {
      "text": "A 60-year-old woman with a history of heart failure and an initial ejection fraction (EF) of 35% undergoes serial follow-ups after optimized medical therapy. Her repeat echocardiogram shows an EF improvement to 48%. According to the current joint consensus classification, heart failure with improving EF is diagnosed if:",
      "options": [
        {
          "label": "A",
          "text": "EF >10% improvement",
          "correct": true
        },
        {
          "label": "B",
          "text": "EF >5% improvement",
          "correct": false
        },
        {
          "label": "C",
          "text": "EF >15% improvement",
          "correct": false
        },
        {
          "label": "D",
          "text": "EF >20% improvement",
          "correct": false
        }
      ],
      "correct_answer": "A. EF >10% improvement",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) EF >10% improvement</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Heart failure with improving EF (HFimpEF) is diagnosed when there is an improvement in EF of >10% from a baseline EF <40% . This category highlights patients who were initially diagnosed with heart failure with reduced ejection fraction (HFrEF) and demonstrate significant improvement following medical therapy, reflecting partial recovery of myocardial function.</li><li>\u2022 >10% from a baseline EF <40%</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. EF >5% improvement: While any improvement is beneficial, a \u226510% improvement is required to meet the HFimpEF criteria.</li><li>\u2022 Option B. EF >5% improvement:</li><li>\u2022 Option C. EF >15% improvement: This threshold is unnecessarily high and not part of the current classification criteria.</li><li>\u2022 Option C. EF >15% improvement:</li><li>\u2022 Option D. EF >20% improvement: Such an improvement may occur but is not required for the diagnosis of HFimpEF.</li><li>\u2022 Option D. EF >20% improvement:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The diagnosis of heart failure with improving EF (HFimpEF) requires >10% improvement in EF from a baseline of <40%. This category emphasizes the potential for myocardial recovery with optimal medical therapy.</li><li>\u27a4 >10% improvement</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d4ca7793",
      "audio": ""
    },
    {
      "text": "A 65-year-old man with heart failure with reduced ejection fraction (HFrEF) is being considered for therapy. Which of the following is the first line drug?",
      "options": [
        {
          "label": "A",
          "text": "ARNI (Sacubitril-Valsartan)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Eplerenone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Torsemide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tafamidis",
          "correct": false
        }
      ],
      "correct_answer": "A. ARNI (Sacubitril-Valsartan)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) ARNI (Sacubitril-Valsartan)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Angiotensin receptor-neprilysin inhibitors (ARNIs), specifically Sacubitril-Valsartan, have demonstrated substantial benefits in HFrEF. Compared to traditional ACE inhibitors or ARBs, ARNIs provide an additional 20% reduction in cardiovascular death and heart failure hospitalization , as shown in the PARADIGM-HF trial. Sacubitril inhibits neprilysin, increasing natriuretic peptides while Valsartan blocks the angiotensin receptor to counteract the renin-angiotensin system.</li><li>\u2022 additional 20% reduction in cardiovascular death and heart failure hospitalization</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Eplerenone: A mineralocorticoid receptor antagonist (MRA) that has been used for HFrEF for years but does not offer the same recent and additional benefits as ARNIs.</li><li>\u2022 Option B. Eplerenone:</li><li>\u2022 Option C. Torsemide: A long-acting loop diuretic used for symptom relief in heart failure, but it provides no mortality benefit.</li><li>\u2022 Option C. Torsemide:</li><li>\u2022 Option D. Tafamidis: Used for transthyretin cardiac amyloidosis, not HFrEF.</li><li>\u2022 Option D. Tafamidis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Sacubitril-Valsartan (ARNI) is a revolutionary treatment for HFrEF, providing significant mortality and morbidity benefits compared to traditional therapies. It represents a cornerstone in modern heart failure management.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4813866c",
      "audio": ""
    },
    {
      "text": "A 17-year-old boy presents with exertional dyspnea and syncope. On physical examination, a systolic murmur is heard at the left lower sternal border. Which of the following maneuvers is expected to reduce the intensity and duration of the murmur in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Standing",
          "correct": false
        },
        {
          "label": "B",
          "text": "Valsalva",
          "correct": false
        },
        {
          "label": "C",
          "text": "Squatting",
          "correct": true
        },
        {
          "label": "D",
          "text": "Exercise",
          "correct": false
        }
      ],
      "correct_answer": "C. Squatting",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Squatting</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In hypertrophic cardiomyopathy (HCM), the murmur is caused by left ventricular outflow tract (LVOT) obstruction due to septal hypertrophy and systolic anterior motion (SAM) of the mitral valve. Squatting increases venous return and afterload , which enlarges the left ventricular cavity, reducing the obstruction and thereby decreasing the intensity and duration of the murmur.</li><li>\u2022 Squatting increases venous return and afterload</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Standing: Reduces venous return and left ventricular cavity size, worsening the obstruction and increasing the murmur.</li><li>\u2022 Option A. Standing:</li><li>\u2022 Option B. Valsalva: Reduces preload, decreasing LV cavity size, which exacerbates obstruction and intensifies the murmur.</li><li>\u2022 Option B. Valsalva:</li><li>\u2022 Option D. Exercise: Increases heart rate and contractility, worsening LVOT obstruction and murmur intensity.</li><li>\u2022 Option D. Exercise:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Maneuvers that increase venous return or afterload (e.g., squatting) alleviate the LVOT obstruction in HCM, reducing murmur intensity, whereas maneuvers that decrease preload or LV cavity size (e.g., standing, Valsalva) exacerbate the obstruction.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c1be24fe",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman with a history of hypertension presents to the emergency room with loss of consciousness, chest pain, and diaphoresis. On examination, she is hemodynamically unstable, and bilateral pulses are unequal. An ECG reveals nonspecific ST-T changes. What is the next best investigation?",
      "options": [
        {
          "label": "A",
          "text": "MRI",
          "correct": false
        },
        {
          "label": "B",
          "text": "Transesophageal echocardiography (TEE)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cardiac enzymes",
          "correct": false
        },
        {
          "label": "D",
          "text": "X-ray",
          "correct": false
        }
      ],
      "correct_answer": "B. Transesophageal echocardiography (TEE)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Transesophageal echocardiography (TEE)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation of chest pain, diaphoresis, and unequal pulses is highly suggestive of aortic dissection . Transesophageal echocardiography (TEE) is the investigation of choice in unstable patients, as it can be performed rapidly at the bedside and provides high sensitivity and specificity for detecting dissection. TEE can identify the intimal flap, true and false lumens, and involvement of the aortic valve or coronary ostia.</li><li>\u2022 aortic dissection</li><li>\u2022 Transesophageal echocardiography (TEE)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. MRI: While MRI provides excellent imaging of the aorta, it is time-consuming and not suitable for unstable patients.</li><li>\u2022 Option A. MRI:</li><li>\u2022 Option C. Cardiac enzymes: These may help in evaluating myocardial infarction but do not confirm or rule out aortic dissection, which is the likely diagnosis.</li><li>\u2022 Option C. Cardiac enzymes:</li><li>\u2022 Option D. X-ray: Chest X-ray may show mediastinal widening in aortic dissection, but it is nonspecific and insufficient for definitive diagnosis.</li><li>\u2022 Option D. X-ray:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In suspected aortic dissection, the choice of imaging depends on the patient\u2019s hemodynamic status. TEE is preferred in unstable patients , while CT aortogram is suitable for stable cases. Early diagnosis and management are critical to prevent complications.</li><li>\u27a4 TEE is preferred in unstable patients</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e6a55cc6",
      "audio": ""
    },
    {
      "text": "A 36-year-old man presents with headache and a burning sensation in the head. Physical examination reveals feeble lower limb pulses and elevated blood pressure (190/100 mmHg). A chest X-ray is done and shown. What is the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Aortic aneurysms",
          "correct": false
        },
        {
          "label": "B",
          "text": "Aortic dissection",
          "correct": false
        },
        {
          "label": "C",
          "text": "Coarctation of the aorta",
          "correct": true
        },
        {
          "label": "D",
          "text": "Atrial septal defect (ASD)",
          "correct": false
        }
      ],
      "correct_answer": "C. Coarctation of the aorta",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20141114.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Coarctation of the aorta</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The combination of hypertension, feeble lower limb pulses, and rib notching on chest X-ray is classic for coarctation of the aorta . Coarctation leads to increased upper body blood pressure and decreased lower body perfusion. Rib notching occurs due to collateral circulation through intercostal arteries compensating for the obstruction in the aorta.</li><li>\u2022 coarctation of the aorta</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Aortic aneurysms: Typically present with signs of rupture or dissection, not rib erosion or pulse discrepancies.</li><li>\u2022 Option A. Aortic aneurysms:</li><li>\u2022 Option B. Aortic dissection: Causes chest pain and unequal pulses in the upper and lower limbs but does not cause rib notching or chronic hypertension patterns.</li><li>\u2022 Option B. Aortic dissection:</li><li>\u2022 Option D. Atrial septal defect (ASD): A pre-tricuspid left-to-right shunt causing right heart failure; it is unrelated to rib notching or systemic hypertension.</li><li>\u2022 Option D. Atrial septal defect (ASD):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Coarctation of the aorta is characterized by systemic hypertension, reduced lower limb pulses, and rib notching due to collateral formation, making it a key diagnosis in young hypertensive patients with these findings.</li><li>\u27a4 Coarctation of the aorta</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a69c5e90",
      "audio": ""
    },
    {
      "text": "A 30-year-old male presents with episodic palpitations and dizziness. An ECG is done, and it is shown below. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "RVH (Right Ventricular Hypertrophy)",
          "correct": false
        },
        {
          "label": "B",
          "text": "RBBB (Right Bundle Branch Block)",
          "correct": false
        },
        {
          "label": "C",
          "text": "WPW (Wolff-Parkinson-White syndrome)",
          "correct": true
        },
        {
          "label": "D",
          "text": "ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy)",
          "correct": false
        }
      ],
      "correct_answer": "C. WPW (Wolff-Parkinson-White syndrome)",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-25%20183738.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) WPW (Wolff-Parkinson-White syndrome)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The ECG findings of tall R waves in V1 , short PR interval , and the presence of delta waves are diagnostic of Wolff-Parkinson-White (WPW) syndrome. WPW is a pre-excitation syndrome caused by an accessory pathway (Bundle of Kent) that bypasses the AV node, leading to a characteristic ECG pattern and episodes of tachyarrhythmia due to reentrant circuits.</li><li>\u2022 tall R waves in V1</li><li>\u2022 short PR interval</li><li>\u2022 delta waves</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. RVH: Tall R waves in V1 can occur in RVH, but it is not associated with a short PR interval or delta waves.</li><li>\u2022 Option A. RVH:</li><li>\u2022 Option B. RBBB: RBBB shows a widened QRS complex with an rsR' pattern in V1, not a short PR interval or delta waves.</li><li>\u2022 Option B. RBBB:</li><li>\u2022 Option D. ARVC: This condition may show epsilon waves and T-wave inversions in the right precordial leads but not the pre-excitation findings seen in WPW.</li><li>\u2022 Option D. ARVC:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The combination of short PR interval , delta waves , and tall R waves in V1 is characteristic of WPW syndrome , which can cause symptomatic arrhythmias due to accessory pathway conduction.</li><li>\u27a4 short PR interval</li><li>\u27a4 delta waves</li><li>\u27a4 tall R waves in V1</li><li>\u27a4 WPW syndrome</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a68ea8fe",
      "audio": ""
    },
    {
      "text": "A 60-year-old male presents for a routine ECG and is shown. What is the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Left ventricular hypertrophy (LVH)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Right ventricular hypertrophy (RVH)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Right atrial enlargement",
          "correct": false
        },
        {
          "label": "D",
          "text": "Left atrial enlargement",
          "correct": false
        }
      ],
      "correct_answer": "A. Left ventricular hypertrophy (LVH)",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-25%20183917.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Left ventricular hypertrophy (LVH)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The ECG findings are consistent with Sokolow-Lyon criteria for left ventricular hypertrophy, which include:</li><li>\u2022 Sokolow-Lyon criteria</li><li>\u2022 SV1 + RV5/6 > 35 mm R in V5/6 > 25 mm R in aVL > 11 mm</li><li>\u2022 SV1 + RV5/6 > 35 mm</li><li>\u2022 SV1 + RV5/6 > 35 mm</li><li>\u2022 R in V5/6 > 25 mm</li><li>\u2022 R in V5/6 > 25 mm</li><li>\u2022 R in aVL > 11 mm</li><li>\u2022 R in aVL > 11 mm</li><li>\u2022 Other criteria such as the Cornell voltage criteria (RaVL + SV3 > 28 mm in men or >20 mm in women) may also indicate LVH. These voltage criteria reflect the increased myocardial mass associated with left ventricular hypertrophy.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Right ventricular hypertrophy (RVH): Characterized by a rightward axis, tall R in V1, and deep S in V5/V6, not seen here.</li><li>\u2022 Option B. Right ventricular hypertrophy (RVH):</li><li>\u2022 Option C. Right atrial enlargement: Typically shows peaked P waves >2.5 mm in lead II, which are not described here.</li><li>\u2022 Option C. Right atrial enlargement:</li><li>\u2022 Option D. Left atrial enlargement: Indicated by a wide, notched P wave in lead II or a biphasic P wave in V1, absent in this ECG.</li><li>\u2022 Option D. Left atrial enlargement:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Left ventricular hypertrophy (LVH) is identified on ECG using voltage criteria such as Sokolow-Lyon and Cornell voltage, reflecting increased myocardial mass and often associated with hypertension or valvular heart disease.</li><li>\u27a4 Left ventricular hypertrophy (LVH)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bbf61ac2",
      "audio": ""
    },
    {
      "text": "A 65-year-old man presents to the emergency department with complaints of fatigue and a recent episode of transient loss of consciousness while walking. He denies chest pain or palpitations. On physical examination, his pulse is slow and irregular, with a heart rate of 35/min. An ECG is performed and is shown. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Mobitz Type 1 AV Block",
          "correct": false
        },
        {
          "label": "B",
          "text": "Complete Heart Block",
          "correct": true
        },
        {
          "label": "C",
          "text": "Sinus Bradycardia",
          "correct": false
        },
        {
          "label": "D",
          "text": "1st Degree AV Block",
          "correct": false
        }
      ],
      "correct_answer": "B. Complete Heart Block",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20152730.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20152749.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Complete Heart Block</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The ECG findings of varying PR intervals with fixed and independent PP and RR intervals are diagnostic of Complete Heart Block (CHB) . This indicates a lack of communication between the atria and ventricles, with the ventricles relying on an escape rhythm for contraction. The patient's transient loss of consciousness and fatigue are consistent with Stokes-Adams syndrome , which occurs due to inadequate cardiac output during periods of extreme bradycardia or asystole.</li><li>\u2022 Complete Heart Block (CHB)</li><li>\u2022 Stokes-Adams syndrome</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Mobitz Type 1 AV Block: Characterized by progressive prolongation of the PR interval followed by a dropped beat, which is not described here.</li><li>\u2022 Option A. Mobitz Type 1 AV Block:</li><li>\u2022 Option C. Sinus Bradycardia: Features a heart rate <60 bpm with regular atrial and ventricular activity; there is no dissociation between the atria and ventricles.</li><li>\u2022 Option C. Sinus Bradycardia:</li><li>\u2022 Option D. 1st Degree AV Block: Defined by a prolonged PR interval >200 ms, but the PR interval remains constant, unlike the variation seen in CHB.</li><li>\u2022 Option D. 1st Degree AV Block:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Complete Heart Block is diagnosed by atrioventricular dissociation with independent atrial and ventricular rhythms. It requires prompt intervention, such as temporary pacing, to prevent complications like Stokes-Adams attacks.</li><li>\u27a4 Complete Heart Block</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "04608052",
      "audio": ""
    },
    {
      "text": "A 58-year-old man with a history of hypertension and diabetes is admitted to the emergency room with severe chest pain radiating to his left arm. He is diagnosed with an acute myocardial infarction (AMI), undergoes successful revascularization, and is hospitalized for a week. During his hospital stay, he develops a ventricular tachycardia (VT) on the day of discharge. What is the most appropriate management?",
      "options": [
        {
          "label": "A",
          "text": "Implantable Cardioverter Defibrillator (ICD)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Repeat Coronary Angiogram",
          "correct": false
        },
        {
          "label": "C",
          "text": "Amiodarone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lignocaine",
          "correct": false
        }
      ],
      "correct_answer": "A. Implantable Cardioverter Defibrillator (ICD)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Implantable Cardioverter Defibrillator (ICD)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Sustained VT occurring more than 48 hours after an acute myocardial infarction (AMI) is classified as late VT and is usually caused by scar-related reentry circuits. In this scenario, the most effective treatment for preventing sudden cardiac death is the implantation of an ICD. Amiodarone may be used as adjunctive therapy, but ICD placement is the definitive treatment.</li><li>\u2022 late VT</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Repeat Coronary Angiogram: Indicated only if there are clinical signs of recurrent ischemia, which is not described here.</li><li>\u2022 Option B.</li><li>\u2022 Repeat Coronary Angiogram:</li><li>\u2022 Option C. Amiodarone: Can be used for acute stabilization but is not definitive for long-term prevention of VT.</li><li>\u2022 Option C.</li><li>\u2022 Amiodarone:</li><li>\u2022 Option D. Lignocaine: Is not recommended for long-term management of VT and is less effective compared to ICD therapy.</li><li>\u2022 Option D.</li><li>\u2022 Lignocaine:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 An ICD is the treatment of choice for sustained VT that occurs more than 48 hours after an MI, as it is the most effective strategy to prevent sudden cardiac death in this population.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "eb0358ba",
      "audio": ""
    },
    {
      "text": "A 30-year-old male presents with palpitations and giddiness for the past 2 hours. On arrival, his blood pressure is 80/60 mmHg. ECG is shown. What is the next step in the management of this patient?",
      "options": [
        {
          "label": "A",
          "text": "Carotid sinus massage",
          "correct": false
        },
        {
          "label": "B",
          "text": "Adenosine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Electrical Cardioversion",
          "correct": true
        },
        {
          "label": "D",
          "text": "IV metoprolol",
          "correct": false
        }
      ],
      "correct_answer": "C. Electrical Cardioversion",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-25%20184220.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20152841.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Electrical Cardioversion</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In a patient with hemodynamic instability (evidenced by BP 80/60 mmHg) and AVNRT, immediate synchronized cardioversion is the first-line treatment. Cardioversion restores normal sinus rhythm quickly and is the safest option in unstable patients.</li><li>\u2022 hemodynamic instability</li><li>\u2022 immediate synchronized cardioversion</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Carotid sinus massage: This is an initial maneuver for stable AVNRT, not appropriate in hemodynamically unstable patients.</li><li>\u2022 Option A. Carotid sinus massage:</li><li>\u2022 Option B. Adenosine: Effective in terminating AVNRT, but cardioversion is preferred in unstable patients as it provides immediate and reliable restoration of sinus rhythm.</li><li>\u2022 Option B. Adenosine:</li><li>\u2022 Option D. IV metoprolol: Beta-blockers may be used in stable patients for rate control, but they are not first-line in hemodynamically unstable AVNRT.</li><li>\u2022 Option D. IV metoprolol:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with hemodynamically unstable tachyarrhythmias , synchronized cardioversion is the treatment of choice, regardless of the underlying rhythm, to stabilize the patient promptly.</li><li>\u27a4 hemodynamically unstable tachyarrhythmias</li><li>\u27a4 synchronized cardioversion</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "71eeb132",
      "audio": ""
    },
    {
      "text": "A 28-year-old man presents with recurrent episodes of palpitations and occasional dizziness. He is otherwise healthy, with no significant past medical history. During an electrophysiological study, a shortened HV interval is observed on intracardiac ECG. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "WPW syndrome",
          "correct": true
        },
        {
          "label": "B",
          "text": "Rheumatic fever",
          "correct": false
        },
        {
          "label": "C",
          "text": "Infective endocarditis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sinus tachycardia",
          "correct": false
        }
      ],
      "correct_answer": "A. WPW syndrome",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20152910.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20152926.jpg"
      ],
      "explanation": "<p><strong>Ans. A) WPW syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The HV interval represents the conduction time between the His bundle and the ventricular myocardium. A shortened HV interval is a hallmark of Wolff-Parkinson-White (WPW) syndrome , where an accessory pathway (the Bundle of Kent) bypasses the AV node, leading to pre-excitation of the ventricles. This results in a shorter conduction time and a characteristic ECG pattern, including a shortened PR interval and delta waves.</li><li>\u2022 HV interval</li><li>\u2022 shortened HV interval</li><li>\u2022 Wolff-Parkinson-White (WPW) syndrome</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Rheumatic fever: Primarily affects the heart valves and conduction system, potentially causing AV blocks, but does not typically shorten the HV interval.</li><li>\u2022 Option B. Rheumatic fever:</li><li>\u2022 Option C. Infective endocarditis: Can cause conduction disturbances due to abscess formation near the conduction system but does not lead to a shortened HV interval.</li><li>\u2022 Option C. Infective endocarditis:</li><li>\u2022 Option D. Sinus tachycardia: Increases heart rate but does not affect the HV interval directly.</li><li>\u2022 Option D. Sinus tachycardia:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A shortened HV interval is diagnostic of pre-excitation syndromes , such as WPW syndrome, due to the presence of an accessory conduction pathway bypassing the normal AV nodal delay.</li><li>\u27a4 shortened HV interval</li><li>\u27a4 pre-excitation syndromes</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a3b0cbeb",
      "audio": ""
    },
    {
      "text": "A 12-year-old child presents with recurrent episodes of transient weakness on the right side of the body and slurred speech. Angiogram is done and is shown. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Necrotizing arteritis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Moyamoya disease",
          "correct": true
        },
        {
          "label": "C",
          "text": "Fibromuscular dysplasia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Primary central nervous system vasculitis",
          "correct": false
        }
      ],
      "correct_answer": "B. Moyamoya disease",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20152943.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Moyamoya disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Moyamoya disease is a chronic occlusive cerebrovascular disorder primarily involving the distal internal carotid artery and its branches, particularly the middle cerebral artery (MCA) and anterior cerebral artery (ACA). The hallmark \"puff of smoke\" appearance on angiography is caused by the development of a dense collateral network of lenticulostriate arteries. These collateral vessels form in response to arterial occlusion and are prone to rupture or thrombosis, leading to ischemic or hemorrhagic strokes.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Necrotizing arteritis: This is associated with systemic vasculitis and does not produce the characteristic collateral pattern seen in Moyamoya disease.</li><li>\u2022 Option A. Necrotizing arteritis:</li><li>\u2022 Option C. Fibromuscular dysplasia: Primarily affects the renal and carotid arteries with a \"string of beads\" appearance on angiography, not a \"puff of smoke.\"</li><li>\u2022 Option C. Fibromuscular dysplasia:</li><li>\u2022 Option D. Primary central nervous system vasculitis: Affects medium and small cerebral vessels, but does not produce the collateral circulation characteristic of Moyamoya disease.</li><li>\u2022 Option D. Primary central nervous system vasculitis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The \"puff of smoke\" appearance on angiography is a pathognomonic feature of Moyamoya disease , a progressive occlusive disorder requiring prompt diagnosis to prevent ischemic and hemorrhagic complications.</li><li>\u27a4 Moyamoya disease</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2710a49f",
      "audio": ""
    },
    {
      "text": "All of the following are components of the ABCD2 score for assessing stroke risk after a transient ischemic attack (TIA), except:",
      "options": [
        {
          "label": "A",
          "text": "Age",
          "correct": false
        },
        {
          "label": "B",
          "text": "Blood pressure",
          "correct": false
        },
        {
          "label": "C",
          "text": "Creatinine levels",
          "correct": true
        },
        {
          "label": "D",
          "text": "Diabetes",
          "correct": false
        }
      ],
      "correct_answer": "C. Creatinine levels",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Creatinine levels</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The ABCD2 score is used to predict the risk of stroke within 2 days following a TIA. It includes:</li><li>\u2022 ABCD2 score</li><li>\u2022 Age > 60 years (1 point) Blood pressure \u2265140/90 mmHg at initial evaluation (1 point) Clinical features of TIA (speech disturbance = 1 point, unilateral weakness = 2 points) Duration of TIA symptoms (10\u201359 minutes = 1 point, \u226560 minutes = 2 points) Diabetes mellitus (1 point)</li><li>\u2022 Age > 60 years (1 point)</li><li>\u2022 Age > 60 years (1 point)</li><li>\u2022 Blood pressure \u2265140/90 mmHg at initial evaluation (1 point)</li><li>\u2022 Blood pressure \u2265140/90 mmHg at initial evaluation (1 point)</li><li>\u2022 Clinical features of TIA (speech disturbance = 1 point, unilateral weakness = 2 points)</li><li>\u2022 Clinical features of TIA (speech disturbance = 1 point, unilateral weakness = 2 points)</li><li>\u2022 Duration of TIA symptoms (10\u201359 minutes = 1 point, \u226560 minutes = 2 points)</li><li>\u2022 Duration of TIA symptoms (10\u201359 minutes = 1 point, \u226560 minutes = 2 points)</li><li>\u2022 Diabetes mellitus (1 point)</li><li>\u2022 Diabetes mellitus (1 point)</li><li>\u2022 Creatinine levels are not part of the ABCD2 score.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Age: Patients >60 years are assigned 1 point.</li><li>\u2022 Option A. Age:</li><li>\u2022 Option B. Blood pressure: A BP \u2265140/90 mmHg is assigned 1 point.</li><li>\u2022 Option B. Blood pressure:</li><li>\u2022 Option D. Diabetes: A history of diabetes adds 1 point.</li><li>\u2022 Option D. Diabetes:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The ABCD2 score assesses stroke risk based on age , blood pressure , clinical features , duration of symptoms , and diabetes , but creatinine levels are not included.</li><li>\u27a4 ABCD2 score</li><li>\u27a4 age</li><li>\u27a4 blood pressure</li><li>\u27a4 clinical features</li><li>\u27a4 duration of symptoms</li><li>\u27a4 diabetes</li><li>\u27a4 creatinine levels</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "351ce886",
      "audio": ""
    },
    {
      "text": "A 60-year-old man with a history of poorly controlled hypertension presents to the emergency department with sudden onset weakness on the right side of his body and slurred speech. A CT scan reveals an intracerebral hemorrhage. What is the most common site?",
      "options": [
        {
          "label": "A",
          "text": "Thalamus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Putamen",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cerebellum",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pons",
          "correct": false
        }
      ],
      "correct_answer": "B. Putamen",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Putamen</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Hypertensive intracerebral hemorrhage (ICH) typically results from the rupture of small penetrating arteries caused by long-standing hypertension. The putamen , a part of the basal ganglia, is the most common site of hypertensive hemorrhage. Hemorrhage in this location often involves the adjacent internal capsule, leading to contralateral hemiparesis as a key clinical sign.</li><li>\u2022 putamen</li><li>\u2022 contralateral hemiparesis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Thalamus: Although a common site, it is less frequently affected than the putamen. Thalamic hemorrhages may cause sensory deficits and gaze disturbances.</li><li>\u2022 Option A. Thalamus:</li><li>\u2022 Option C. Cerebellum: Cerebellar hemorrhages are less common and present with ataxia and gait instability.</li><li>\u2022 Option C. Cerebellum:</li><li>\u2022 Option D. Pons: Pontine hemorrhages are also less frequent and are typically devastating, causing quadriparesis or coma.</li><li>\u2022 Option D. Pons:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The putamen is the most common site for hypertensive intracerebral hemorrhage, often presenting with contralateral hemiparesis due to involvement of the internal capsule. Early identification and management are critical to improving outcomes.</li><li>\u27a4 putamen</li><li>\u27a4 contralateral hemiparesis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "89766ab9",
      "audio": ""
    },
    {
      "text": "A 55-year-old man presents with headaches and visual disturbances that have worsened over the past few weeks. Neurological examination reveals a left-sided third cranial nerve palsy. An MRI reveals a large berry aneurysm at the bifurcation of the middle cerebral artery. What is the definition of a giant aneurysm based on size?",
      "options": [
        {
          "label": "A",
          "text": ">1.5 cm",
          "correct": false
        },
        {
          "label": "B",
          "text": ">2.0 cm",
          "correct": false
        },
        {
          "label": "C",
          "text": ">2.5 cm",
          "correct": true
        },
        {
          "label": "D",
          "text": ">3.0 cm",
          "correct": false
        }
      ],
      "correct_answer": "C. >2.5 cm",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) >2.5 cm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Giant aneurysms are defined as aneurysms with a diameter >2.5 cm , accounting for approximately 5% of all intracranial aneurysms. They commonly occur at the terminal internal carotid artery , middle cerebral artery (MCA) bifurcation , and the top of the basilar artery . These aneurysms are associated with:</li><li>\u2022 Giant aneurysms</li><li>\u2022 >2.5 cm</li><li>\u2022 terminal internal carotid artery</li><li>\u2022 middle cerebral artery (MCA) bifurcation</li><li>\u2022 top of the basilar artery</li><li>\u2022 A rupture risk of ~6% within the first year, which remains elevated over time. Symptoms due to compression of adjacent brain structures or cranial nerves, even before rupture.</li><li>\u2022 A rupture risk of ~6% within the first year, which remains elevated over time.</li><li>\u2022 Symptoms due to compression of adjacent brain structures or cranial nerves, even before rupture.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. >1.5 cm: Aneurysms of this size are considered large but not classified as giant.</li><li>\u2022 Option A. >1.5 cm:</li><li>\u2022 Option B. >2.0 cm: Similar to above, this threshold is used for large aneurysms but not for giant aneurysms.</li><li>\u2022 Option B. >2.0 cm:</li><li>\u2022 Option D. >3.0 cm: This size exceeds the threshold for a giant aneurysm but is not the established definition.</li><li>\u2022 Option D. >3.0 cm:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Giant aneurysms are defined as those with a diameter >2.5 cm , carry significant rupture risks, and often cause symptoms due to compression of nearby structures. Early diagnosis and management are critical.</li><li>\u27a4 Giant aneurysms</li><li>\u27a4 >2.5 cm</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f0df96db",
      "audio": ""
    },
    {
      "text": "A 70-year-old woman with a history of uncontrolled hypertension presents with sudden loss of vision in both eyes. Neurological examination reveals preserved pupillary light reflexes. Despite being blind, the patient insists that her vision is normal. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Bilateral infarction in the distal ACAs",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bilateral infarction in the distal MCAs",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bilateral infarction in the distal PCAs",
          "correct": true
        },
        {
          "label": "D",
          "text": "Any of the above",
          "correct": false
        }
      ],
      "correct_answer": "C. Bilateral infarction in the distal PCAs",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Bilateral infarction in the distal PCAs</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Anton\u2019s syndrome results from bilateral infarction in the distal posterior cerebral arteries (PCAs) , which supply the primary visual cortex. This condition leads to cortical blindness , characterized by complete loss of vision despite preserved pupillary light reflexes. Patients often exhibit visual anosognosia , meaning they are unaware of or deny their blindness, a hallmark feature of Anton\u2019s syndrome.</li><li>\u2022 bilateral infarction in the distal posterior cerebral arteries (PCAs)</li><li>\u2022 cortical blindness</li><li>\u2022 anosognosia</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Bilateral infarction in the distal ACAs: Leads to frontal lobe deficits, including abulia (lack of will) and paraplegia, not cortical blindness.</li><li>\u2022 Option A. Bilateral infarction in the distal ACAs:</li><li>\u2022 Option B. Bilateral infarction in the distal MCAs: Causes significant motor and sensory deficits, but not cortical blindness.</li><li>\u2022 Option B. Bilateral infarction in the distal MCAs:</li><li>\u2022 Option D. Any of the above: Anton\u2019s syndrome specifically requires infarction in the distal PCAs affecting the visual cortex.</li><li>\u2022 Option D. Any of the above:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anton\u2019s syndrome is a rare condition of cortical blindness caused by bilateral PCA infarction , characterized by preserved pupillary light reflexes and denial of blindness (anosognosia). Early recognition is crucial for accurate diagnosis and management.</li><li>\u27a4 cortical blindness</li><li>\u27a4 bilateral PCA infarction</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "92f158e1",
      "audio": ""
    },
    {
      "text": "A 55-year-old man presents with syncope during physical activity, especially while performing dumbbell exercises. On examination, a bruit is noted in the supraclavicular region. What is the most appropriate test?",
      "options": [
        {
          "label": "A",
          "text": "CT Angiogram of neck",
          "correct": true
        },
        {
          "label": "B",
          "text": "Vertebral Artery Doppler",
          "correct": false
        },
        {
          "label": "C",
          "text": "MRI brain",
          "correct": false
        },
        {
          "label": "D",
          "text": "Treadmill ECG",
          "correct": false
        }
      ],
      "correct_answer": "A. CT Angiogram of neck",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) CT Angiogram of neck</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation is suggestive of subclavian steal syndrome, characterized by syncope during upper extremity exertion due to retrograde blood flow in the vertebral artery caused by proximal subclavian artery stenosis or occlusion. A CT angiogram of the neck provides detailed visualization of the subclavian and vertebral arteries, helping confirm the diagnosis by identifying the site and severity of stenosis or occlusion.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Vertebral Artery Doppler : can identify reversed vertebral artery flow, supporting the diagnosis of subclavian steal syndrome, but it does not identify the site of subclavian artery stenosis as comprehensively as a CT angiogram.</li><li>\u2022 Option B. Vertebral Artery Doppler</li><li>\u2022 Option C. MRI brain :  is not indicated as the primary test since the symptoms are due to vascular obstruction rather than a primary brain pathology.</li><li>\u2022 Option C. MRI brain</li><li>\u2022 Option D. Treadmill ECG : is used for cardiac ischemia evaluation, which is not relevant in this case as the symptoms are localized to arm exertion and vascular compromise.</li><li>\u2022 Option D. Treadmill ECG</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 CT angiogram of the neck is the investigation of choice for subclavian steal syndrome, providing a detailed assessment of vascular anatomy and identifying the underlying cause of symptoms.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9748013e",
      "audio": ""
    },
    {
      "text": "A 65-year-old man, Mohan, presents to the neurology clinic with complaints of slowed movements, difficulty walking, and a resting tremor in his right hand. His wife mentions that he has trouble maintaining balance and frequently feels unsteady. On examination, he has cogwheel rigidity and a stooped posture. Which of the following is not considered a cardinal motor feature?",
      "options": [
        {
          "label": "A",
          "text": "Rest tremor",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bradykinesia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Masked facies",
          "correct": true
        },
        {
          "label": "D",
          "text": "Postural instability",
          "correct": false
        }
      ],
      "correct_answer": "C. Masked facies",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Masked facies</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient has Parkinson\u2019s disease. Masked facies (or hypomimia) refers to reduced facial expressivity seen in Parkinson\u2019s disease but is not classified as a cardinal motor feature . The cardinal motor features of Parkinson\u2019s disease include:</li><li>\u2022 cardinal motor feature</li><li>\u2022 Bradykinesia (slowness of movement) Rest tremor (most noticeable at rest) Rigidity (stiffness of muscles) Postural instability (balance difficulties, typically in later stages).</li><li>\u2022 Bradykinesia (slowness of movement)</li><li>\u2022 Bradykinesia</li><li>\u2022 Rest tremor (most noticeable at rest)</li><li>\u2022 Rest tremor</li><li>\u2022 Rigidity (stiffness of muscles)</li><li>\u2022 Rigidity</li><li>\u2022 Postural instability (balance difficulties, typically in later stages).</li><li>\u2022 Postural instability</li><li>\u2022 Masked facies, along with micrographia, reduced eye blinking, drooling, hypophonia, and freezing, are considered additional motor features but not cardinal criteria.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Rest tremor: A hallmark symptom of Parkinson\u2019s disease and one of its cardinal motor features.</li><li>\u2022 Option A. Rest tremor:</li><li>\u2022 Option B. Bradykinesia: Essential for diagnosis and a cardinal feature of Parkinson\u2019s disease.</li><li>\u2022 Option B. Bradykinesia:</li><li>\u2022 Option D. Postural instability: Often seen in advanced stages and is a cardinal feature of Parkinson\u2019s disease.</li><li>\u2022 Option D. Postural instability:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The cardinal motor features of Parkinson\u2019s disease are rest tremor, bradykinesia, rigidity, and postural instability. Masked facies is a common feature but not included in the cardinal criteria.</li><li>\u27a4 rest tremor, bradykinesia, rigidity, and postural instability.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "38a2b6e7",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman, diagnosed with Parkinson\u2019s disease, has been on levodopa therapy for five years. She presents with symptoms of motor fluctuations, including wearing-off effects and dyskinesias. Which of the following factors is LEAST likely associated with an increased risk of levodopa-induced motor complications?",
      "options": [
        {
          "label": "A",
          "text": "Old patients",
          "correct": true
        },
        {
          "label": "B",
          "text": "Severe disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "Higher doses of levodopa",
          "correct": false
        },
        {
          "label": "D",
          "text": "Women",
          "correct": false
        }
      ],
      "correct_answer": "A. Old patients",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Old patients</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Levodopa-induced motor complications, such as wearing-off and dyskinesias, are less commonly seen in older patients. They are more frequently observed in younger individuals , likely due to their longer disease duration and greater sensitivity to dopaminergic fluctuations. The other factors, including severe disease, higher doses of levodopa, and female gender, are strongly associated with an increased risk of these complications.</li><li>\u2022 younger individuals</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Severe disease: Advanced stages of Parkinson\u2019s disease increase the likelihood of motor complications due to greater neuronal loss and reduced buffering capacity.</li><li>\u2022 Option B. Severe disease:</li><li>\u2022 Option C. Higher doses of levodopa: High doses lead to increased dopaminergic fluctuations, predisposing patients to motor complications.</li><li>\u2022 Option C. Higher doses of levodopa:</li><li>\u2022 Option D. Women: Women are more prone to developing motor complications, possibly due to differences in dopamine metabolism and pharmacodynamics.</li><li>\u2022 Option D. Women:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Levodopa-induced motor complications are more common in younger patients , those with severe disease , higher levodopa doses , and women , while older patients are less likely to experience these issues.</li><li>\u27a4 younger patients</li><li>\u27a4 severe disease</li><li>\u27a4 higher levodopa doses</li><li>\u27a4 women</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c28844aa",
      "audio": ""
    },
    {
      "text": "A 70-year-old man, with a 10-year history of Parkinson\u2019s disease, presents with progressive memory impairment, difficulty with daily activities, and confusion over the last few months. On examination, he shows signs of cognitive decline. His current medications include levodopa, Pramipexole, amantadine, trihexyphenidyl, and tolcapone Which of the following drugs should be stopped first to manage his cognitive symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Pramipexole",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amantadine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anticholinergics",
          "correct": true
        },
        {
          "label": "D",
          "text": "Tolcapone",
          "correct": false
        }
      ],
      "correct_answer": "C. Anticholinergics",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Anticholinergics</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Anticholinergic medications like trihexyphenidyl are associated with cognitive side effects, especially in elderly patients and those with pre-existing cognitive impairment or dementia. In Parkinson\u2019s patients who develop dementia, anticholinergics are the first drugs to be stopped, as their risks outweigh their benefits in such cases. The sequence for discontinuing drugs in Parkinson\u2019s patients with dementia is: anticholinergics \u2192 amantadine \u2192 dopamine agonists \u2192 COMT inhibitors \u2192 MAO-B inhibitors, with levodopa being continued at the lowest effective dose.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Pramipexole: It is dopamine receptor agonist and can be discontinued after anticholinergics and amantadine, as they have a relatively lower cognitive impact.</li><li>\u2022 Option A. Pramipexole:</li><li>\u2022 Option B. Amantadine: Although it can cause cognitive side effects, it is stopped after anticholinergics in patients with Parkinson\u2019s disease and dementia.</li><li>\u2022 Option B. Amantadine:</li><li>\u2022 Option D. Tolcapone: It is a COMT inhibitor and generally these drugs have minimal cognitive impact. However, LFTs have to be monitored with Tolcapone.</li><li>\u2022 Option D. Tolcapone:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In Parkinson\u2019s disease patients who develop dementia, anticholinergics are the first drugs to be stopped due to their significant impact on cognitive function. Medication adjustments aim to balance motor symptom control with preservation of cognitive abilities.</li><li>\u27a4 anticholinergics</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5da382b5",
      "audio": ""
    },
    {
      "text": "A 22-year-old woman, Ananya, presents with a history of recurrent severe headaches accompanied by temporary weakness on one side of her body. Her mother and maternal uncle have similar episodes of hemiparesis associated with migraines. Genetic testing is planned to confirm the diagnosis. Which of the following gene mutations is most likely responsible for familial hemiplegic migraine type 1 (FHM1)?",
      "options": [
        {
          "label": "A",
          "text": "CACNA1A",
          "correct": true
        },
        {
          "label": "B",
          "text": "ATP1A2",
          "correct": false
        },
        {
          "label": "C",
          "text": "SCN1A",
          "correct": false
        },
        {
          "label": "D",
          "text": "SCN2A",
          "correct": false
        }
      ],
      "correct_answer": "A. CACNA1A",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) CACNA1A</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Familial hemiplegic migraine type 1 (FHM1) is caused by mutations in the CACNA1A gene, which encodes the Cav 2.1 (P/Q)\u2013type voltage-gated calcium channel. These channels are critical for neuronal excitability and synaptic transmission. Mutations in CACNA1A alter calcium channel function, predisposing individuals to migraines with aura and hemiparesis.</li><li>\u2022 Familial hemiplegic migraine type 1 (FHM1)</li><li>\u2022 CACNA1A</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. ATP1A2: Mutations in ATP1A2, encoding the Na+-K+ ATPase pump, are associated with FHM type 2 , not type 1. These mutations affect ion homeostasis in neurons and glial cells.</li><li>\u2022 Option B. ATP1A2:</li><li>\u2022 FHM type 2</li><li>\u2022 Option C. SCN1A: Mutations in SCN1A, encoding a neuronal voltage-gated sodium channel, cause FHM type 3 , characterized by similar migraine symptoms.</li><li>\u2022 Option C. SCN1A:</li><li>\u2022 FHM type 3</li><li>\u2022 Option D. SCN2A: While SCN2A mutations are implicated in epilepsy, they are not associated with familial hemiplegic migraine.</li><li>\u2022 Option D. SCN2A:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 CACNA1A gene mutations are responsible for FHM type 1 , highlighting the role of voltage-gated calcium channels in the pathophysiology of migraines. Other types of FHM involve mutations in ATP1A2 (type 2) and SCN1A (type 3).</li><li>\u27a4 CACNA1A gene mutations</li><li>\u27a4 FHM type 1</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "906cff45",
      "audio": ""
    },
    {
      "text": "A 40-year-old man, Arjun, presents to the emergency department with severe, unilateral headache centered around his left eye. He describes the pain as excruciating and states that it began suddenly about 30 minutes ago. He also has tearing and redness in the left eye, along with nasal congestion. Which of the following is the treatment of choice?",
      "options": [
        {
          "label": "A",
          "text": "Oral sumatriptan",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lidocaine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Oxygen inhalation",
          "correct": true
        },
        {
          "label": "D",
          "text": "Topiramate",
          "correct": false
        }
      ],
      "correct_answer": "C. Oxygen inhalation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Oxygen inhalation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 For an acute attack of cluster headache , 100% oxygen inhalation at a flow rate of 12-15 L/min for 15\u201320 minutes is the treatment of choice. Oxygen is highly effective in terminating cluster headache attacks quickly, likely due to its vasoconstrictive and neuromodulatory effects in the trigeminovascular system. It is safe and provides rapid relief in most patients.</li><li>\u2022 acute attack of cluster headache</li><li>\u2022 100% oxygen inhalation</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Oral sumatriptan: While sumatriptan is effective in treating migraines, its oral form is not suitable for cluster headaches due to its slower onset of action. The subcutaneous form of sumatriptan is a second-line option for cluster headache.</li><li>\u2022 Option A. Oral sumatriptan:</li><li>\u2022 Option B. Lidocaine: Intranasal lidocaine can provide some relief but is not the first-line treatment.</li><li>\u2022 Option B. Lidocaine:</li><li>\u2022 Option D. Topiramate: This is used as a preventive treatment for cluster headaches, not for acute attacks.</li><li>\u2022 Option D. Topiramate:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The treatment of choice for an acute attack of cluster headache is oxygen inhalation , which provides rapid and effective relief. Subcutaneous sumatriptan is a secondary option for patients who do not respond to oxygen.</li><li>\u27a4 treatment of choice for an acute attack of cluster headache</li><li>\u27a4 oxygen inhalation</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6a878ea6",
      "audio": ""
    },
    {
      "text": "A 60-year-old woman, presents with severe, recurrent, and sharp stabbing pain on the right side of her face, triggered by activities such as chewing and brushing her teeth. Neurological examination is normal. MRI shows compression of the trigeminal nerve root by a nearby blood vessel. Which of the following blood vessels is most commonly involved in the disorder?",
      "options": [
        {
          "label": "A",
          "text": "Basilar artery",
          "correct": false
        },
        {
          "label": "B",
          "text": "Posterior communicating artery",
          "correct": false
        },
        {
          "label": "C",
          "text": "Superior cerebellar artery",
          "correct": true
        },
        {
          "label": "D",
          "text": "Inferior cerebellar artery",
          "correct": false
        }
      ],
      "correct_answer": "C. Superior cerebellar artery",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Superior cerebellar artery</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical picture is suggestive of trigeminal neuralgia. The superior cerebellar artery (SCA) is the most common vessel responsible for compression of the trigeminal nerve root in trigeminal neuralgia. Vascular compression at the root entry zone leads to demyelination of the nerve, resulting in ectopic discharges and severe pain. In some cases, a tortuous vein or other arteries may also contribute to the condition.</li><li>\u2022 superior cerebellar artery (SCA)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Basilar artery: While the basilar artery is a major brainstem artery, it is not commonly implicated in trigeminal nerve compression.</li><li>\u2022 Option A. Basilar artery:</li><li>\u2022 Option B. Posterior communicating artery: This artery is located in the Circle of Willis and is not typically involved in trigeminal neuralgia.</li><li>\u2022 Option B. Posterior communicating artery:</li><li>\u2022 Option D. Inferior cerebellar artery: Although near the trigeminal nerve, this vessel is less commonly involved compared to the superior cerebellar artery.</li><li>\u2022 Option D. Inferior cerebellar artery:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The superior cerebellar artery is the most commonly involved blood vessel in trigeminal neuralgia , often causing nerve compression at the root entry zone, which leads to the characteristic paroxysmal facial pain.</li><li>\u27a4 superior cerebellar artery</li><li>\u27a4 trigeminal neuralgia</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5bafd922",
      "audio": ""
    },
    {
      "text": "A 50-year-old woman, Meena, presents with progressive weakness that worsens throughout the day, along with difficulty swallowing and frequent episodes of nasal regurgitation. She also reports episodes of shortness of breath, particularly at night. Examination reveals fatigable weakness and bulbar involvement. Antibody testing is performed to confirm the diagnosis. Which of the following antibodies is most likely associated with the presentation ?",
      "options": [
        {
          "label": "A",
          "text": "Anti-AChR antibody",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti-MuSK antibody",
          "correct": true
        },
        {
          "label": "C",
          "text": "Anti-LRP4 antibody",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anti-GQ1b antibody",
          "correct": false
        }
      ],
      "correct_answer": "B. Anti-MuSK antibody",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Anti-MuSK antibody</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In Myasthenia Gravis (MG) , anti-MuSK (Muscle-Specific Kinase) antibodies are associated with a subtype characterized by prominent bulbar weakness (affecting swallowing and speech) and frequent episodes of respiratory depression. MuSK antibodies disrupt the clustering of acetylcholine receptors (AChRs) at the neuromuscular junction, leading to severe symptoms, particularly in the bulbar and respiratory muscles. These patients often require more aggressive treatment compared to those with anti-AChR antibodies.</li><li>\u2022 Myasthenia Gravis (MG)</li><li>\u2022 anti-MuSK (Muscle-Specific Kinase) antibodies</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Anti-AChR antibody: Found in most MG cases, but bulbar weakness and respiratory symptoms are less severe compared to MuSK-positive MG.</li><li>\u2022 Option A. Anti-AChR antibody:</li><li>\u2022 Option C. Anti-LRP4 antibody: Rarely associated with MG; typically presents with milder and more generalized symptoms.</li><li>\u2022 Option C. Anti-LRP4 antibody:</li><li>\u2022 Option D. Anti-GQ1b antibody: Seen in Miller Fisher syndrome and not associated with MG.</li><li>\u2022 Option D. Anti-GQ1b antibody:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anti-MuSK antibody-positive MG is associated with severe bulbar weakness and a higher risk of respiratory depression , requiring early diagnosis and careful management.</li><li>\u27a4 Anti-MuSK antibody-positive MG</li><li>\u27a4 bulbar weakness</li><li>\u27a4 respiratory depression</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0e96d397",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman, Pooja, presents with complaints of fatigable weakness, especially in the proximal muscles and eyelids. Repetitive nerve stimulation (RNS) is planned to confirm the diagnosis. Which of the following statements regarding RNS?",
      "options": [
        {
          "label": "A",
          "text": "Anti-AChE medication should be stopped 6\u201312 h before testing",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is best to test weak muscles or proximal muscle groups",
          "correct": false
        },
        {
          "label": "C",
          "text": "In myasthenic patients, there is a rapid reduction of >10% in the amplitude of the evoked responses",
          "correct": false
        },
        {
          "label": "D",
          "text": "All are true",
          "correct": true
        }
      ],
      "correct_answer": "D. All are true",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) All are true</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Repetitive nerve stimulation (RNS) is a diagnostic test for myasthenia gravis (MG) that evaluates neuromuscular transmission.</li><li>\u2022 Repetitive nerve stimulation (RNS)</li><li>\u2022 Option A. Anti-AChE medication should be stopped 6\u201312 hours before testing to prevent interference with results and provide a true measure of neuromuscular transmission impairment.</li><li>\u2022 Option A. Anti-AChE medication should be stopped 6\u201312 hours before testing</li><li>\u2022 Option B. It is best to test weak muscles or proximal muscle groups , as these are more likely to exhibit abnormalities in MG.</li><li>\u2022 Option B. It is best to test weak muscles or proximal muscle groups</li><li>\u2022 Option C. In myasthenic patients, there is a rapid reduction of >10% in the amplitude of the evoked responses , reflecting a defect in neuromuscular transmission due to reduced acetylcholine availability at the receptor.</li><li>\u2022 Option C. In myasthenic patients, there is a rapid reduction of >10% in the amplitude of the evoked responses</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Repetitive nerve stimulation is a key diagnostic tool for myasthenia gravis and requires appropriate preparation (stopping anti-AChE medication) and testing of weak or proximal muscles. A reduction in amplitude >10% confirms a neuromuscular transmission defect.</li><li>\u27a4 myasthenia gravis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f8ec15de",
      "audio": ""
    },
    {
      "text": "Which of the following hormones uses the JAK/STAT signaling pathway?",
      "options": [
        {
          "label": "A",
          "text": "BMP",
          "correct": false
        },
        {
          "label": "B",
          "text": "PRL",
          "correct": true
        },
        {
          "label": "C",
          "text": "Activin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Insulin",
          "correct": false
        }
      ],
      "correct_answer": "B. PRL",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-19%20130811.jpg"
      ],
      "explanation": "<p><strong>Ans. B) PRL</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Prolactin (PRL) uses the JAK/STAT (Janus kinase/signal transducer and activator of transcription) signaling pathway. Upon binding to its receptor, prolactin activates JAK kinases, which phosphorylate the receptor, allowing STAT proteins to bind and translocate to the nucleus to regulate gene transcription. This pathway is also used by growth hormone (GH) and other cytokine-like hormones.</li><li>\u2022 Prolactin (PRL)</li><li>\u2022 JAK/STAT (Janus kinase/signal transducer and activator of transcription)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. BMP: Bone morphogenetic proteins (BMP) use the serine/threonine kinase signaling pathway via the SMAD proteins.</li><li>\u2022 Option A. BMP:</li><li>\u2022 serine/threonine kinase</li><li>\u2022 Option C. Activin: Activin also uses the serine/threonine kinase pathway.</li><li>\u2022 Option C. Activin:</li><li>\u2022 serine/threonine kinase</li><li>\u2022 Option D. Insulin: Insulin utilizes the Receptor Tyrosine Kinase (RTK) signaling pathway, not JAK/STAT.</li><li>\u2022 Option D. Insulin:</li><li>\u2022 Receptor Tyrosine Kinase (RTK)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The JAK/STAT signaling pathway is utilized by hormones like prolactin (PRL) and growth hormone (GH) , enabling the regulation of specific genes critical for their physiological functions.</li><li>\u27a4 JAK/STAT signaling pathway</li><li>\u27a4 prolactin (PRL)</li><li>\u27a4 growth hormone (GH)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d1fcdc36",
      "audio": ""
    },
    {
      "text": "A 5-year-old boy presents with polyuria, polydipsia, and dehydration. He has increased levels of antidiuretic hormone (ADH), and urine osmolality remains low even after water deprivation and desmopressin test. Some of his family members are affected by this condition. Which type of mutation is most likely responsible for his condition?",
      "options": [
        {
          "label": "A",
          "text": "XL, activating arginine vasopressin receptor 2 mutation",
          "correct": false
        },
        {
          "label": "B",
          "text": "XL, inactivating arginine vasopressin receptor 2 mutation",
          "correct": true
        },
        {
          "label": "C",
          "text": "AD, activating arginine vasopressin receptor 2 mutation",
          "correct": false
        },
        {
          "label": "D",
          "text": "AD, inactivating arginine vasopressin receptor 2 mutation",
          "correct": false
        }
      ],
      "correct_answer": "B. XL, inactivating arginine vasopressin receptor 2 mutation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) XL, inactivating arginine vasopressin receptor 2 mutation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The boy's presentation is consistent with nephrogenic diabetes insipidus (NDI), characterized by polyuria, polydipsia, and an inability to concentrate urine despite high levels of ADH. The condition remains unresponsive to desmopressin (a synthetic ADH analog). Inherited nephrogenic diabetes insipidus is most commonly caused by X-linked (XL) inactivating mutations in the arginine vasopressin receptor 2 (AVPR2) gene, which is located on the X chromosome. This mutation impairs the kidney\u2019s ability to respond to ADH, leading to the observed symptoms.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. XL, activating arginine vasopressin receptor 2 mutation: XL, activating mutations of the AVPR2 gene would cause increased receptor activity, which is inconsistent with the features of nephrogenic diabetes insipidus.</li><li>\u2022 Option A. XL, activating arginine vasopressin receptor 2 mutation:</li><li>\u2022 Option C. AD, activating arginine vasopressin receptor 2 mutation: AD, activating mutations of the AVPR2 gene would not explain resistance to ADH.</li><li>\u2022 Option C. AD, activating arginine vasopressin receptor 2 mutation:</li><li>\u2022 Option D. AD, inactivating arginine vasopressin receptor 2 mutation: AD, inactivating mutations of the AVPR2 gene are rare, and most familial cases of nephrogenic diabetes insipidus are X-linked rather than autosomal dominant.</li><li>\u2022 Option D. AD, inactivating arginine vasopressin receptor 2 mutation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Nephrogenic diabetes insipidus is most commonly caused by X-linked inactivating mutations in the AVPR2 gene, leading to ADH resistance and impaired urinary concentration.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "57fdc8ca",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman, Rina, presents with symptoms of fatigue, and headache. Laboratory tests reveal mild hyperprolactinemia and low cortisol levels. MRI shows a prominent pituitary mass suspicious of lymphocytic hypophysitis. What is the most likely patient population affected?",
      "options": [
        {
          "label": "A",
          "text": "HIV/AIDS",
          "correct": false
        },
        {
          "label": "B",
          "text": "Intracranial metastasis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Postpartum women",
          "correct": true
        },
        {
          "label": "D",
          "text": "Postmenopausal women",
          "correct": false
        }
      ],
      "correct_answer": "C. Postpartum women",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Postpartum women</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Lymphocytic hypophysitis is an autoimmune inflammatory condition of the pituitary gland that occurs most commonly in postpartum women . It typically presents with symptoms of pituitary dysfunction, including fatigue, headache, hyperprolactinemia, and hypopituitarism. MRI often shows an enlarged pituitary gland that can mimic a pituitary adenoma. The postpartum period is thought to trigger the autoimmune process due to hormonal and immunological changes.</li><li>\u2022 Lymphocytic hypophysitis</li><li>\u2022 postpartum women</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. HIV/AIDS: While pituitary dysfunction may occur in HIV/AIDS, lymphocytic hypophysitis is not specifically associated with this population.</li><li>\u2022 Option A. HIV/AIDS:</li><li>\u2022 Option B. Intracranial metastasis: Pituitary metastasis may mimic a pituitary mass but is unrelated to lymphocytic hypophysitis.</li><li>\u2022 Option B. Intracranial metastasis:</li><li>\u2022 Option D. Postmenopausal women: Lymphocytic hypophysitis is rare in postmenopausal women, as it predominantly affects younger, postpartum women.</li><li>\u2022 Option D. Postmenopausal women:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Lymphocytic hypophysitis most commonly occurs in postpartum women , presenting with a pituitary mass and symptoms of pituitary dysfunction, such as mild hyperprolactinemia and hypopituitarism.</li><li>\u27a4 Lymphocytic hypophysitis</li><li>\u27a4 postpartum women</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bb86efd9",
      "audio": ""
    },
    {
      "text": "A 45-year-old man, Anil, presents with headaches and progressive visual loss over the past few months. MRI reveals a pituitary adenoma with suprasellar extension compressing the optic chiasm. Which of the following statements is not true?",
      "options": [
        {
          "label": "A",
          "text": "Pituitary adenomas frequently extend in a suprasellar direction",
          "correct": false
        },
        {
          "label": "B",
          "text": "Headache is a common feature",
          "correct": false
        },
        {
          "label": "C",
          "text": "Headache severity correlates with adenoma size or extension",
          "correct": true
        },
        {
          "label": "D",
          "text": "Suprasellar extension can lead to visual loss",
          "correct": false
        }
      ],
      "correct_answer": "C. Headache severity correlates with adenoma size or extension",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Headache severity correlates with adenoma size or extension</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Headache severity correlates poorly with adenoma size or extension. Even small intrasellar tumors without suprasellar extension can cause headaches due to pressure effects on the sellar diaphragm or surrounding structures. Thus, the size or direction of tumor extension is not a reliable predictor of headache severity.</li><li>\u2022 Headache severity correlates poorly with adenoma size or extension.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Pituitary adenomas frequently extend in a suprasellar direction: Correct. The dorsal sellar diaphragm offers the least resistance to tumor growth, leading to frequent suprasellar extension.</li><li>\u2022 Option A. Pituitary adenomas frequently extend in a suprasellar direction:</li><li>\u2022 Option B. Headache is a common feature: Correct. Headaches are often reported in patients with pituitary adenomas, regardless of tumor size.</li><li>\u2022 Option B. Headache is a common feature:</li><li>\u2022 Option D. Suprasellar extension can lead to visual loss: Correct. Suprasellar extension can compress the optic chiasm, resulting in bitemporal hemianopia or other visual deficits.</li><li>\u2022 Option D. Suprasellar extension can lead to visual loss:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While headaches are common in pituitary adenomas , their severity does not reliably correlate with tumor size or extension. Suprasellar growth often leads to visual loss, particularly through optic chiasm compression.</li><li>\u27a4 headaches are common in pituitary adenomas</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c09ac15b",
      "audio": ""
    },
    {
      "text": "A 40-year-old man, Ravi, presents with progressive enlargement of his hands and feet, coarsened facial features, and deepening of his voice over the past few years. On examination, he has frontal bossing, an enlarged jaw, and macroglossia. What is the most appropriate screening test for this condition?",
      "options": [
        {
          "label": "A",
          "text": "Serum GH levels",
          "correct": false
        },
        {
          "label": "B",
          "text": "ACTH reserve",
          "correct": false
        },
        {
          "label": "C",
          "text": "Serum IGF-1 levels",
          "correct": true
        },
        {
          "label": "D",
          "text": "Insulin tolerance test",
          "correct": false
        }
      ],
      "correct_answer": "C. Serum IGF-1 levels",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Serum IGF-1 levels</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Serum IGF-1 levels are the most reliable screening test for acromegaly. IGF-1 (insulin-like growth factor-1) is produced in response to growth hormone (GH) and reflects GH activity over time, providing a stable measure unaffected by the episodic nature of GH secretion. Elevated age-matched serum IGF-1 levels are a hallmark of acromegaly and confirm the need for further diagnostic testing.</li><li>\u2022 Serum IGF-1 levels</li><li>\u2022 screening test</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Serum GH levels: GH levels are pulsatile and vary throughout the day, making them unreliable for screening. GH suppression testing after glucose is used for confirmation.</li><li>\u2022 Option A. Serum GH levels:</li><li>\u2022 Option B. ACTH reserve: This is used to evaluate adrenal insufficiency and is unrelated to acromegaly.</li><li>\u2022 Option B. ACTH reserve:</li><li>\u2022 Option D. Insulin tolerance test: Used to assess pituitary function or GH deficiency, not for screening acromegaly.</li><li>\u2022 Option D. Insulin tolerance test:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The screening test for acromegaly is an age-matched serum IGF-1 level , which provides a stable and accurate measure of GH activity and guides further diagnostic evaluation.</li><li>\u27a4 screening test for acromegaly</li><li>\u27a4 age-matched serum IGF-1 level</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ebb99d97",
      "audio": ""
    },
    {
      "text": "A 22-year-old woman, Priya, is diagnosed with diabetes mellitus. She has a strong family history of diabetes, with her father and grandmother diagnosed in their early 20s. Genetic testing reveals a mutation in the HNF1A gene. Which of the following features are characteristic of the disease?",
      "options": [
        {
          "label": "A",
          "text": "Autosomal dominant inheritance",
          "correct": false
        },
        {
          "label": "B",
          "text": "Early onset of hyperglycemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Impaired insulin secretion",
          "correct": false
        },
        {
          "label": "D",
          "text": "All of the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All of the above",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) All of the above</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Maturity-Onset Diabetes of the Young (MODY) is a monogenic form of diabetes with the following key features:</li><li>\u2022 Maturity-Onset Diabetes of the Young (MODY)</li><li>\u2022 Autosomal dominant inheritance: MODY is caused by mutations in specific genes involved in insulin secretion, such as HNF1A (most common \u2013 MODY 3) , HNF4A , or GCK , and follows an autosomal dominant pattern. Early onset of hyperglycemia: Typically presents before age 25 and sometimes as early as the neonatal period. Impaired insulin secretion: Insulin secretion is impaired, but there is no insulin resistance as seen in type 2 diabetes.</li><li>\u2022 Autosomal dominant inheritance: MODY is caused by mutations in specific genes involved in insulin secretion, such as HNF1A (most common \u2013 MODY 3) , HNF4A , or GCK , and follows an autosomal dominant pattern.</li><li>\u2022 Autosomal dominant inheritance:</li><li>\u2022 HNF1A (most common \u2013 MODY 3)</li><li>\u2022 HNF4A</li><li>\u2022 GCK</li><li>\u2022 Early onset of hyperglycemia: Typically presents before age 25 and sometimes as early as the neonatal period.</li><li>\u2022 Early onset of hyperglycemia:</li><li>\u2022 Impaired insulin secretion: Insulin secretion is impaired, but there is no insulin resistance as seen in type 2 diabetes.</li><li>\u2022 Impaired insulin secretion:</li><li>\u2022 Key Features of MODY:</li><li>\u2022 Key Features of MODY:</li><li>\u2022 No insulin resistance : Differentiates MODY from type 2 diabetes. Non-obese patients: Most MODY patients are non-obese, unlike type 2 diabetes. Specific gene mutations: Helps differentiate MODY from other diabetes types. Family history of diabetes in multiple generations: Common due to autosomal dominant inheritance.</li><li>\u2022 No insulin resistance : Differentiates MODY from type 2 diabetes.</li><li>\u2022 No insulin resistance</li><li>\u2022 Non-obese patients: Most MODY patients are non-obese, unlike type 2 diabetes.</li><li>\u2022 Non-obese patients:</li><li>\u2022 Specific gene mutations: Helps differentiate MODY from other diabetes types.</li><li>\u2022 Specific gene mutations:</li><li>\u2022 Family history of diabetes in multiple generations: Common due to autosomal dominant inheritance.</li><li>\u2022 Family history of diabetes in multiple generations:</li><li>\u2022 Each feature (A, B, C) is individually correct, making the most appropriate answer D. All of the above .</li><li>\u2022 D. All of the above</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Maturity-Onset Diabetes of the Young (MODY) is characterized by autosomal dominant inheritance , early onset of hyperglycemia , and impaired insulin secretion , making it distinct from type 1 and type 2 diabetes. Genetic testing is essential for diagnosis and tailored management.</li><li>\u27a4 Maturity-Onset Diabetes of the Young (MODY)</li><li>\u27a4 autosomal dominant inheritance</li><li>\u27a4 early onset of hyperglycemia</li><li>\u27a4 impaired insulin secretion</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "81e46efd",
      "audio": ""
    },
    {
      "text": "A 35-year-old man has been fasting for 18 hours as part of a religious observance. During the fasting state, which of the following processes is not typically observed?",
      "options": [
        {
          "label": "A",
          "text": "Increased gluconeogenesis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Increased glycogenolysis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Increased glucose uptake in skeletal muscle and fat",
          "correct": true
        },
        {
          "label": "D",
          "text": "Increased lipolysis",
          "correct": false
        }
      ],
      "correct_answer": "C. Increased glucose uptake in skeletal muscle and fat",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Increased glucose uptake in skeletal muscle and fat</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In the fasting state , low insulin levels and increased glucagon activity shift the body\u2019s metabolic focus to maintaining blood glucose levels for essential tissues like the brain:</li><li>\u2022 fasting state</li><li>\u2022 Increased gluconeogenesis: The liver produces glucose from precursors like amino acids and glycerol to sustain blood glucose levels. Increased glycogenolysis: Stored glycogen in the liver is broken down into glucose to meet immediate energy demands. Increased lipolysis: Fat stores are broken down into free fatty acids and glycerol to provide energy and gluconeogenic substrates.</li><li>\u2022 Increased gluconeogenesis: The liver produces glucose from precursors like amino acids and glycerol to sustain blood glucose levels.</li><li>\u2022 Increased gluconeogenesis:</li><li>\u2022 Increased glycogenolysis: Stored glycogen in the liver is broken down into glucose to meet immediate energy demands.</li><li>\u2022 Increased glycogenolysis:</li><li>\u2022 Increased lipolysis: Fat stores are broken down into free fatty acids and glycerol to provide energy and gluconeogenic substrates.</li><li>\u2022 Increased lipolysis:</li><li>\u2022 However, glucose uptake in skeletal muscle and fat is reduced in the fasting state due to low insulin levels, preserving glucose for critical tissues such as the brain and red blood cells.</li><li>\u2022 glucose uptake in skeletal muscle and fat is reduced</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Increased gluconeogenesis: This is a primary mechanism for maintaining blood glucose during fasting.</li><li>\u2022 Option A. Increased gluconeogenesis:</li><li>\u2022 Option B. Increased glycogenolysis: Occurs early in fasting to release glucose from liver glycogen stores.</li><li>\u2022 Option B. Increased glycogenolysis:</li><li>\u2022 Option D. Increased lipolysis: Provides energy and gluconeogenic substrates during prolonged fasting.</li><li>\u2022 Option D. Increased lipolysis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the fasting state , the body conserves glucose for essential functions by reducing glucose uptake in skeletal muscle and fat , while promoting gluconeogenesis, glycogenolysis, and lipolysis to maintain blood glucose levels.</li><li>\u27a4 fasting state</li><li>\u27a4 glucose uptake in skeletal muscle and fat</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "62e2441f",
      "audio": ""
    },
    {
      "text": "A 12-year-old girl, Ananya, with a family history of type 1 diabetes mellitus (T1D), is identified as being at high risk for developing the disease. She has multiple islet cell autoantibodies and impaired glucose tolerance, consistent with stage 2 T1D. Which of the following drugs is approved for delaying the onset of stage 3?",
      "options": [
        {
          "label": "A",
          "text": "Rituximab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Teplizumab",
          "correct": true
        },
        {
          "label": "C",
          "text": "Golimumab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Teprotumumab",
          "correct": false
        }
      ],
      "correct_answer": "B. Teplizumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Teplizumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Teplizumab is an Fc receptor-nonbinding anti-CD3 monoclonal antibody that modulates T-cell activity to delay the progression of autoimmune destruction of \u03b2-cells. A 14-day course of teplizumab has been shown to delay the onset of stage 3 T1D in high-risk individuals (those with multiple autoantibodies and dysglycemia, i.e., stage 2 T1D) by a median of 2.7 years , offering a significant therapeutic advance.</li><li>\u2022 Teplizumab</li><li>\u2022 anti-CD3 monoclonal antibody</li><li>\u2022 2.7 years</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Rituximab: A monoclonal antibody against CD20 used in autoimmune diseases like rheumatoid arthritis and certain lymphomas, but not approved for delaying T1D.</li><li>\u2022 Option A. Rituximab:</li><li>\u2022 Option C. Golimumab: A TNF-\u03b1 inhibitor used in autoimmune conditions such as rheumatoid arthritis and ulcerative colitis, but not in T1D prevention.</li><li>\u2022 Option C. Golimumab:</li><li>\u2022 Option D. Teprotumumab: An IGF-1R inhibitor used for thyroid eye disease, unrelated to T1D.</li><li>\u2022 Option D. Teprotumumab:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Teplizumab is the first drug approved to delay the onset of stage 3 type 1 diabetes in individuals at high risk, representing a milestone in preventive treatment for autoimmune diabetes.</li><li>\u27a4 Teplizumab</li><li>\u27a4 delay the onset of stage 3 type 1 diabetes</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ff10b699",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with type 2 diabetes is undergoing routine monitoring of her glycemic control. Due to recent changes in her medication, her physician orders a fructosamine assay instead of an HbA1c test. The fructosamine assay reflects glycemic status for what duration?",
      "options": [
        {
          "label": "A",
          "text": "1 Week",
          "correct": false
        },
        {
          "label": "B",
          "text": "2 Weeks",
          "correct": true
        },
        {
          "label": "C",
          "text": "3 Weeks",
          "correct": false
        },
        {
          "label": "D",
          "text": "4 Weeks",
          "correct": false
        }
      ],
      "correct_answer": "B. 2 Weeks",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 2 Weeks</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The fructosamine assay measures glycated proteins, primarily glycated albumin , in the blood. Since the half-life of albumin is approximately 14\u201321 days, the assay reflects the average glycemic status over the prior 2 weeks . This test is particularly useful in situations where short-term glycemic changes need to be assessed, such as after medication adjustments or in conditions affecting red blood cells that impact HbA1c accuracy.</li><li>\u2022 fructosamine assay</li><li>\u2022 glycated albumin</li><li>\u2022 prior 2 weeks</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. 1 Week: The assay reflects a longer duration due to the albumin half-life.</li><li>\u2022 Option A. 1 Week:</li><li>\u2022 Option C. 3 Weeks: While close, the test predominantly reflects the prior 2 weeks of glycemia.</li><li>\u2022 Option C. 3 Weeks:</li><li>\u2022 Option D. 4 Weeks: The test does not capture glycemic control for this long due to albumin turnover.</li><li>\u2022 Option D. 4 Weeks:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The fructosamine assay reflects glycemic status over the prior 2 weeks and is particularly useful for short-term monitoring or when HbA1c results may be unreliable.</li><li>\u27a4 fructosamine assay</li><li>\u27a4 prior 2 weeks</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e886ec85",
      "audio": ""
    },
    {
      "text": "A 55-year-old man with type 2 diabetes mellitus has uncontrolled sugars. His medical history reveals a family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2 (MEN 2). Which of the following medications is contraindicated in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Liraglutide",
          "correct": true
        },
        {
          "label": "C",
          "text": "Canagliflozin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pioglitazone",
          "correct": false
        }
      ],
      "correct_answer": "B. Liraglutide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Liraglutide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Liraglutide , a GLP-1 receptor agonist , is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2) . Preclinical studies in rodents demonstrated an increased risk of thyroid C-cell tumors with GLP-1 receptor agonists, prompting the FDA to issue a black box warning for these medications.</li><li>\u2022 Liraglutide</li><li>\u2022 GLP-1 receptor agonist</li><li>\u2022 medullary thyroid carcinoma (MTC)</li><li>\u2022 multiple endocrine neoplasia type 2 (MEN 2)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Metformin: A first-line medication that lowers glucose through AMP-activated protein kinase activation; it has no association with thyroid tumors.</li><li>\u2022 Option A. Metformin:</li><li>\u2022 Option C. Canagliflozin: An SGLT2 inhibitor, it works by promoting renal glucose excretion and is not linked to thyroid malignancies.</li><li>\u2022 Option C. Canagliflozin:</li><li>\u2022 Option D. Pioglitazone: A thiazolidinedione that improves insulin sensitivity, unrelated to thyroid cancer risk.</li><li>\u2022 Option D. Pioglitazone:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 GLP-1 receptor agonists like liraglutide are contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or MEN 2 due to an associated risk of thyroid C-cell tumors.</li><li>\u27a4 GLP-1 receptor agonists</li><li>\u27a4 liraglutide</li><li>\u27a4 medullary thyroid carcinoma (MTC)</li><li>\u27a4 MEN 2</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "809de527",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman with type 1 diabetes mellitus presents to the emergency department with nausea, vomiting, and abdominal pain. Lab investigations reveal a glucose level of 400 mg/dL, sodium 125 mmol/L, serum osmolality 300 mOsm/mL, positive urine ketones, and a serum bicarbonate level of 20 mmol/L. Which of the following is unlikely?",
      "options": [
        {
          "label": "A",
          "text": "Sodium concentration of 125 mmol/L",
          "correct": false
        },
        {
          "label": "B",
          "text": "Serum osmolality of 300 mOsm/mL",
          "correct": false
        },
        {
          "label": "C",
          "text": "Urine ketones positive",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serum bicarbonate >18 mmol/L",
          "correct": true
        }
      ],
      "correct_answer": "D. Serum bicarbonate >18 mmol/L",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Serum bicarbonate >18 mmol/L</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In diabetic ketoacidosis (DKA) , serum bicarbonate levels are typically <18 mmol/L , reflecting metabolic acidosis. A bicarbonate level >18 mmol/L would exclude DKA as the diagnosis. This feature helps differentiate DKA from hyperosmolar hyperglycemic state (HHS), where bicarbonate levels are typically normal (>18 mmol/L).</li><li>\u2022 diabetic ketoacidosis (DKA)</li><li>\u2022 serum bicarbonate levels are typically <18 mmol/L</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Sodium concentration of 125 mmol/L: Mild hyponatremia is common in DKA due to hyperglycemia-induced osmotic shifts.</li><li>\u2022 Option A. Sodium concentration of 125 mmol/L:</li><li>\u2022 Option B. Serum osmolality of 300 mOsm/mL: This is within the range seen in DKA (300\u2013320 mOsm/mL).</li><li>\u2022 Option B. Serum osmolality of 300 mOsm/mL:</li><li>\u2022 Option C. Urine ketones positive: Positive ketones in urine or serum are a hallmark of DKA, resulting from elevated ketone production due to insulin deficiency.</li><li>\u2022 Option C. Urine ketones positive:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Serum bicarbonate <18 mmol/L is a defining feature of DKA , reflecting significant metabolic acidosis. Bicarbonate >18 mmol/L is inconsistent with DKA and may indicate another condition, such as HHS or mild hyperglycemia.</li><li>\u27a4 Serum bicarbonate <18 mmol/L</li><li>\u27a4 DKA</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5a3700f5",
      "audio": ""
    },
    {
      "text": "A 40-year-old woman presents with recurrent kidney stones, fatigue, and abdominal pain. Lab tests reveal hypercalcemia and an elevated parathyroid hormone (PTH) level. Imaging confirms the presence of parathyroid hyperplasia. What is the most common feature of the syndrome?",
      "options": [
        {
          "label": "A",
          "text": "Gastrinoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Primary hyperparathyroidism",
          "correct": true
        },
        {
          "label": "C",
          "text": "Prolactinoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Adrenal cortical tumor",
          "correct": false
        }
      ],
      "correct_answer": "B. Primary hyperparathyroidism",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Primary hyperparathyroidism</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation is suggestive of Multiple Endocrine Neoplasia type 1 (MEN1), an autosomal dominant syndrome characterized by the \"3 P's\": parathyroid tumors, pancreatic neuroendocrine tumors, and pituitary tumors. Primary hyperparathyroidism due to parathyroid hyperplasia or adenomas is the most common and earliest manifestation of MEN1.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Gastrinoma : is a pancreatic neuroendocrine tumor commonly seen in MEN1 but is not the most common feature.</li><li>\u2022 Option A. Gastrinoma</li><li>\u2022 Option C. Prolactinoma :  is a pituitary tumor associated with MEN1 but occurs less frequently than primary hyperparathyroidism.</li><li>\u2022 Option C. Prolactinoma</li><li>\u2022 Option D. Adrenal cortical tumors : can occur in MEN1 but are not a defining or common feature.</li><li>\u2022 Option D. Adrenal cortical tumors</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Primary hyperparathyroidism is the most common and earliest feature of MEN1, often presenting with hypercalcemia and associated complications such as recurrent kidney stones.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "980c5774",
      "audio": ""
    },
    {
      "text": "A 10-year-old girl presents with tetany, muscle spasms, hyperpigmentation, and shock, following a respiratory infection. There are a couple of members in the family suffering from the same disorder. Which of the following is the first manifestation in this disorder?",
      "options": [
        {
          "label": "A",
          "text": "Type 1 DM",
          "correct": false
        },
        {
          "label": "B",
          "text": "Mucocutaneous candidiasis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hypoparathyroidism",
          "correct": false
        },
        {
          "label": "D",
          "text": "Adrenal insufficiency",
          "correct": false
        }
      ],
      "correct_answer": "B. Mucocutaneous candidiasis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Mucocutaneous candidiasis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical scenario suggests Autoimmune Polyendocrine Syndrome Type 1 (APS-1), which is characterized by a triad of mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. Mucocutaneous candidiasis is usually the first manifestation, occurring in childhood due to immune dysfunction targeting fungal pathogens. Hypoparathyroidism and adrenal insufficiency typically develop later.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Type 1 DM: is more commonly associated with Autoimmune Polyendocrine Syndrome Type 2 (APS-2) and is not an initial feature of APS-1.</li><li>\u2022 Option A. Type 1 DM:</li><li>\u2022 Option C. Hypoparathyroidism: is part of the APS-1 triad but usually develops after mucocutaneous candidiasis.</li><li>\u2022 Option C. Hypoparathyroidism:</li><li>\u2022 Option D. Adrenal insufficiency: occurs later in the disease course of APS-1 and is not typically the first manifestation.</li><li>\u2022 Option D. Adrenal insufficiency:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In Autoimmune Polyendocrine Syndrome Type 1, mucocutaneous candidiasis is the earliest manifestation, followed by hypoparathyroidism and adrenal insufficiency. Early recognition of this progression is crucial for timely diagnosis and management.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c84c86f3",
      "audio": ""
    },
    {
      "text": "A 45-year-old man with a history of smoking presents with progressive shortness of breath. A pulmonary function test is performed, and the flow-volume loop is analyzed. Which of the following parameters can be directly assessed using the flow-volume loop?",
      "options": [
        {
          "label": "A",
          "text": "Residual volume",
          "correct": false
        },
        {
          "label": "B",
          "text": "Total lung capacity",
          "correct": false
        },
        {
          "label": "C",
          "text": "Functional residual capacity",
          "correct": false
        },
        {
          "label": "D",
          "text": "FEV1/FVC",
          "correct": true
        }
      ],
      "correct_answer": "D. FEV1/FVC",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20153700.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) FEV1/FVC</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The flow-volume loop provides graphical representation of airflow against lung volume during forced inspiration and expiration. The following parameters can be obtained:</li><li>\u2022 flow-volume loop</li><li>\u2022 FEV1/FVC: The ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) can be derived, as both parameters are captured during the test. Patterns of obstruction or restriction: The shape of the loop can differentiate between obstructive (e.g., COPD) and restrictive (e.g., pulmonary fibrosis) lung diseases.</li><li>\u2022 FEV1/FVC: The ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) can be derived, as both parameters are captured during the test.</li><li>\u2022 FEV1/FVC:</li><li>\u2022 Patterns of obstruction or restriction: The shape of the loop can differentiate between obstructive (e.g., COPD) and restrictive (e.g., pulmonary fibrosis) lung diseases.</li><li>\u2022 Patterns of obstruction or restriction:</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Residual volume: Cannot be directly measured from the flow-volume loop. It requires additional tests like body plethysmography or nitrogen washout.</li><li>\u2022 Option A. Residual volume:</li><li>\u2022 Option B. Total lung capacity: Also requires plethysmography or imaging, as it includes residual volume.</li><li>\u2022 Option B. Total lung capacity:</li><li>\u2022 Option C. Functional residual capacity: Cannot be measured using the flow-volume loop; it is derived from static lung volume measurements.</li><li>\u2022 Option C. Functional residual capacity:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The flow-volume loop is primarily used to assess FEV1/FVC and evaluate patterns of airflow, making it valuable for diagnosing and differentiating obstructive and restrictive lung diseases. Parameters like residual volume and total lung capacity require other testing modalities.</li><li>\u27a4 flow-volume loop</li><li>\u27a4 FEV1/FVC</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7fdf66dc",
      "audio": ""
    },
    {
      "text": "A 74-year-old man with a history of smoking and working as a roofer presents with a 5-year history of gradually progressive dyspnea and dry cough. He also reports knee pain and occasional swelling, but no fever or weight loss. Physical examination reveals bilateral end-inspiratory crackles. Pulmonary function testing shows restrictive lung disease with a low DLCO. Chest radiograph suggests bilateral lower zone-predominant lesions. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Emphysema",
          "correct": false
        },
        {
          "label": "B",
          "text": "Asbestosis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Pneumonia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bronchogenic Carcinoma",
          "correct": false
        }
      ],
      "correct_answer": "B. Asbestosis",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20153900.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Asbestosis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Asbestosis is a restrictive lung disease caused by chronic inhalation of asbestos fibers. This patient has a significant occupational exposure history (working as a roofer for 40 years), and his clinical presentation includes progressive dyspnea, dry cough, and restrictive spirometry findings (low total lung capacity, FVC, and DLCO). The chest radiograph showing bilateral lower zone-predominant lesions is characteristic of asbestosis, a form of interstitial lung disease caused by asbestos exposure. The presence of crackles on lung auscultation also supports this diagnosis.</li><li>\u2022 Asbestosis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Emphysema: Emphysema typically presents with an obstructive pattern on spirometry (decreased FEV1/FVC ratio). Although late-stage emphysema can show pseudo-restriction, it does not fit this patient\u2019s restrictive spirometry and occupational exposure history.</li><li>\u2022 Option A. Emphysema:</li><li>\u2022 obstructive</li><li>\u2022 Option C. Pneumonia: Pneumonia is an acute infection that would likely present with fever, hypoxemia, and more acute symptoms, which this patient does not have.</li><li>\u2022 Option C. Pneumonia:</li><li>\u2022 Option D. Bronchogenic carcinoma: While bronchogenic carcinoma may cause progressive dyspnea and cough, it typically presents with additional signs like weight loss, clubbing, or hemoptysis. The normal FEV1/FVC ratio and the characteristic restrictive lung pattern on spirometry do not support this diagnosis.</li><li>\u2022 Option D. Bronchogenic carcinoma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Asbestosis is strongly associated with long-term asbestos exposure and presents with a restrictive lung disease pattern, as seen in this patient. The bilateral lower zone-predominant lesions on chest radiograph and the history of occupational exposure are key diagnostic clues.</li><li>\u27a4 Asbestosis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "956bfef4",
      "audio": ""
    },
    {
      "text": "A 60-year-old man with a history of prostate cancer presents with worsening breathlessness, chest pain, and syncope. On arrival, his heart rate is 125 bpm with a shock index >1. CTPA confirms pulmonary embolism. Cardiac troponin and BNP levels are normal, and an echocardiogram shows reduced right ventricular function. Based on the clinical scenario, which of the following is recommended for in-hospital treatment?",
      "options": [
        {
          "label": "A",
          "text": "LMWH",
          "correct": true
        },
        {
          "label": "B",
          "text": "Warfarin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bivalirudin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Alteplase",
          "correct": false
        }
      ],
      "correct_answer": "A. LMWH",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) LMWH</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient is diagnosed with intermediate-low risk pulmonary embolism (PE) , likely due to his underlying malignancy (prostate cancer). Low-molecular-weight heparin (LMWH) is the preferred anticoagulant in patients with cancer-associated PE because it is effective, does not require frequent monitoring, and is generally safer in this patient population. It is also the first-line agent for managing PE in intermediate-low risk patients who have no contraindications for anticoagulation.</li><li>\u2022 intermediate-low risk pulmonary embolism (PE)</li><li>\u2022 Low-molecular-weight heparin (LMWH)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Warfarin: Although warfarin is used for long-term anticoagulation, it requires careful monitoring (INR), has multiple drug interactions, and is not preferred in the acute phase of PE, especially in cancer patients.</li><li>\u2022 Option B. Warfarin:</li><li>\u2022 Option C. Bivalirudin: A direct thrombin inhibitor used in cases of heparin-induced thrombocytopenia (HIT) . It is not the first choice for managing PE unless there is a contraindication to heparin.</li><li>\u2022 Option C. Bivalirudin:</li><li>\u2022 heparin-induced thrombocytopenia (HIT)</li><li>\u2022 Option D. Alteplase: Alteplase is a systemic thrombolytic used in high-risk (massive) PE patients with hemodynamic instability, but this patient\u2019s clinical status suggests intermediate-low risk PE, for which thrombolysis is not routinely indicated.</li><li>\u2022 Option D. Alteplase:</li><li>\u2022 Alteplase</li><li>\u2022 systemic thrombolytic</li><li>\u2022 high-risk (massive) PE</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In intermediate-low risk pulmonary embolism , especially in patients with malignancy, LMWH is the most appropriate in-hospital treatment for managing PE, as it is effective, safe, and does not require stringent monitoring like warfarin. Thrombolytic therapy (alteplase) is typically reserved for high-risk PE patients with hemodynamic instability.</li><li>\u27a4 intermediate-low risk pulmonary embolism</li><li>\u27a4 LMWH</li><li>\u27a4 high-risk PE</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ce6fcf04",
      "audio": ""
    },
    {
      "text": "A 50-year-old man with a family history of colorectal cancer presents with palpitations and syncope. On arrival, an ECG is performed, and the results are suggestive of right ventricular (RV) strain. Which of the following statements about the ECG findings in pulmonary embolism (PE) is not true?",
      "options": [
        {
          "label": "A",
          "text": "Sinus tachycardia is the most common finding",
          "correct": false
        },
        {
          "label": "B",
          "text": "S1Q3T3 is pathognomonic of pulmonary embolism",
          "correct": true
        },
        {
          "label": "C",
          "text": "T-wave inversion in septal and inferior leads suggests PE",
          "correct": false
        },
        {
          "label": "D",
          "text": "The above ECG shows RV strain",
          "correct": false
        }
      ],
      "correct_answer": "B. S1Q3T3 is pathognomonic of pulmonary embolism",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-25%20184504.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) S1Q3T3 is pathognomonic of pulmonary embolism</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 S1Q3T3 , which refers to an S wave in lead I , Q wave in lead III , and T wave inversion in lead III , is commonly considered a suggestive sign of pulmonary embolism (PE), but it is not pathognomonic . This pattern can also occur in other conditions that cause acute right ventricular strain , such as acute asthma , COPD exacerbation , or cor pulmonale . Therefore, while it is a classic ECG finding , it is not exclusive to PE.</li><li>\u2022 S1Q3T3</li><li>\u2022 S wave in lead I</li><li>\u2022 Q wave in lead III</li><li>\u2022 T wave inversion in lead III</li><li>\u2022 suggestive sign</li><li>\u2022 pulmonary embolism</li><li>\u2022 not pathognomonic</li><li>\u2022 acute right ventricular strain</li><li>\u2022 acute asthma</li><li>\u2022 COPD exacerbation</li><li>\u2022 cor pulmonale</li><li>\u2022 classic ECG finding</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Sinus tachycardia is the most common finding: Sinus tachycardia is indeed the most common and early ECG finding in patients with PE, occurring due to the body's response to hypoxia and decreased cardiac output.</li><li>\u2022 Option A. Sinus tachycardia is the most common finding:</li><li>\u2022 Sinus tachycardia</li><li>\u2022 Option C. T-wave inversion in septal and inferior leads suggests PE: T-wave inversion in the septal (V1-V2) and inferior leads (II, III, aVF) can be seen in PE due to right ventricular strain.</li><li>\u2022 Option C. T-wave inversion in septal and inferior leads suggests PE:</li><li>\u2022 T-wave inversion</li><li>\u2022 septal</li><li>\u2022 inferior leads</li><li>\u2022 Option D. The above ECG shows RV strain: This is a typical finding in PE. Right ventricular strain can be seen on ECG as right axis deviation , T-wave inversion , and ST-segment changes in the right precordial leads (V1-V3), suggesting RV overload.</li><li>\u2022 Option D. The above ECG shows RV strain:</li><li>\u2022 Right ventricular strain</li><li>\u2022 right axis deviation</li><li>\u2022 T-wave inversion</li><li>\u2022 ST-segment changes</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While S1Q3T3 is a classic ECG finding in PE , it is not pathognomonic , as it can also occur in other conditions that cause acute right heart strain. Sinus tachycardia , T-wave inversions , and right ventricular strain are more reliable signs of pulmonary embolism .</li><li>\u27a4 S1Q3T3</li><li>\u27a4 ECG finding in PE</li><li>\u27a4 pathognomonic</li><li>\u27a4 Sinus tachycardia</li><li>\u27a4 T-wave inversions</li><li>\u27a4 right ventricular strain</li><li>\u27a4 pulmonary embolism</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9bd00ae3",
      "audio": ""
    },
    {
      "text": "A patient undergoes right heart catheterization to evaluate for pulmonary hypertension. What is the cutoff for diagnosing pulmonary hypertension based on the mean pulmonary artery pressure (mPAP) measurement?",
      "options": [
        {
          "label": "A",
          "text": ">20 mmHg",
          "correct": true
        },
        {
          "label": "B",
          "text": ">25 mmHg",
          "correct": false
        },
        {
          "label": "C",
          "text": ">35 mmHg",
          "correct": false
        },
        {
          "label": "D",
          "text": ">30 mmHg",
          "correct": false
        }
      ],
      "correct_answer": "A. >20 mmHg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) >20 mmHg</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure (mPAP) greater than 20 mmHg . This is the threshold used to diagnose PH based on right heart catheterization, as per ESC guidelines on pulmonary hypertension (2022). An mPAP above this threshold indicates the presence of pulmonary hypertension, regardless of the underlying cause.</li><li>\u2022 Pulmonary hypertension (PH)</li><li>\u2022 mean pulmonary artery pressure (mPAP)</li><li>\u2022 20 mmHg</li><li>\u2022 ESC guidelines on pulmonary hypertension</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. >25 mmHg: An mPAP of >25 mmHg is used in old definitions of PH but it has been revised in 2018 (WHO).</li><li>\u2022 Option B. >25 mmHg:</li><li>\u2022 >25 mmHg</li><li>\u2022 Option C. >35 mmHg: This is the cut off for diagnosing PH via echocardiogram using RVSP (RV systolic pressure).</li><li>\u2022 Option C. >35 mmHg:</li><li>\u2022 Option D. >30 mmHg: Incorrect since the cut off for diagnosing PH is 20mm Hg.</li><li>\u2022 Option D. >30 mmHg:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pulmonary hypertension is diagnosed when the mean pulmonary artery pressure (mPAP) exceeds 20 mmHg during right heart catheterization, which is the diagnostic gold standard for assessing pulmonary vascular resistance and pressures.</li><li>\u27a4 Pulmonary hypertension</li><li>\u27a4 mean pulmonary artery pressure (mPAP)</li><li>\u27a4 20 mmHg</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "196daab5",
      "audio": ""
    },
    {
      "text": "A 36-year-old woman with pulmonary hypertension undergoes right heart catheterization and is found to have a positive vasoreactivity test. Which of the following drugs are recommended in the management of this patient?",
      "options": [
        {
          "label": "A",
          "text": "Nifedipine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Ambrisentan",
          "correct": false
        },
        {
          "label": "C",
          "text": "Epoprostenol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Iloprost",
          "correct": false
        }
      ],
      "correct_answer": "A. Nifedipine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Nifedipine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Vasoreactivity testing during right heart catheterization involves the administration of inhaled nitric oxide or adenosine to assess the pulmonary artery pressure (PAP) response. A positive vasoreactivity test is defined as a >10 mmHg decrease in mean pulmonary artery pressure (mPAP) leading to a final mPAP <40 mmHg. In patients who show a positive response, the treatment of choice is high-dose long-acting calcium channel blockers (CCBs) , such as nifedipine , diltiazem , or amlodipine . These drugs are indicated for Class II pulmonary hypertension with a positive vasoreactivity test, as they help to improve pulmonary vasodilation and reduce pulmonary pressures.</li><li>\u2022 Vasoreactivity testing</li><li>\u2022 nitric oxide</li><li>\u2022 adenosine</li><li>\u2022 >10 mmHg decrease</li><li>\u2022 high-dose long-acting calcium channel blockers (CCBs)</li><li>\u2022 nifedipine</li><li>\u2022 diltiazem</li><li>\u2022 amlodipine</li><li>\u2022 Class II pulmonary hypertension</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Ambrisentan: This is an endothelin receptor antagonist (ERA) used for pulmonary arterial hypertension (PAH) , but it is not typically indicated in patients with positive vasoreactivity testing, as these patients may respond well to calcium channel blockers.</li><li>\u2022 Option B. Ambrisentan:</li><li>\u2022 endothelin receptor antagonist (ERA)</li><li>\u2022 pulmonary arterial hypertension (PAH)</li><li>\u2022 Option C. Epoprostenol: This is a prostacyclin analog used in more advanced or non-vasoreactive cases of pulmonary hypertension, typically when patients do not respond to vasodilators or CCBs.</li><li>\u2022 Option C. Epoprostenol:</li><li>\u2022 prostacyclin analog</li><li>\u2022 Option D. Iloprost: This is another prostacyclin analog used for pulmonary hypertension, typically for more severe forms of PAH, and is not indicated for patients with a positive vasoreactivity test who can benefit from CCBs.</li><li>\u2022 Option D. Iloprost:</li><li>\u2022 prostacyclin analog</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with Class II pulmonary hypertension who demonstrate a positive vasoreactivity test , high-dose long-acting calcium channel blockers such as nifedipine are recommended, as they can help reduce pulmonary artery pressures and improve symptoms.</li><li>\u27a4 Class II pulmonary hypertension</li><li>\u27a4 positive vasoreactivity test</li><li>\u27a4 high-dose long-acting calcium channel blockers</li><li>\u27a4 nifedipine</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6161093d",
      "audio": ""
    },
    {
      "text": "A 50-year-old woman presents with sudden onset chest pain and syncope. An ECG shows sinus tachycardia, and a CT pulmonary angiogram (CTPA) confirms the diagnosis of pulmonary embolism. A chest radiograph is provided. What is the sign seen on this chest X-ray?",
      "options": [
        {
          "label": "A",
          "text": "Hampton's Hump",
          "correct": false
        },
        {
          "label": "B",
          "text": "Palla sign",
          "correct": true
        },
        {
          "label": "C",
          "text": "Westermark sign",
          "correct": false
        },
        {
          "label": "D",
          "text": "Split pleura sign",
          "correct": false
        }
      ],
      "correct_answer": "B. Palla sign",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20154444.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Palla sign</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Palla sign refers to the enlargement of the right descending pulmonary artery , which is sometimes seen in the chest radiograph of patients with pulmonary embolism (PE). This enlargement can mimic a right hilar mass and is often a result of right heart strain or pulmonary artery dilation due to the obstructed pulmonary circulation. Palla sign is an important indicator on chest X-ray when PE is suspected.</li><li>\u2022 Palla sign</li><li>\u2022 enlargement of the right descending pulmonary artery</li><li>\u2022 right heart strain</li><li>\u2022 pulmonary artery dilation</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Hampton's Hump: A wedge-shaped opacity at the lung periphery often seen on X-ray in pulmonary embolism . It represents infarction caused by PE but does not involve the right pulmonary artery.</li><li>\u2022 Option A. Hampton's Hump:</li><li>\u2022 wedge-shaped opacity</li><li>\u2022 pulmonary embolism</li><li>\u2022 Option C. Westermark sign: Refers to a loss of vascular markings or hypoperfusion seen distal to a pulmonary embolism. It suggests a localized area of reduced blood flow but is not directly related to pulmonary artery enlargement.</li><li>\u2022 Option C. Westermark sign:</li><li>\u2022 loss of vascular markings</li><li>\u2022 hypoperfusion</li><li>\u2022 Option D. Split pleura sign: Seen in cases of pleural effusion , particularly in conditions like empyema , and is not a sign associated with pulmonary embolism.</li><li>\u2022 Option D. Split pleura sign:</li><li>\u2022 pleural effusion</li><li>\u2022 empyema</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Palla sign , the enlargement of the right descending pulmonary artery , is a key finding in the chest X-ray of patients with pulmonary embolism , indicating right heart strain and pulmonary artery dilation . It can mimic a mass at the right hilum, helping to support the diagnosis of PE.</li><li>\u27a4 Palla sign</li><li>\u27a4 enlargement of the right descending pulmonary artery</li><li>\u27a4 chest X-ray of patients with pulmonary embolism</li><li>\u27a4 right heart strain</li><li>\u27a4 pulmonary artery dilation</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7d3be93c",
      "audio": ""
    },
    {
      "text": "A 60-year-old man with a history of COPD is admitted to the hospital with worsening shortness of breath and is placed on high-flow nasal oxygen (HFNO) for acute hypoxemic respiratory failure. His vitals and parameters are as follows: Respiratory rate: 28 breaths/min SpO\u2082: 92% FiO\u2082: 0.5 What is the calculated ROX index for this patient, and what does it indicate about the likelihood of HFNO success?",
      "options": [
        {
          "label": "A",
          "text": "4.6; low likelihood of HFNO success",
          "correct": true
        },
        {
          "label": "B",
          "text": "7.2; high likelihood of HFNO success",
          "correct": false
        },
        {
          "label": "C",
          "text": "3.8; moderate likelihood of HFNO success",
          "correct": false
        },
        {
          "label": "D",
          "text": "6.5; high likelihood of HFNO success",
          "correct": false
        }
      ],
      "correct_answer": "A. 4.6; low likelihood of HFNO success",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 4.6; low likelihood of HFNO success</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The ROX index is calculated using the formula:</li><li>\u2022 ROX index = SpO\u2082 / FiO\u2082</li><li>\u2022 Substituting the given values:</li><li>\u2022 ROX index=92/0.528=18428=4.6</li><li>\u2022 A ROX index <4.88 at 12 hours of HFNO therapy is associated with a high likelihood of requiring intubation, indicating HFNO is less likely to succeed.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. 7.2; high likelihood of HFNO success: This value indicates effective HFNO therapy, which is not consistent with the patient's respiratory rate and SpO\u2082.</li><li>\u2022 Option B.</li><li>\u2022 7.2; high likelihood of HFNO success:</li><li>\u2022 Option C. 3.8; moderate likelihood of HFNO success: A ROX index this low suggests poor HFNO performance but does not match the calculated value.</li><li>\u2022 Option C.</li><li>\u2022 3.8; moderate likelihood of HFNO success:</li><li>\u2022 Option D. 6.5; high likelihood of HFNO success: This value is inconsistent with the given parameters and would suggest better oxygenation and ventilatory control than described.</li><li>\u2022 Option D.</li><li>\u2022 6.5; high likelihood of HFNO success:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The ROX index is a critical tool for assessing HFNO effectiveness in patients with hypoxemic respiratory failure. Values <4.88 suggest a need for close monitoring and consideration of intubation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a397b23e",
      "audio": ""
    },
    {
      "text": "A 65-year-old male with COPD is admitted with worsening fever, fatigue, and shortness of breath. Chest X-ray reveals left lower lobe consolidation. Despite treatment and resolution of the pneumonia, the patient develops worsening dyspnea and elevated pCO2 on attempts to wean from mechanical ventilation. Which of the following tests would be most appropriate in identifying the cause of weaning failure?",
      "options": [
        {
          "label": "A",
          "text": "Muscle Biopsy",
          "correct": false
        },
        {
          "label": "B",
          "text": "ENMG",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hypoxic response test",
          "correct": false
        },
        {
          "label": "D",
          "text": "EtCO2 measurements",
          "correct": false
        }
      ],
      "correct_answer": "B. ENMG",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) ENMG</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient is likely experiencing critical illness-related neuromuscular atrophy (CINMA), which is a common cause of weaning failure in critically ill patients, especially those who have been on prolonged mechanical ventilation. ENMG (electroneuromyography) is an important diagnostic tool in this context as it helps identify neuromuscular dysfunction and distinguishes CINMA from other causes of respiratory failure. CINMA results from prolonged immobility, systemic inflammation, and the effects of mechanical ventilation, leading to muscle weakness and impaired respiratory effort.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Muscle Biopsy: Muscle biopsy, though a diagnostic option for certain neuromuscular disorders, is invasive and generally not the first-line test for diagnosing CINMA. Moreover, muscle biopsy results may be non-specific and are not immediately helpful in the acute setting.</li><li>\u2022 Option A. Muscle Biopsy:</li><li>\u2022 Option C. Hypoxic response test: The hypoxic response test is used to evaluate ventilatory control and is not specific to identifying neuromuscular weakness or CINMA. This test assesses the body's response to low oxygen levels, but it is not suitable for identifying weaning failure due to neuromuscular impairment.</li><li>\u2022 Option C. Hypoxic response test:</li><li>\u2022 Option D. EtCO2 measurements: End-tidal CO2 (EtCO2) measurements are useful for monitoring ventilation during mechanical ventilation and assessing gas exchange. However, EtCO2 alone does not provide specific information regarding the cause of weaning failure, especially when the issue is neuromuscular in nature, such as CINMA.</li><li>\u2022 Option D. EtCO2 measurements:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with weaning failure after mechanical ventilation, ENMG is a crucial diagnostic tool for identifying critical illness-related neuromuscular atrophy (CINMA), which can impair respiratory muscle function and hinder successful weaning from ventilation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0b8e3c05",
      "audio": ""
    },
    {
      "text": "A 50-year-old gentleman presents with dry cough and shortness of breath. Spirometry shows an FEV1/FVC ratio of 0.8 with low DLCO. A contrast-enhanced CT (CECT) of the thorax reveals bilateral hilar lymphadenopathy with peribronchial infiltrates in the upper lobes. A small pericardial effusion and mild ascites are noted. Bronchoalveolar lavage (BAL) reveals lymphocytosis with no AFB, CBNAAT, and sterile cultures. Transbronchial needle aspiration from a lymph node shows multiple well-formed non-caseating granulomas. What is the next appropriate investigation for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Liver biopsy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Transbronchial lung biopsy",
          "correct": false
        },
        {
          "label": "C",
          "text": "6-minute walking test",
          "correct": false
        },
        {
          "label": "D",
          "text": "Echocardiography",
          "correct": true
        }
      ],
      "correct_answer": "D. Echocardiography",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Echocardiography</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient's presentation with dry cough, shortness of breath, bilateral hilar lymphadenopathy, peribronchial lung infiltrates, and non-caseating granulomas strongly suggests pulmonary sarcoidosis. The presence of pericardial effusion and ascites raises concern for elevated right-sided heart pressures or cardiac involvement, which are common complications of sarcoidosis. The next appropriate step is to perform echocardiography to assess pulmonary pressures, right ventricular function, and potential cardiac involvement, which can be seen in sarcoidosis.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Liver biopsy: There is no indication for a liver biopsy in this patient, as there is no clinical or radiologic evidence of liver involvement. The primary focus here is on assessing the cardiac status due to the pericardial effusion and ascites.</li><li>\u2022 Option A. Liver biopsy:</li><li>\u2022 Option B. Transbronchial lung biopsy: The diagnosis of sarcoidosis has already been established with the transbronchial needle aspiration revealing non-caseating granulomas. A transbronchial lung biopsy is not required in this patient as the diagnosis is confirmed.</li><li>\u2022 Option B. Transbronchial lung biopsy:</li><li>\u2022 Option C. 6-minute walking test: The 6-minute walking test is used to assess functional capacity in patients with pulmonary diseases but does not provide diagnostic information. It would not help in determining the underlying cause of the pericardial effusion or ascites in this case.</li><li>\u2022 Option C. 6-minute walking test:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In a patient with confirmed sarcoidosis and signs of possible cardiac involvement (e.g., pericardial effusion, ascites), the next step should be echocardiography to evaluate for cardiac involvement, particularly elevated pulmonary or filling pressures.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ad1d0fd5",
      "audio": ""
    },
    {
      "text": "A 55-year-old male presents with a 6-month history of increasing shortness of breath, persistent dry cough, and fatigue. He has a long history of smoking, smoking a pack per day for 30 years, but he quit 5 years ago. On physical examination, he has mild crackles on auscultation of both lungs, and his oxygen saturation is 91% on room air. High-resolution CT (HRCT) reveals ground-glass opacities with centrilobular nodules prominently in upper lobes. Pulmonary function tests show a mild restrictive pattern with a reduced DLCO. Based on the clinical presentation and imaging findings, which of the following conditions is most likely in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Respiratory bronchiolitis-associated ILD",
          "correct": true
        },
        {
          "label": "B",
          "text": "Desquamative interstitial pneumonia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Langerhans cell histiocytosis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Usual interstitial pneumonia",
          "correct": false
        }
      ],
      "correct_answer": "A. Respiratory bronchiolitis-associated ILD",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Respiratory bronchiolitis-associated ILD</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient's presentation, including a history of smoking, progressive dyspnea, dry cough, and findings on HRCT such as ground-glass opacities with centrilobular nodules, in upper zones, is most consistent with respiratory bronchiolitis-associated ILD (RB-ILD). RB-ILD is often seen in smokers and manifests with these characteristic imaging features. The condition is associated with mild restrictive lung disease and a reduced DLCO.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Desquamative interstitial pneumonia (DIP): DIP is also a smoking-related ILD, but it typically presents with more diffuse ground-glass opacities in lower zones on imaging and is characterized by the presence of alveolar macrophages. It generally presents with more prominent symptoms and imaging findings than RB-ILD.</li><li>\u2022 Option B. Desquamative interstitial pneumonia (DIP):</li><li>\u2022 ground-glass opacities</li><li>\u2022 lower zones</li><li>\u2022 Option C. Langerhans cell histiocytosis: Langerhans cell histiocytosis is a smoking-related ILD that typically presents with cystic lesions on imaging, not the centrilobular nodules and ground-glass opacities seen in RB-ILD. It can cause airway inflammation and fibrosis, often seen in smokers.</li><li>\u2022 Option C. Langerhans cell histiocytosis:</li><li>\u2022 Option D. Usual interstitial pneumonia (UIP): UIP is commonly associated with idiopathic pulmonary fibrosis (IPF) and is not specifically related to smoking. The HRCT pattern seen in UIP is distinct, with honeycombing and reticulations, which are not seen in this patient's imaging.</li><li>\u2022 Option D. Usual interstitial pneumonia (UIP):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Respiratory bronchiolitis-associated ILD is a smoking-related interstitial lung disease that presents with ground-glass opacities and centrilobular nodules on imaging. It is important to differentiate it from other smoking-related ILDs, like DIP or Langerhans cell histiocytosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c9bb2cfc",
      "audio": ""
    },
    {
      "text": "A 69-year-old male, with a history of smoking and asbestos exposure between the ages of 30 and 55 years, complains of right-sided chest pain, breathlessness on exertion, and cough. A chest radiograph shows a right pleural effusion associated with nodular pleural thickening. Thoracentesis reveals a bloody-colored pleural effusion. Which of the following statements is false for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Thoracoscopy is the preferred diagnostic procedure",
          "correct": false
        },
        {
          "label": "B",
          "text": "Thoracentesis may cause spread of the tumor into the chest wall",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tobacco use has played a significant role in the development of mesothelioma",
          "correct": true
        },
        {
          "label": "D",
          "text": "Calretinin and Wilms tumor antigen-1 are two immunohistochemical markers with diagnostic value for mesothelioma",
          "correct": false
        }
      ],
      "correct_answer": "C. Tobacco use has played a significant role in the development of mesothelioma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Tobacco use has played a significant role in the development of mesothelioma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Mesothelioma is primarily associated with asbestos exposure, not tobacco use. This malignancy typically develops 20-25 years after asbestos exposure, which aligns with the patient\u2019s history. Tobacco use is not carcinogenic to the pleura, and therefore does not significantly contribute to the development of mesothelioma.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Thoracoscopy is the preferred diagnostic procedure: This is correct. Thoracoscopy is preferred for the diagnosis of mesothelioma, as it allows direct visualization of the pleura and provides tissue for histopathological examination. It is especially helpful for obtaining a definitive diagnosis when cytology from thoracentesis is suspicious but not conclusive.</li><li>\u2022 Option A. Thoracoscopy is the preferred diagnostic procedure:</li><li>\u2022 Option B. Thoracentesis may cause spread of the tumor into the chest wall: This is true. Although rare, thoracentesis can result in the spread of malignant cells from the pleura into the chest wall, particularly in cases of pleural malignancy such as mesothelioma.</li><li>\u2022 Option B. Thoracentesis may cause spread of the tumor into the chest wall:</li><li>\u2022 Option D. Calretinin and Wilms tumor antigen-1 are two immunohistochemical markers with diagnostic value for mesothelioma: This is correct. Calretinin and Wilms tumor antigen-1 (WT-1) are commonly used immunohistochemical markers that help in the diagnosis of mesothelioma. They help distinguish mesothelioma from other tumors, such as lung adenocarcinoma.</li><li>\u2022 Option D. Calretinin and Wilms tumor antigen-1 are two immunohistochemical markers with diagnostic value for mesothelioma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Mesothelioma is strongly linked to asbestos exposure and typically develops many years after exposure. Tobacco use does not contribute significantly to the development of mesothelioma, which distinguishes it from other lung cancers like small-cell or squamous cell carcinoma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5b7acfd9",
      "audio": ""
    },
    {
      "text": "Which of the following is not used in the management of asthma?",
      "options": [
        {
          "label": "A",
          "text": "Salbutamol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Roflumilast",
          "correct": true
        },
        {
          "label": "C",
          "text": "Benralizumab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dupilumab",
          "correct": false
        }
      ],
      "correct_answer": "B. Roflumilast",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Roflumilast</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Roflumilast is not used in asthma management. It is primarily indicated for the treatment of chronic obstructive pulmonary disease (COPD), particularly in stage E (severe) COPD where patients have poor response to maximum bronchodilator and steroid therapy. It is a phosphodiesterase-4 (PDE-4) inhibitor that helps reduce inflammation and exacerbations in COPD, but it does not have a role in asthma treatment.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Salbutamol: Salbutamol is a short-acting beta-agonist (SABA) commonly used as a rescue inhaler in asthma for quick relief of bronchospasm. It is part of the standard management for asthma, especially during exacerbations.</li><li>\u2022 Option A. Salbutamol:</li><li>\u2022 Option C. Benralizumab: Benralizumab is a monoclonal antibody used in the treatment of severe eosinophilic asthma. It is an IL-5 receptor antagonist that reduces eosinophil levels, helping in the management of asthma that is not controlled by standard therapy.</li><li>\u2022 Option C. Benralizumab:</li><li>\u2022 Option D. Dupilumab: Dupilumab is another monoclonal antibody used in the treatment of severe asthma, specifically in patients with eosinophilic asthma or those with a history of allergic asthma. It is an IL-4 receptor antagonist that helps reduce inflammation by blocking both IL-4 and IL-13 signaling.</li><li>\u2022 Option D. Dupilumab:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Roflumilast is used in COPD management, not asthma. In contrast, biologicals like benralizumab and dupilumab are used for severe eosinophilic asthma, while salbutamol is a standard rescue medication for asthma exacerbations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6a73910a",
      "audio": ""
    },
    {
      "text": "A 69-year-old man with chronic obstructive pulmonary disease (COPD) has been admitted to the hospital three times over the last year for COPD exacerbations. His current SpO2 is 91% on room air. Pulmonary function tests (PFT) show an FEV1 of 45% predicted. Which of the following treatments is most likely to decrease the frequency of his exacerbations?",
      "options": [
        {
          "label": "A",
          "text": "Daily azithromycin 500 mg",
          "correct": true
        },
        {
          "label": "B",
          "text": "Continuous oxygen at 2 L/min",
          "correct": false
        },
        {
          "label": "C",
          "text": "Nocturnal BiPAP machine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Corticosteroids",
          "correct": false
        }
      ],
      "correct_answer": "A. Daily azithromycin 500 mg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Daily azithromycin 500 mg</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Long-term use of azithromycin (500 mg daily) has been shown to reduce the frequency of COPD exacerbations, particularly in patients with frequent exacerbations. Azithromycin has anti-inflammatory properties and inhibits quorum sensing, which can reduce bacterial load and inflammation in the airways, leading to fewer exacerbations. This treatment is especially useful in patients with moderate to severe COPD and frequent exacerbations.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Continuous oxygen at 2 L/min: While continuous oxygen therapy is essential for COPD patients with chronic hypoxemia, it does not reduce the frequency of exacerbations. Oxygen therapy is primarily used to improve oxygenation and reduce the risk of complications in patients with chronic respiratory failure. The target saturation is typically 88-92% during exacerbations.</li><li>\u2022 Option B. Continuous oxygen at 2 L/min:</li><li>\u2022 Option C. Nocturnal BiPAP machine: Nocturnal BiPAP (Bilevel Positive Airway Pressure) is indicated for patients with worsening chronic type 2 respiratory failure and respiratory acidosis, usually in severe COPD cases with nocturnal hypoventilation. It is not typically used to reduce the frequency of exacerbations but rather to support ventilation in patients with respiratory acidosis or sleep-disordered breathing.</li><li>\u2022 Option C. Nocturnal BiPAP machine:</li><li>\u2022 Option D. Corticosteroids: While systemic steroids are often used during acute exacerbations of COPD to reduce inflammation and improve recovery, they are not used for long-term prevention of exacerbations. Long-term steroid use has potential side effects and is generally not recommended for reducing exacerbation frequency in COPD patients.</li><li>\u2022 Option D. Corticosteroids:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Long-term treatment with azithromycin can reduce the frequency of COPD exacerbations due to its anti-inflammatory effects and inhibition of bacterial growth. Oxygen therapy and BiPAP are important for managing respiratory failure but do not reduce the frequency of exacerbations, while IV steroids are used for acute exacerbations but not for prevention.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f5817366",
      "audio": ""
    },
    {
      "text": "A 20-year-old male with a history of episodic wheezing, chest tightness, and persistent symptoms despite high-dose inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA), long-acting beta agonists (LABA), oral steroids, and montelukast, presents with worsening dyspnea on exertion (DOE) and wheeze. Common secondary causes, including CXR, skin precipitins, and food triggers, have been ruled out. Phenotyping shows elevated IgE and FeNO levels (50 ppb). Which of the following is true about his condition?",
      "options": [
        {
          "label": "A",
          "text": "Good response to anti-IgE therapy",
          "correct": true
        },
        {
          "label": "B",
          "text": "Poor response to Biologicals",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bronchial thermoplasty is an effective option",
          "correct": false
        },
        {
          "label": "D",
          "text": "Biologicals after treatment optimization",
          "correct": false
        }
      ],
      "correct_answer": "A. Good response to anti-IgE therapy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Good response to anti-IgE therapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient likely has severe asthma, given his persistent symptoms despite step 5 GINA treatment (which includes high-dose ICS, LAMA, LABA, and oral steroids). Severe asthma in this case is characterized by type 2 inflammation, as indicated by elevated FeNO and IgE levels. Anti-IgE therapy, such as omalizumab, targets IgE, which plays a key role in allergic inflammation, and is highly effective in patients with elevated IgE levels, providing a good treatment option for this patient.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Poor response to Biologicals: This patient is more likely to respond well to biologicals because of his elevated IgE and FeNO levels, which indicate a type 2 inflammation-driven asthma. Biologicals, especially anti-IgE (like omalizumab), are highly effective in treating this type of asthma, contrary to the suggestion of poor response.</li><li>\u2022 Option B. Poor response to Biologicals:</li><li>\u2022 Option C. Bronchial thermoplasty is an effective option: Bronchial thermoplasty is a treatment option for severe asthma, but it is generally considered when asthma is not well controlled despite optimal pharmacological therapy, and there is no significant type 2 inflammation (e.g., elevated IgE or FeNO). This patient shows evidence of type 2 inflammation, so biological therapy targeting the inflammatory pathway is preferred over bronchial thermoplasty.</li><li>\u2022 Option C. Bronchial thermoplasty is an effective option:</li><li>\u2022 Option D. Biologicals after treatment optimization: While optimizing treatment is important in severe asthma, this patient\u2019s phenotype suggests a strong potential benefit from immediate biological therapy due to the elevated IgE and FeNO levels. Delaying biological therapy after further optimization is not recommended when clear indications are present.</li><li>\u2022 Option D. Biologicals after treatment optimization:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with severe asthma and evidence of type 2 inflammation (elevated IgE and FeNO), anti-IgE therapy (such as omalizumab) is a highly effective treatment option and should be considered early in management.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "15458136",
      "audio": ""
    },
    {
      "text": "A patient underwent an aortic aneurysm repair and developed a rise in creatinine in the 2 nd post-op week, along with a lacy rash on both lower limbs. The most likely pathology is:",
      "options": [
        {
          "label": "A",
          "text": "Contrast-associated acute kidney injury (AKI)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Atheroembolic renal disease",
          "correct": true
        },
        {
          "label": "C",
          "text": "Renal vein thrombosis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thrombotic microangiopathy",
          "correct": false
        }
      ],
      "correct_answer": "B. Atheroembolic renal disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Atheroembolic renal disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Atheroembolic renal disease occurs when cholesterol crystals from atherosclerotic plaques are embolized into small renal arteries, causing ischemia and acute kidney injury (AKI). This condition can develop after procedures such as aortic aneurysm repair, particularly if there is manipulation of the aorta or large arteries. The gradual rise in creatinine over weeks (typically after D4-7) and the presence of a lacy rash (= livedo reticularis, suggesting cutaneous embolization) are characteristic of atheroembolic disease. This condition is typically associated with a slower progression of renal dysfunction compared to other causes of AKI.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Contrast-associated AKI: While contrast-induced nephropathy can cause acute renal injury after the administration of contrast, it typically presents more rapidly, usually within 24-48 hours, following the procedure. It is less likely in this patient given the two-week delay in the rise of creatinine and the associated rash, which points more toward atheroembolic disease.</li><li>\u2022 Option A. Contrast-associated AKI:</li><li>\u2022 Option C. Renal vein thrombosis: Renal vein thrombosis can lead to acute kidney injury, but it typically presents with flank pain, hematuria, and other signs of venous congestion rather than a gradual rise in creatinine. Additionally, the presence of a lacy rash and the timing of this condition following aortic aneurysm repair make renal vein thrombosis less likely.</li><li>\u2022 Option C. Renal vein thrombosis:</li><li>\u2022 Option D. Thrombotic microangiopathy: Thrombotic microangiopathy (TMA) includes conditions like hemolytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), which are associated with microvascular thrombi, hemolysis, and thrombocytopenia. TMA often presents with more acute manifestations, including hemolytic anemia, thrombocytopenia, and organ failure, which are not described in this case. The subacute nature of the renal dysfunction and the rash makes TMA less likely.</li><li>\u2022 Option D. Thrombotic microangiopathy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Atheroembolic renal disease is a common cause of subacute renal dysfunction after procedures like aortic aneurysm repair. The condition is characterized by cholesterol embolization into small renal arteries, leading to progressive renal impairment and systemic signs such as a lacy rash due to cutaneous embolization.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "574f6227",
      "audio": ""
    },
    {
      "text": "A 60-year-old male with end-stage kidney disease (ESKD) has been undergoing hemodialysis for the past 2 years. What is the major cause of death in patients with end-stage kidney disease like this patient?",
      "options": [
        {
          "label": "A",
          "text": "Cerebrovascular disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "Malignancy",
          "correct": false
        },
        {
          "label": "C",
          "text": "Infectious disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cardiovascular disease",
          "correct": true
        }
      ],
      "correct_answer": "D. Cardiovascular disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Cardiovascular disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Cardiovascular disease is the leading cause of death in patients with end-stage kidney disease (ESKD), particularly in those on dialysis. Patients with ESKD have an increased risk of cardiovascular events due to a combination of factors, including hypertension, diabetes, dyslipidemia, and the pro-inflammatory environment created by kidney dysfunction. Cardiovascular mortality and event rates are significantly higher in patients receiving dialysis compared to those who have undergone kidney transplantation, although they remain high in both populations.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Cerebrovascular disease: Cerebrovascular disease, while a common cause of morbidity in ESKD, is not the leading cause of death in these patients. Cardiovascular events such as myocardial infarction and heart failure are more commonly fatal.</li><li>\u2022 Option A. Cerebrovascular disease:</li><li>\u2022 Option B. Malignancy: Malignancy is an important cause of morbidity and mortality in patients with ESKD, especially in those with prolonged dialysis treatment. However, cardiovascular disease still remains the leading cause of death in these patients.</li><li>\u2022 Option B. Malignancy:</li><li>\u2022 Option C. Infectious disease: Infections, particularly related to dialysis access sites and peritoneal dialysis, are common in patients with ESKD. However, infectious diseases are less frequently the primary cause of death compared to cardiovascular events.</li><li>\u2022 Option C. Infectious disease:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Cardiovascular disease is the major cause of death in patients with end-stage kidney disease, highlighting the need for careful management of cardiovascular risk factors in this population.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e26116f4",
      "audio": ""
    },
    {
      "text": "A 50-year-old male undergoing continuous ambulatory peritoneal dialysis (CAPD) for the past 4 months presents with abdominal pain and cloudy effluent for the past 1 day. The CAPD fluid analysis shows a total WBC count of 175 cells/mm\u00b3 with 80% neutrophils. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Fibrin clot",
          "correct": false
        },
        {
          "label": "B",
          "text": "Encapsulating peritoneal sclerosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "CAPD peritonitis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Tunnel infection",
          "correct": false
        }
      ],
      "correct_answer": "C. CAPD peritonitis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) CAPD Peritonitis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient\u2019s presentation of abdominal pain, cloudy effluent, and an elevated WBC count in the peritoneal fluid with a predominance of neutrophils is consistent with CAPD peritonitis. Peritonitis is one of the most common complications of peritoneal dialysis, typically caused by a break in sterile technique during exchanges. Peritonitis is defined by a peritoneal fluid WBC count greater than 100 cells/mm\u00b3, with at least 50% being polymorphonuclear neutrophils. The diagnosis is confirmed by these findings, and it requires prompt treatment with intraperitoneal antibiotics.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Fibrin clot: A fibrin clot in the peritoneal fluid is typically seen in the context of a sterile reaction to dialysis fluid or after an episode of peritoneal dialysis. It does not cause the significant elevation in neutrophils seen in peritonitis. This is not consistent with the patient\u2019s symptoms or lab findings.</li><li>\u2022 Option A. Fibrin clot:</li><li>\u2022 Option B. Encapsulating Peritoneal Sclerosis (EPS): Encapsulating peritoneal sclerosis is a rare but serious complication of long-term peritoneal dialysis, characterized by the progressive fibrosis of the peritoneum, leading to bowel obstruction and fluid retention. However, it does not present with acute pain, cloudy effluent, or an elevated WBC count. EPS typically develops over months or years and would not present acutely with peritonitis symptoms.</li><li>\u2022 Option B. Encapsulating Peritoneal Sclerosis (EPS):</li><li>\u2022 Option D. Tunnel infection: Tunnel infections are localized infections involving the peritoneal dialysis catheter. While they can present with redness and pain along the catheter tract, they do not typically cause abdominal pain and cloudy effluent. The WBC count in the effluent would not be elevated to the same degree as seen in peritonitis, and the neutrophil count would not be as high.</li><li>\u2022 Option D. Tunnel infection:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 CAPD peritonitis is a common complication in peritoneal dialysis, characterized by abdominal pain, cloudy effluent, and an elevated peritoneal fluid WBC count with predominance of neutrophils. Prompt treatment with antibiotics is required to manage this infection.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b126c9ab",
      "audio": ""
    },
    {
      "text": "A 55-year-old male with a history of diabetes mellitus presents for routine follow-up. His estimated glomerular filtration rate (eGFR) is calculated at 37 mL/min according to the CKD-EPI formula. Based on this information, which category of chronic kidney disease (CKD) does he fall into?",
      "options": [
        {
          "label": "A",
          "text": "Stage 3A",
          "correct": false
        },
        {
          "label": "B",
          "text": "Stage 3B",
          "correct": true
        },
        {
          "label": "C",
          "text": "Stage 4",
          "correct": false
        },
        {
          "label": "D",
          "text": "Stage 5",
          "correct": false
        }
      ],
      "correct_answer": "B. Stage 3B",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Stage 3B</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient\u2019s eGFR of 37 mL/min places him in Stage 3B of chronic kidney disease (CKD). Stage 3 is divided into 2 subcategories:</li><li>\u2022 Stage 3A : eGFR between 45-59 mL/min Stage 3B : eGFR between 30-44 mL/min</li><li>\u2022 Stage 3A : eGFR between 45-59 mL/min</li><li>\u2022 Stage 3A</li><li>\u2022 Stage 3B : eGFR between 30-44 mL/min</li><li>\u2022 Stage 3B</li><li>\u2022 Since his eGFR is 37 mL/min, it fits into Stage 3B. At this stage, the patient has a higher risk of progression to end-stage renal disease (ESRD), and close monitoring is required, including management of underlying conditions such as diabetes, hypertension, and proteinuria.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Stage 3A: Stage 3A is characterized by an eGFR between 45-59 mL/min. Since the patient\u2019s eGFR is 37 mL/min, he does not fit into this category.</li><li>\u2022 Option A. Stage 3A:</li><li>\u2022 Option C. Stage 4: Stage 4 CKD is defined by an eGFR between 15-29 mL/min. Since the patient\u2019s eGFR is 37 mL/min, he does not meet the criteria for Stage 4.</li><li>\u2022 Option C. Stage 4:</li><li>\u2022 Option D. Stage 5: Stage 5 CKD, also known as end-stage renal disease (ESRD), occurs when the eGFR is less than 15 mL/min. This patient\u2019s eGFR is 37 mL/min, so he does not qualify for Stage 5.</li><li>\u2022 Option D. Stage 5:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Stage 3B CKD is characterized by an eGFR between 30-44 mL/min, and it carries a higher risk of progression to end-stage renal disease. Close monitoring and management of risk factors are critical at this stage to prevent further deterioration of kidney function.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "383026fa",
      "audio": ""
    },
    {
      "text": "A 55-year-old female with a history of rheumatoid arthritis (RA) presents to the clinic with weakness. Which region of the spine is most commonly affected in rheumatoid arthritis?",
      "options": [
        {
          "label": "A",
          "text": "Cervical spine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Thoracic spine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lumbar spine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sacrum",
          "correct": false
        }
      ],
      "correct_answer": "A. Cervical spine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Cervical spine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The cervical spine is the most commonly affected region in rheumatoid arthritis (RA). Specifically, atlantoaxial involvement, which is the instability of the first cervical vertebra (C1) on the second (C2), is a hallmark of cervical spine involvement in RA. This instability can lead to compressive myelopathy and neurologic dysfunction if it progresses. Although neurological symptoms may not be present at first, they can develop with increasing instability. Unlike the spondyloarthropathies, RA rarely affects the thoracic or lumbar spine significantly.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Thoracic spine: While the thoracic spine can be affected in rheumatoid arthritis, it is less commonly involved than the cervical spine. RA typically affects the smaller joints in the neck and upper cervical spine more than the thoracic region.</li><li>\u2022 Option B. Thoracic spine:</li><li>\u2022 Option C. Lumbar spine: The lumbar spine is rarely involved in rheumatoid arthritis. The lower spine is typically spared in RA, with the main involvement occurring in the peripheral joints and cervical spine.</li><li>\u2022 Option C. Lumbar spine:</li><li>\u2022 Option D. Sacrum: The sacrum is also rarely involved in rheumatoid arthritis. While sacroiliac joint involvement may be seen in spondyloarthropathies, it is not a typical feature of RA.</li><li>\u2022 Option D. Sacrum:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The cervical spine, especially the atlantoaxial joint, is the most common region affected by rheumatoid arthritis. It can lead to significant complications such as compressive myelopathy due to instability between C1 and C2.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7bf35996",
      "audio": ""
    },
    {
      "text": "A 55-year-old female with a long history of rheumatoid arthritis (RA) presents with unexplained neutropenia and splenomegaly. Further investigation reveals clonal expansion of T-cell large granular lymphocytes. Which of the following statements is not true regarding the condition?",
      "options": [
        {
          "label": "A",
          "text": "Develop late in the course of the disease",
          "correct": true
        },
        {
          "label": "B",
          "text": "It has a chronic, indolent course",
          "correct": false
        },
        {
          "label": "C",
          "text": "It leads to neutropenia and splenomegaly",
          "correct": false
        },
        {
          "label": "D",
          "text": "Develop early in the course of the disease",
          "correct": false
        }
      ],
      "correct_answer": "A. Develop late in the course of the disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Develop late in the course of the disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 T-cell large granular lymphocyte leukemia (T-LGL) can occur early in the course of rheumatoid arthritis (RA), unlike other conditions like Felty\u2019s syndrome, which typically develops later in the course of severe RA. T-LGL is characterized by chronic, indolent clonal growth of large granular lymphocytes (LGLs), leading to neutropenia and splenomegaly. This condition often occurs earlier in the disease course compared to Felty's syndrome, which is the main reason option A is incorrect.</li><li>\u2022 early</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. It has a chronic, indolent course: This is true. T-LGL has a chronic and indolent course, meaning it typically progresses slowly and is not immediately life-threatening. However, its long-term effects, including neutropenia and splenomegaly, require careful monitoring.</li><li>\u2022 Option B. It has a chronic, indolent course:</li><li>\u2022 Option C. It leads to neutropenia and splenomegaly: This is also correct. T-LGL is associated with neutropenia, which is a reduction in neutrophils, and splenomegaly, which is an enlargement of the spleen. These symptoms are due to the clonal expansion of large granular lymphocytes and can be seen in the patient\u2019s laboratory findings.</li><li>\u2022 Option C. It leads to neutropenia and splenomegaly:</li><li>\u2022 Option D. Develop early in the course of the disease: This is correct. Unlike Felty\u2019s syndrome, which often develops later in severe RA, T-LGL can develop early in the course of the disease. This is important to distinguish when evaluating a patient with RA and unexplained hematologic findings.</li><li>\u2022 Option D. Develop early in the course of the disease:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 T-cell large granular lymphocyte leukemia (T-LGL) in rheumatoid arthritis may develop early in the disease and is characterized by a chronic, indolent course, with neutropenia and splenomegaly being common features. It differs from Felty\u2019s syndrome, which typically appears later in the course of RA.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9c7830be",
      "audio": ""
    },
    {
      "text": "A 28-year-old male with sickle cell anemia presents to the clinic for evaluation of new therapy options. The patient has frequent episodes of pain, fatigue, and hemolysis. The physician recommends Voxelotor. What of the following regarding the drug is incorrect?",
      "options": [
        {
          "label": "A",
          "text": "Decreases the affinity of the hemoglobin molecule for O2",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreases the P50",
          "correct": false
        },
        {
          "label": "C",
          "text": "Reduces polymerization of HbS",
          "correct": false
        },
        {
          "label": "D",
          "text": "Induces high levels of HbF",
          "correct": true
        }
      ],
      "correct_answer": "D. Induces high levels of HbF",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Induces high levels of HbF</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Induces high levels of HbF : Incorrect. Voxelotor does not induce fetal hemoglobin ( HbF ). This is the mechanism of hydroxyurea , which increases HbF to reduce sickling.</li><li>\u2022 Induces high levels of HbF</li><li>\u2022 Voxelotor</li><li>\u2022 not</li><li>\u2022 HbF</li><li>\u2022 hydroxyurea</li><li>\u2022 Voxelotor is an oral therapy for sickle cell disease (SCD) that improves hemoglobin levels by preventing sickling of red blood cells.</li><li>\u2022 Voxelotor</li><li>\u2022 sickle cell disease (SCD)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Decreases the affinity of the hemoglobin molecule for O\u2082 : Correct. Voxelotor increases hemoglobin\u2019s oxygen affinity, stabilizing the oxygenated form and reducing sickling.</li><li>\u2022 Option A. Decreases the affinity of the hemoglobin molecule for O\u2082</li><li>\u2022 Option B. Decreases the P50 : Correct. By increasing hemoglobin's oxygen affinity, Voxelotor lowers the P50 (the partial pressure of oxygen at which hemoglobin is 50% saturated), making it hold onto oxygen more tightly.</li><li>\u2022 Option B. Decreases the P50</li><li>\u2022 P50</li><li>\u2022 Option C. Reduces polymerization of HbS : Correct. The key therapeutic effect of Voxelotor is inhibiting HbS polymerization , which prevents sickling and hemolysis.</li><li>\u2022 Option C. Reduces polymerization of HbS</li><li>\u2022 HbS polymerization</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Voxelotor works by increasing hemoglobin\u2019s oxygen affinity, thereby reducing HbS polymerization and improving hemoglobin levels. It does not induce HbF \u2014 a mechanism specific to hydroxyurea in sickle cell disease management.</li><li>\u27a4 Voxelotor</li><li>\u27a4 reducing HbS polymerization</li><li>\u27a4 not</li><li>\u27a4 HbF</li><li>\u27a4 hydroxyurea</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2d075279",
      "audio": ""
    },
    {
      "text": "A 45-year-old female with a recent history of starting hydralazine for hypertension presents with new-onset fatigue, joint pain, and a butterfly-shaped rash across her cheeks. Laboratory tests reveal a positive antinuclear antibody (ANA) test with a speckled pattern. What is the most likely to be positive this patient?",
      "options": [
        {
          "label": "A",
          "text": "Anti-histone",
          "correct": true
        },
        {
          "label": "B",
          "text": "Anti ds-DNA",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti Sm",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anti Ro",
          "correct": false
        }
      ],
      "correct_answer": "A. Anti-histone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Anti-histone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient most likely has drug-induced lupus (DIL), which is commonly associated with the presence of anti-histone antibodies . Drug-induced lupus is characterized by a clinical presentation similar to systemic lupus erythematosus (SLE), but it occurs after exposure to certain drugs like hydralazine, procainamide, and isoniazid. The hallmark of drug-induced lupus is the presence of anti-histone antibodies , which are typically not seen in classic SLE.</li><li>\u2022 drug-induced lupus</li><li>\u2022 anti-histone antibodies</li><li>\u2022 anti-histone antibodies</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Anti ds-DNA: Anti-dsDNA antibodies are highly specific for systemic lupus erythematosus (SLE) and are seen in about 50% of SLE cases, particularly in patients with kidney involvement. These antibodies are not characteristic of drug-induced lupus.</li><li>\u2022 Option B. Anti ds-DNA:</li><li>\u2022 Option C. Anti Sm: Anti-Sm antibodies are specific for SLE and are found in about 30% of patients with the disease. They are not typically associated with drug-induced lupus.</li><li>\u2022 Option C. Anti Sm:</li><li>\u2022 Option D. Anti Ro: Anti-Ro antibodies are associated with autoimmune diseases such as Sj\u00f6gren\u2019s syndrome, subacute cutaneous lupus erythematosus (SCLE), and neonatal lupus, but not with drug-induced lupus.</li><li>\u2022 Option D. Anti Ro:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anti-histone antibodies are commonly positive in drug-induced lupus, especially when the patient has a history of taking medications like hydralazine. These antibodies help distinguish drug-induced lupus from other autoimmune diseases, such as SLE, which is more commonly associated with anti-dsDNA and anti-Sm antibodies.</li><li>\u27a4 Anti-histone antibodies</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f5d4632b",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman with systemic lupus erythematosus (SLE) is pregnant and has a history of a previous miscarriage. Her obstetrician orders tests to screen for neonatal lupus in the fetus. Which of the following antibodies is most commonly associated with it?",
      "options": [
        {
          "label": "A",
          "text": "Anti RNA polymerase I",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti Kinetochore",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti Scl-70",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anti Ro",
          "correct": true
        }
      ],
      "correct_answer": "D. Anti Ro",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Anti Ro</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Anti-Ro (also known as SS-A ) antibodies are most commonly associated with neonatal lupus . Neonatal lupus can result in a variety of manifestations in the newborn, including congenital heart block and a characteristic rash. The presence of anti-Ro antibodies in the mother can pass to the fetus and cause these complications. This is one of the key antibodies to be monitored during pregnancy in women with systemic lupus erythematosus (SLE) or Sj\u00f6gren\u2019s syndrome.</li><li>\u2022 Anti-Ro</li><li>\u2022 SS-A</li><li>\u2022 neonatal lupus</li><li>\u2022 anti-Ro antibodies</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Anti RNA polymerase I: Anti-RNA polymerase I antibodies are associated with nucleolar ANA patterns and are seen in systemic sclerosis, particularly in patients with limited scleroderma (PSS). These antibodies are not typically linked to neonatal lupus.</li><li>\u2022 Option A. Anti RNA polymerase I:</li><li>\u2022 nucleolar ANA patterns</li><li>\u2022 Option B. Anti Kinetochore: Anti-Kinetochore antibodies are associated with a centromere ANA pattern and are seen in CREST syndrome (limited scleroderma). They are not related to neonatal lupus.</li><li>\u2022 Option B. Anti Kinetochore:</li><li>\u2022 centromere ANA pattern</li><li>\u2022 CREST syndrome</li><li>\u2022 Option C. Anti Scl-70: Anti-Scl-70 antibodies are associated with diffuse systemic sclerosis and are typically linked to fibrosis of the skin and internal organs, such as the lungs. These antibodies are not associated with neonatal lupus.</li><li>\u2022 Option C. Anti Scl-70:</li><li>\u2022 diffuse systemic sclerosis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anti-Ro (SS-A) antibodies are associated with neonatal lupus and can lead to severe complications in the fetus, such as congenital heart block and skin rashes. Monitoring these antibodies is important in pregnant women with autoimmune diseases like lupus or Sj\u00f6gren's syndrome.</li><li>\u27a4 Anti-Ro (SS-A)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ed5797f7",
      "audio": ""
    },
    {
      "text": "A 30-year-old male with a history of chronic low back pain and morning stiffness is diagnosed with ankylosing spondylitis. Which of the following is the most common extraarticular manifestation?",
      "options": [
        {
          "label": "A",
          "text": "Heart block",
          "correct": false
        },
        {
          "label": "B",
          "text": "Inflammatory bowel disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anterior uveitis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Aortic regurgitation",
          "correct": false
        }
      ],
      "correct_answer": "C. Anterior uveitis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Anterior uveitis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The most common extraarticular manifestation of ankylosing spondylitis is acute anterior uveitis , which affects up to 50% of patients with this condition. Anterior uveitis typically presents with symptoms such as eye pain, photophobia, and redness. The attacks are often unilateral and may recur, sometimes involving the opposite eye. If left untreated, it can lead to cataracts or secondary glaucoma.</li><li>\u2022 acute anterior uveitis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Heart block: While heart block can occur in ankylosing spondylitis, it is a much less common extraarticular manifestation. Heart block is usually seen in advanced disease, particularly in those with aortic root involvement, but it is not as frequent as anterior uveitis.</li><li>\u2022 Option A. Heart block:</li><li>\u2022 Option B. Inflammatory bowel disease: Inflammatory bowel disease (IBD) is an extraarticular manifestation of ankylosing spondylitis, but it is less common than anterior uveitis. When it does occur, it is typically seen in the form of Crohn's disease or ulcerative colitis.</li><li>\u2022 Option B. Inflammatory bowel disease:</li><li>\u2022 Option D. Aortic regurgitation: Aortic regurgitation can occur in ankylosing spondylitis due to aortitis, but it is a rare manifestation. It is more commonly associated with long-standing disease and can contribute to heart failure if severe.</li><li>\u2022 Option D. Aortic regurgitation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anterior uveitis is the most common extraarticular manifestation of ankylosing spondylitis, occurring in up to 50% of patients. It is important for clinicians to monitor for uveitis in these patients, as untreated cases can lead to complications like cataracts and glaucoma.</li><li>\u27a4 Anterior uveitis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9dddf5c9",
      "audio": ""
    },
    {
      "text": "A 30-year-old male presents with pain, swelling, and redness in his knee and ankle joints, which developed after an episode of gastroenteritis. Laboratory tests reveal the presence of reactive arthritis. He tests negative for HLA-B27. Which of the following infections is most likely?",
      "options": [
        {
          "label": "A",
          "text": "Shigella",
          "correct": false
        },
        {
          "label": "B",
          "text": "Yersinia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Campylobacter",
          "correct": true
        },
        {
          "label": "D",
          "text": "Salmonella",
          "correct": false
        }
      ],
      "correct_answer": "C. Campylobacter",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Campylobacter</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 While Shigella , Yersinia , and Salmonella infections are more commonly associated with HLA-B27 positivity in reactive arthritis, Campylobacter-induced reactive arthritis shows little or no association with HLA-B27. Campylobacter is one of the common bacterial triggers of reactive arthritis, but it does not exhibit the same strong HLA-B27 association seen with other pathogens like Shigella and Yersinia.</li><li>\u2022 Shigella</li><li>\u2022 Yersinia</li><li>\u2022 Salmonella</li><li>\u2022 Campylobacter-induced reactive arthritis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Shigella: Shigella is one of the pathogens most commonly associated with reactive arthritis, and about 60-85% of patients who develop ReA triggered by Shigella are HLA-B27 positive. This makes Shigella a strong candidate for HLA-B27-associated reactive arthritis.</li><li>\u2022 Option A. Shigella:</li><li>\u2022 Option B. Yersinia: Yersinia, particularly Yersinia enterocolitica , is also frequently associated with reactive arthritis, and like Shigella, a significant proportion of patients with Yersinia-triggered ReA are HLA-B27 positive.</li><li>\u2022 Option B. Yersinia:</li><li>\u2022 Yersinia enterocolitica</li><li>\u2022 Option D. Salmonella: Salmonella infection, particularly Salmonella enteritidis , is another common trigger for reactive arthritis. Although the prevalence of HLA-B27 in Salmonella-associated ReA is lower compared to Shigella or Yersinia, Salmonella still has some association with HLA-B27 in ReA cases.</li><li>\u2022 Option D. Salmonella:</li><li>\u2022 Salmonella enteritidis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While Shigella , Yersinia , and Salmonella infections have a significant association with HLA-B27 in reactive arthritis, Campylobacter infection shows little or no such association.</li><li>\u27a4 Shigella</li><li>\u27a4 Yersinia</li><li>\u27a4 Salmonella</li><li>\u27a4 Campylobacter</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ecefa76c",
      "audio": ""
    },
    {
      "text": "A 45-year-old male with psoriatic arthritis and moderate skin involvement is being considered for oral therapy. He has mild joint involvement and no significant radiographic joint damage or axial involvement. Which of the following oral medications is approved for treatment?",
      "options": [
        {
          "label": "A",
          "text": "Tofacitinib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Leflunomide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Apremilast",
          "correct": true
        },
        {
          "label": "D",
          "text": "Secukinumab",
          "correct": false
        }
      ],
      "correct_answer": "C. Apremilast",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Apremilast</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Apremilast is an oral phosphodiesterase-4 (PDE-4) inhibitor approved for the treatment of psoriatic arthritis and psoriasis . Apremilast works by inhibiting the enzyme PDE-4, which plays a role in the inflammatory response. It is an effective treatment option for PsA, particularly in patients without significant radiographic joint damage or axial involvement. While it may not be as potent as biologics for PsA, it is favored for its more favorable safety profile.</li><li>\u2022 Apremilast</li><li>\u2022 psoriatic arthritis</li><li>\u2022 psoriasis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Tofacitinib: Tofacitinib is an oral Janus kinase (JAK) inhibitor that is approved for the treatment of rheumatoid arthritis , psoriatic arthritis , and ulcerative colitis . It is effective for PsA but works through a different mechanism than apremilast (JAK inhibition vs PDE-4 inhibition).</li><li>\u2022 Option A. Tofacitinib:</li><li>\u2022 rheumatoid arthritis</li><li>\u2022 psoriatic arthritis</li><li>\u2022 ulcerative colitis</li><li>\u2022 Option B. Leflunomide: Leflunomide is an immunosuppressive drug that inhibits pyrimidine synthesis and is used for the treatment of rheumatoid arthritis and psoriatic arthritis . However, it is not a phosphodiesterase-4 inhibitor and is not the correct answer for this specific question.</li><li>\u2022 Option B. Leflunomide:</li><li>\u2022 rheumatoid arthritis</li><li>\u2022 psoriatic arthritis</li><li>\u2022 Option D. Secukinumab: Secukinumab is a biologic agent that targets interleukin-17A (IL-17A) and is used in the treatment of psoriatic arthritis , psoriasis , and ankylosing spondylitis . It is not an oral medication, making it an incorrect answer for this question, which specifically asks about an oral phosphodiesterase-4 inhibitor.</li><li>\u2022 Option D. Secukinumab:</li><li>\u2022 interleukin-17A (IL-17A)</li><li>\u2022 psoriatic arthritis</li><li>\u2022 psoriasis</li><li>\u2022 ankylosing spondylitis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Apremilast is the only oral phosphodiesterase-4 inhibitor approved for the treatment of psoriatic arthritis and psoriasis , offering a more favorable safety profile than biologics.</li><li>\u27a4 Apremilast</li><li>\u27a4 psoriatic arthritis</li><li>\u27a4 psoriasis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1be58de3",
      "audio": ""
    },
    {
      "text": "A 28-year-old female with systemic lupus erythematosus (SLE) presents to the clinic with symptoms of depression and psychosis. On examination, she has no other major systemic involvement. Which of the following is most likely to correlate with her neuropsychiatric symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Anti-dsDNA",
          "correct": false
        },
        {
          "label": "B",
          "text": "Antiribosomal P",
          "correct": true
        },
        {
          "label": "C",
          "text": "Anti-Sm",
          "correct": false
        },
        {
          "label": "D",
          "text": "Antihistone",
          "correct": false
        }
      ],
      "correct_answer": "B. Antiribosomal P",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Antiribosomal P</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Anti-ribosomal P antibodies are associated with neuropsychiatric lupus , including depression and psychosis. These antibodies specifically target the ribosomal protein, and their presence in serum has been shown to correlate with neuropsychiatric manifestations of lupus. In some cases, the positive test for anti-ribosomal P can help explain mood disorders or psychosis in patients with lupus.</li><li>\u2022 Anti-ribosomal P</li><li>\u2022 neuropsychiatric lupus</li><li>\u2022 anti-ribosomal P</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Anti-dsDNA: Anti-dsDNA antibodies are strongly associated with systemic lupus erythematosus (SLE) and can correlate with disease activity, especially lupus nephritis. However, anti-dsDNA antibodies are not typically associated with neuropsychiatric symptoms such as depression or psychosis.</li><li>\u2022 Option A. Anti-dsDNA: Anti-dsDNA</li><li>\u2022 systemic lupus erythematosus</li><li>\u2022 anti-dsDNA</li><li>\u2022 Option C. Anti-Sm: Anti-Sm antibodies are specific for SLE but are not specifically linked to neuropsychiatric lupus. They are often present in SLE patients, especially in those of African or Asian descent, but they do not correlate with the neuropsychiatric manifestations of the disease.</li><li>\u2022 Option C. Anti-Sm: Anti-Sm</li><li>\u2022 Option D. Antihistone: Antihistone antibodies are most often seen in drug-induced lupus rather than in SLE . They are not typically associated with neuropsychiatric symptoms but are more commonly linked to skin rashes, arthralgia, and fever.</li><li>\u2022 Option D. Antihistone: Antihistone</li><li>\u2022 drug-induced lupus</li><li>\u2022 SLE</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anti-ribosomal P antibodies are associated with neuropsychiatric manifestations, such as depression and psychosis, in systemic lupus erythematosus . Testing for these antibodies can help identify the cause of mood and psychiatric disorders in patients with lupus.</li><li>\u27a4 Anti-ribosomal P</li><li>\u27a4 systemic lupus erythematosus</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b820b3af",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman with systemic lupus erythematosus (SLE) is pregnant and has a history of a previous miscarriage with congenital heart block in the fetus. Laboratory tests reveal that she is positive for anti-Ro antibodies. What is the most effective treatment to reduce the chance of heart block in a subsequent fetus?",
      "options": [
        {
          "label": "A",
          "text": "Azathioprine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cyclophosphamide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hydroxychloroquine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Voclosporin",
          "correct": false
        }
      ],
      "correct_answer": "C. Hydroxychloroquine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Hydroxychloroquine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Hydroxychloroquine has been shown to significantly reduce the risk of congenital heart block in fetuses of mothers with anti-Ro antibodies, particularly in those with a history of a previous infant affected by congenital heart block. Hydroxychloroquine treatment during pregnancy in these cases helps prevent the development of heart block, which can be a life-threatening condition. This therapy is recommended for mothers with anti-Ro antibodies to reduce fetal complications.</li><li>\u2022 Hydroxychloroquine</li><li>\u2022 congenital heart block</li><li>\u2022 anti-Ro</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Azathioprine: Azathioprine is an immunosuppressive medication that is used in the treatment of SLE but has not been shown to specifically reduce the risk of congenital heart block in the fetus. It also has potential teratogenic effects and is generally avoided during pregnancy unless absolutely necessary.</li><li>\u2022 Option A. Azathioprine:</li><li>\u2022 Option B. Cyclophosphamide: Cyclophosphamide is another immunosuppressive drug used in severe SLE, but it is generally avoided in pregnancy due to its teratogenic effects and potential harm to the fetus. It is not effective in reducing the risk of congenital heart block in fetuses with anti-Ro antibodies.</li><li>\u2022 Option B. Cyclophosphamide:</li><li>\u2022 Option D. Voclosporin: Voclosporin is an immunosuppressive agent used in lupus nephritis but does not have any evidence supporting its use in preventing congenital heart block in fetuses. Its use in pregnancy is not well-established, and it is not recommended for this indication.</li><li>\u2022 Option D. Voclosporin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hydroxychloroquine is the most effective treatment to reduce the risk of congenital heart block in fetuses of mothers with anti-Ro antibodies, especially in those with a history of a previous infant affected by heart block. It is safe during pregnancy and plays a critical role in preventing fetal complications.</li><li>\u27a4 Hydroxychloroquine</li><li>\u27a4 anti-Ro</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e61e33fe",
      "audio": ""
    },
    {
      "text": "A 40-year-old female presents with Raynaud\u2019s phenomenon and positive anti-centromere antibodies. She has no evidence of skin thickening or fibrosis. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "SSc sine scleroderma",
          "correct": true
        },
        {
          "label": "B",
          "text": "Limited cutaneous SSc",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diffuse cutaneous SSc",
          "correct": false
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "A. SSc sine scleroderma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) SSc sine scleroderma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 SSc sine scleroderma is a subset of systemic sclerosis (SSc) in which patients present with Raynaud's phenomenon and the characteristic clinical and laboratory features of SSc (such as positive anti-centromere antibodies ) but without detectable skin thickening . This form is considered relatively benign compared to other forms of SSc, where skin thickening is a hallmark feature. The term \"sine scleroderma\" refers to the absence of skin involvement despite systemic features.</li><li>\u2022 SSc sine scleroderma</li><li>\u2022 systemic sclerosis (SSc)</li><li>\u2022 Raynaud's phenomenon</li><li>\u2022 clinical and laboratory features</li><li>\u2022 positive anti-centromere antibodies</li><li>\u2022 without detectable skin thickening</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Limited cutaneous SSc: Limited cutaneous systemic sclerosis involves skin thickening that is typically confined to the distal extremities and face. This type of SSc also may involve Raynaud\u2019s phenomenon and autoantibodies such as anti-centromere antibodies , but it is characterized by skin thickening , which is absent in SSc sine scleroderma .</li><li>\u2022 Option B. Limited cutaneous SSc:</li><li>\u2022 anti-centromere antibodies</li><li>\u2022 skin thickening</li><li>\u2022 SSc sine scleroderma</li><li>\u2022 Option C. Diffuse cutaneous SSc: Diffuse cutaneous systemic sclerosis involves widespread skin thickening and fibrosis, often accompanied by severe organ involvement (e.g., lungs, kidneys). This form of SSc is distinct from SSc sine scleroderma , where no skin thickening is observed.</li><li>\u2022 Option C. Diffuse cutaneous SSc:</li><li>\u2022 SSc sine scleroderma</li><li>\u2022 Option D. None of the above: This option is incorrect because SSc sine scleroderma correctly describes the clinical presentation in this case.</li><li>\u2022 Option D. None of the above:</li><li>\u2022 SSc sine scleroderma</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 SSc sine scleroderma is a form of systemic sclerosis where patients exhibit Raynaud's phenomenon and characteristic clinical and laboratory features of scleroderma, but without detectable skin thickening . It is a relatively mild subset of SSc.</li><li>\u27a4 SSc sine scleroderma</li><li>\u27a4 Raynaud's phenomenon</li><li>\u27a4 without detectable skin thickening</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5c9c2b46",
      "audio": ""
    },
    {
      "text": "A 35-year-old male with asthma and eosinophilia presents with worsening symptoms of sinusitis, peripheral neuropathy, and skin rashes. Peripheral smear reveals eosinophilia. Which of the following is not useful for treatment?",
      "options": [
        {
          "label": "A",
          "text": "Mepolizumab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Benralizumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Omalizumab",
          "correct": true
        },
        {
          "label": "D",
          "text": "Rituximab",
          "correct": false
        }
      ],
      "correct_answer": "C. Omalizumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Omalizumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical features suggest eosinophilic granulomatosis with polyangiitis (EGPA), a condition involving eosinophilic-driven inflammation, asthma, and systemic vasculitis. EGPA treatment involves targeting eosinophils or inflammatory mediators like IL-5. Mepolizumab and Benralizumab are effective as they target IL-5 or its receptor, reducing eosinophil counts and disease activity. Omalizumab , an anti-IgE monoclonal antibody, is not effective in treating eosinophilic inflammation in EGPA, as it primarily targets allergic asthma, which does not address the underlying pathology of EGPA.</li><li>\u2022 Mepolizumab</li><li>\u2022 Benralizumab</li><li>\u2022 Omalizumab</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Mepolizumab: Approved for EGPA treatment as it directly targets IL-5, reducing eosinophilic inflammation.</li><li>\u2022 Option A.</li><li>\u2022 Mepolizumab:</li><li>\u2022 Option B. Benralizumab: Depletes eosinophils by targeting the IL-5 receptor and is effective in managing EGPA symptoms.</li><li>\u2022 Option B.</li><li>\u2022 Benralizumab:</li><li>\u2022 Option D. Rituximab: Although not first-line, it is useful in ANCA-positive EGPA or refractory cases by depleting B cells.</li><li>\u2022 Option D.</li><li>\u2022 Rituximab:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 EGPA is primarily managed by targeting eosinophilic inflammation with agents like Mepolizumab and Benralizumab . Omalizumab is not effective, as it does not address the eosinophilic-driven mechanisms of the disease.</li><li>\u27a4 Mepolizumab</li><li>\u27a4 Benralizumab</li><li>\u27a4 Omalizumab</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ca48bab7",
      "audio": ""
    },
    {
      "text": "A 40-year-old male presents to the clinic with palpable purpura on his lower extremities. He has no other features. The skin biopsy confirms small-vessel vasculitis. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Beh\u00e7et\u2019s disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "IgA vasculitis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Idiopathic Cutaneous Vasculitis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Eosinophilic Granulomatosis with Polyangiitis",
          "correct": false
        }
      ],
      "correct_answer": "C. Idiopathic Cutaneous Vasculitis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Idiopathic Cutaneous Vasculitis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The presentation of isolated palpable purpura on the lower extremities, without systemic involvement, is most consistent with idiopathic cutaneous vasculitis , also known as cutaneous leukocytoclastic vasculitis. It is a small-vessel vasculitis primarily limited to the skin and can occur in response to infections, medications, or as an idiopathic process.</li><li>\u2022 idiopathic cutaneous vasculitis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Beh\u00e7et\u2019s disease : Beh\u00e7et\u2019s involves recurrent oral and genital ulcers, uveitis, and other systemic manifestations, which are absent here.</li><li>\u2022 Option A.</li><li>\u2022 Beh\u00e7et\u2019s disease</li><li>\u2022 Option B. IgA vasculitis : While IgA vasculitis (Henoch-Sch\u00f6nlein purpura) can present with palpable purpura, it is more common in children and usually involves systemic features such as abdominal pain, arthritis, and renal involvement.</li><li>\u2022 Option B.</li><li>\u2022 IgA vasculitis</li><li>\u2022 Option D. Eosinophilic granulomatosis with polyangiitis (EGPA) : EGPA is associated with asthma, eosinophilia, and systemic vasculitis, which are not present in this patient.</li><li>\u2022 Option D.</li><li>\u2022 Eosinophilic granulomatosis with polyangiitis (EGPA)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Idiopathic cutaneous vasculitis is characterized by isolated palpable purpura limited to the skin, without systemic involvement. It is often self-limited and distinct from systemic vasculitides, which typically present with additional organ-specific symptoms.</li><li>\u27a4 Idiopathic cutaneous vasculitis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "675b7a1e",
      "audio": ""
    },
    {
      "text": "A 40-year-old female is diagnosed with sarcoidosis after presenting with cough, dyspnea, and fatigue. A chest X-ray reveals is taken and shown. Based on the X-ray findings, what is the most likely stage of her disease?",
      "options": [
        {
          "label": "A",
          "text": "Stage 1",
          "correct": true
        },
        {
          "label": "B",
          "text": "Stage 2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Stage 3",
          "correct": false
        },
        {
          "label": "D",
          "text": "Stage 4",
          "correct": false
        }
      ],
      "correct_answer": "A. Stage 1",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-19%20140835.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Stage 1</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Stage 1 sarcoidosis is characterized by hilar adenopathy alone on chest X-ray, often with involvement of the right paratracheal region . In this case, the X-ray findings of bilateral hilar lymphadenopathy without infiltrates or fibrosis correspond to Stage 1 of the disease, which is typically asymptomatic or mildly symptomatic.</li><li>\u2022 Stage 1</li><li>\u2022 hilar adenopathy alone</li><li>\u2022 right paratracheal region</li><li>\u2022 bilateral hilar lymphadenopathy</li><li>\u2022 Stage 1</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Stage 2: Stage 2 sarcoidosis is characterized by both adenopathy (hilar and/or mediastinal) and pulmonary infiltrates . If the patient had infiltrates in addition to hilar lymphadenopathy, it would indicate Stage 2 rather than Stage 1 .</li><li>\u2022 Option B. Stage 2: Stage 2</li><li>\u2022 adenopathy</li><li>\u2022 pulmonary infiltrates</li><li>\u2022 Stage 2</li><li>\u2022 Stage 1</li><li>\u2022 Option C. Stage 3: Stage 3 sarcoidosis is characterized by pulmonary infiltrates alone, without significant hilar adenopathy. This stage typically presents with more extensive lung involvement and can be associated with symptoms like cough and dyspnea.</li><li>\u2022 Option C. Stage 3: Stage 3</li><li>\u2022 pulmonary infiltrates</li><li>\u2022 Option D. Stage 4: Stage 4 represents the end-stage of sarcoidosis, where fibrosis has developed, leading to lung scarring and irreversible damage. This stage is associated with severe respiratory symptoms, including restrictive lung disease.</li><li>\u2022 Option D. Stage 4: Stage 4</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Stage 1 sarcoidosis is marked by hilar lymphadenopathy without lung infiltrates or fibrosis. The disease typically progresses to Stage 2 and beyond if more severe pulmonary involvement develops.</li><li>\u27a4 Stage 1</li><li>\u27a4 hilar lymphadenopathy</li><li>\u27a4 Stage 2</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1a5cd256",
      "audio": ""
    },
    {
      "text": "A 40-year-old female presents with muscle weakness and the lesions shown in the picture. What is the most likely antibody associated?",
      "options": [
        {
          "label": "A",
          "text": "Anti-MDA5",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti-TIF1",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti-NXP2",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anti-Mi-2",
          "correct": true
        }
      ],
      "correct_answer": "D. Anti-Mi-2",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20154953.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Anti-Mi-2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The lesions shown are Gottron's papules and the patient is likely to be suffering from dermatomyositis. Anti-Mi-2 antibodies are associated with a benign course of dermatomyositis (DM) . Patients with anti-Mi-2 antibodies typically have a more favorable response to treatment, and the disease is less likely to be associated with severe complications like interstitial lung disease (ILD) or cancer , which are seen with other antibodies. These patients generally have classic DM features, including heliotrope rash , Gottron's papules , and proximal muscle weakness .</li><li>\u2022 The lesions shown are Gottron's papules and the patient is likely to be suffering from dermatomyositis. Anti-Mi-2 antibodies</li><li>\u2022 benign</li><li>\u2022 dermatomyositis (DM)</li><li>\u2022 interstitial lung disease (ILD)</li><li>\u2022 cancer</li><li>\u2022 heliotrope rash</li><li>\u2022 Gottron's papules</li><li>\u2022 proximal muscle weakness</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Anti-MDA5: Anti-MDA5 antibodies are associated with a more severe form of dermatomyositis, often characterized by amyopathic DM , severe palmar rash , digital ulcers , and rapidly progressive interstitial lung disease (ILD) . This form of DM carries a poor prognosis , especially due to the development of ILD.</li><li>\u2022 Option A. Anti-MDA5: Anti-MDA5 antibodies</li><li>\u2022 more severe</li><li>\u2022 amyopathic DM</li><li>\u2022 severe palmar rash</li><li>\u2022 digital ulcers</li><li>\u2022 rapidly progressive interstitial lung disease (ILD)</li><li>\u2022 poor prognosis</li><li>\u2022 Option B. Anti-TIF1 (p155): Anti-TIF1 (also known as anti-p155 ) antibodies are associated with increased risk of cancer in patients with dermatomyositis. These patients may also present with muscle weakness and characteristic skin findings, but the presence of anti-TIF1 antibodies is often a marker of malignancy, which can lead to a more complicated disease course.</li><li>\u2022 Option B. Anti-TIF1 (p155): Anti-TIF1</li><li>\u2022 anti-p155</li><li>\u2022 increased risk of cancer</li><li>\u2022 muscle weakness</li><li>\u2022 Option C. Anti-NXP2: Anti-NXP2 antibodies are also associated with an increased risk of malignancy in dermatomyositis, similar to anti-TIF1. These patients tend to have muscle weakness and skin findings but also face a higher risk of cancer , making their prognosis less favorable than patients with anti-Mi-2 antibodies.</li><li>\u2022 Option C. Anti-NXP2: Anti-NXP2 antibodies</li><li>\u2022 increased risk of malignancy</li><li>\u2022 muscle weakness</li><li>\u2022 skin findings</li><li>\u2022 cancer</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anti-Mi-2 antibodies are associated with a benign course of dermatomyositis , with a favorable response to treatment and no significant risk of cancer or severe ILD . This distinguishes them from other antibodies like anti-MDA5 , anti-TIF1 , and anti-NXP2 , which are associated with a more severe disease course .</li><li>\u27a4 Anti-Mi-2 antibodies</li><li>\u27a4 benign course</li><li>\u27a4 dermatomyositis</li><li>\u27a4 a favorable response to treatment</li><li>\u27a4 no significant risk of cancer or severe ILD</li><li>\u27a4 anti-MDA5</li><li>\u27a4 anti-TIF1</li><li>\u27a4 anti-NXP2</li><li>\u27a4 severe disease course</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b7216c95",
      "audio": ""
    },
    {
      "text": "A 28-year-old male presents with severe bleeding and anemia. Peripheral smear is shown below. PT, aPTT and D-dimer are elevated. Which of the following cytogenetic rearrangements is most commonly associated with this disorder?",
      "options": [
        {
          "label": "A",
          "text": "t(9;22)",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(8;14)",
          "correct": false
        },
        {
          "label": "C",
          "text": "t(15;17)",
          "correct": true
        },
        {
          "label": "D",
          "text": "t(8;16)",
          "correct": false
        }
      ],
      "correct_answer": "C. t(15;17)",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-19%20141350.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) t(15;17)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation, along with coagulopathy (elevated PT, aPTT, and D-dimer) and peripheral smear with promyelocytes (with Auer rods = faggot cells) is suggestive of acute promyelocytic leukemia (APL) . APL is characterized by the presence of promyelocytes with Auer rods on peripheral smear and is associated with disseminated intravascular coagulation (DIC), causing severe bleeding. The hallmark cytogenetic abnormality in APL is t(15;17) , which leads to the PML-RARA fusion gene. This translocation disrupts normal retinoic acid receptor (RARA) signaling and differentiation of promyelocytes.</li><li>\u2022 acute promyelocytic leukemia (APL)</li><li>\u2022 t(15;17)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. t(9;22): This translocation is associated with chronic myeloid leukemia (CML) and results in the BCR-ABL fusion gene. It is not linked to APL.</li><li>\u2022 Option A.</li><li>\u2022 t(9;22):</li><li>\u2022 Option B. t(8;14): This is characteristic of Burkitt lymphoma, involving the MYC gene, and is not associated with APL.</li><li>\u2022 Option B.</li><li>\u2022 t(8;14):</li><li>\u2022 Option D. t(8;16): This translocation is associated with acute monocytic leukemia with t(8;16)(p11;p13) but is unrelated to APL.</li><li>\u2022 Option D.</li><li>\u2022 t(8;16):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Acute promyelocytic leukemia (APL) is strongly associated with the t(15;17) translocation, which leads to the PML-RARA fusion gene. It is commonly complicated by coagulopathy (DIC), and early recognition is critical for initiating appropriate treatment with all-trans retinoic acid (ATRA).</li><li>\u27a4 Acute promyelocytic leukemia (APL)</li><li>\u27a4 t(15;17)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "eb00af14",
      "audio": ""
    },
    {
      "text": "A 20-year-old female with mild anemia is suspected of having thalassemia trait based on her clinical presentation. What is the most likely diagnosis based on the hemoglobin fractions and their percentages?",
      "options": [
        {
          "label": "A",
          "text": "HbA: 60-90 HbF: 10-40 HbA2: 4-6",
          "correct": false
        },
        {
          "label": "B",
          "text": "HbA: 94 HbF: 1-2 HbA2: 4-6",
          "correct": true
        },
        {
          "label": "C",
          "text": "HbA: 0-5 HbF: 90-100 HbA2: 2-5",
          "correct": false
        },
        {
          "label": "D",
          "text": "HbE: 50-70 HbF: 30-50",
          "correct": false
        }
      ],
      "correct_answer": "B. HbA: 94 HbF: 1-2 HbA2: 4-6",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) HbA: 94 HbF: 1-2 HbA2: 4-6</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The hemoglobin fractions in thalassemia trait are typically characterized by:</li><li>\u2022 thalassemia trait</li><li>\u2022 HbA : 94% HbF : 1-2% HbA2 : 4-6%</li><li>\u2022 HbA : 94%</li><li>\u2022 HbA</li><li>\u2022 HbF : 1-2%</li><li>\u2022 HbF</li><li>\u2022 HbA2 : 4-6%</li><li>\u2022 HbA2</li><li>\u2022 This is a classic pattern seen in thalassemia minor (or thalassemia trait) , where the patient has normal HbA levels (the main adult hemoglobin), a slightly elevated HbA2 , and a very small percentage of HbF (fetal hemoglobin). The patient may have mild anemia, but usually, there are no significant clinical symptoms.</li><li>\u2022 thalassemia minor (or thalassemia trait)</li><li>\u2022 normal HbA</li><li>\u2022 HbA2</li><li>\u2022 HbF</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. HbA: 60-90 HbF: 10-40 HbA2: 4-6: This pattern is more typical of thalassemia intermedia (non-transfusion-dependent thalassemia). Patients with thalassemia intermedia may have moderate anemia and varying degrees of symptoms. The HbF percentage is much higher compared to thalassemia trait.</li><li>\u2022 Option A. HbA: 60-90 HbF: 10-40 HbA2: 4-6:</li><li>\u2022 thalassemia intermedia</li><li>\u2022 HbF</li><li>\u2022 Option C. HbA: 0-5 HbF: 90-100 HbA2: 2-5: This hemoglobin profile is consistent with thalassemia major (transfusion-dependent thalassemia), which is a more severe form of thalassemia. In this condition, the patient has very little HbA and a very high percentage of HbF . These patients often require regular blood transfusions.</li><li>\u2022 Option C. HbA: 0-5 HbF: 90-100 HbA2: 2-5:</li><li>\u2022 thalassemia major</li><li>\u2022 very little HbA</li><li>\u2022 very high percentage of HbF</li><li>\u2022 Option D. HbE: 50-70 HbF: 30-50: This pattern is characteristic of HbE-beta thalassemia , where the patient has a mixture of HbE (hemoglobin E) and HbF (fetal hemoglobin). This condition is seen in patients with hemoglobin E mutation and beta-thalassemia , common in Southeast Asia.</li><li>\u2022 Option D. HbE: 50-70 HbF: 30-50:</li><li>\u2022 HbE-beta thalassemia</li><li>\u2022 HbE</li><li>\u2022 HbF</li><li>\u2022 hemoglobin E</li><li>\u2022 beta-thalassemia</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In thalassemia trait , the most common hemoglobin fractions are HbA: 94% , HbF: 1-2% , and HbA2: 4-6% , with mild anemia but no significant clinical symptoms.</li><li>\u27a4 thalassemia trait</li><li>\u27a4 HbA: 94%</li><li>\u27a4 HbF: 1-2%</li><li>\u27a4 HbA2: 4-6%</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0e406dda",
      "audio": ""
    },
    {
      "text": "A 60-year-old female presents with fatigue, pallor, and glossitis. She has a history of autoimmune gastritis. Laboratory tests reveal elevated methylmalonic acid. Which of the following is not typically associated with the disease?",
      "options": [
        {
          "label": "A",
          "text": "Gastric output of pepsin, and IF is severely reduced",
          "correct": false
        },
        {
          "label": "B",
          "text": "Gastric output of hydrochloric acid is severely reduced",
          "correct": false
        },
        {
          "label": "C",
          "text": "The serum gastrin level is raised",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serum pepsinogen I levels are high",
          "correct": true
        }
      ],
      "correct_answer": "D. Serum pepsinogen I levels are high",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Serum pepsinogen I levels are high</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient is likely to be suffering from pernicious anemia. It is caused by autoimmune gastritis leading to parietal cell destruction , the following is typically observed:</li><li>\u2022 autoimmune gastritis</li><li>\u2022 parietal cell destruction</li><li>\u2022 Severe reduction in gastric output of hydrochloric acid (achlorhydria). Reduction in gastric output of pepsin and intrinsic factor (IF) , both produced by the parietal cells. This leads to B12 deficiency and hence the elevated methylmalonic acid in this patient. Elevated serum gastrin levels due to feedback stimulation from the lack of gastric acid. Low serum pepsinogen I levels due to diminished secretion from the chief cells in the stomach.</li><li>\u2022 Severe reduction in gastric output of hydrochloric acid (achlorhydria).</li><li>\u2022 Severe reduction</li><li>\u2022 hydrochloric acid</li><li>\u2022 Reduction in gastric output of pepsin and intrinsic factor (IF) , both produced by the parietal cells. This leads to B12 deficiency and hence the elevated methylmalonic acid in this patient.</li><li>\u2022 Reduction</li><li>\u2022 pepsin</li><li>\u2022 intrinsic factor (IF)</li><li>\u2022 Elevated serum gastrin levels due to feedback stimulation from the lack of gastric acid.</li><li>\u2022 Elevated serum gastrin</li><li>\u2022 feedback stimulation</li><li>\u2022 Low serum pepsinogen I levels due to diminished secretion from the chief cells in the stomach.</li><li>\u2022 Low serum pepsinogen I levels</li><li>\u2022 chief cells</li><li>\u2022 Therefore, serum pepsinogen I levels are low , not high, in pernicious anemia, making Option D the correct answer.</li><li>\u2022 serum pepsinogen I levels are low</li><li>\u2022 Option D</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Gastric output of pepsin, and IF is severely reduced: This is true in pernicious anemia, as the loss of parietal cells leads to a reduction in both pepsinogen and intrinsic factor (IF) production.</li><li>\u2022 Option A. Gastric output of pepsin, and IF is severely reduced:</li><li>\u2022 parietal cells</li><li>\u2022 pepsinogen</li><li>\u2022 intrinsic factor (IF)</li><li>\u2022 Option B. Gastric output of hydrochloric acid is severely reduced: This is a hallmark of pernicious anemia , caused by damage to the parietal cells that normally produce hydrochloric acid .</li><li>\u2022 Option B. Gastric output of hydrochloric acid is severely reduced:</li><li>\u2022 pernicious anemia</li><li>\u2022 parietal cells</li><li>\u2022 hydrochloric acid</li><li>\u2022 Option C. The serum gastrin level is raised: In pernicious anemia, the absence of gastric acid (due to parietal cell destruction) leads to increased secretion of gastrin , which is a compensatory response to the lack of acid production.</li><li>\u2022 Option C. The serum gastrin level is raised:</li><li>\u2022 absence of gastric acid</li><li>\u2022 increased secretion of gastrin</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In pernicious anemia , serum pepsinogen I levels are low , not high, due to reduced secretion from the chief cells in the stomach, as part of the overall dysfunction of gastric secretions associated with autoimmune gastritis .</li><li>\u27a4 pernicious anemia</li><li>\u27a4 serum pepsinogen I levels are low</li><li>\u27a4 chief cells</li><li>\u27a4 autoimmune gastritis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7c88ccfb",
      "audio": ""
    },
    {
      "text": "A 60-year-old male presents with mild anemia. He otherwise has no symptoms, and laboratory tests reveal low serum B12 levels. Which of the following conditions is associated with low serum B12 levels that do not indicate a true B12 deficiency?",
      "options": [
        {
          "label": "A",
          "text": "Liver disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "Oral contraceptives",
          "correct": true
        },
        {
          "label": "C",
          "text": "Renal disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Myeloproliferative diseases",
          "correct": false
        }
      ],
      "correct_answer": "B. Oral contraceptives",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Oral contraceptives</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Low serum B12 levels do not always indicate true B12 deficiency. Folate deficiency, TC I (HC) deficiency, oral contraceptives, and multiple myeloma have all been associated with low serum B12 levels that do not indicate B12 deficiency. On the other hand, high serum B12 levels are usually due to raised serum TC I levels and can be due to the presence of liver, renal, or myeloproliferative diseases or to cancer of the breast, colon, or liver.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Liver disease : Liver disease is associated with elevated serum B12 levels due to increased serum transcobalamin I levels.</li><li>\u2022 Option A.</li><li>\u2022 Liver disease</li><li>\u2022 elevated</li><li>\u2022 Option C. Renal disease : Renal disease may also lead to elevated serum B12 due to impaired clearance of transcobalamin-bound B12.</li><li>\u2022 Option C.</li><li>\u2022 Renal disease</li><li>\u2022 elevated</li><li>\u2022 Option D. Myeloproliferative diseases : Myeloproliferative disorders such as chronic myeloid leukemia often show high serum B12 levels due to increased production of transcobalamin I.</li><li>\u2022 Option D.</li><li>\u2022 Myeloproliferative diseases</li><li>\u2022 high</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Low serum B12 levels can occur in conditions that do not reflect true B12 deficiency, such as oral contraceptive use. Conversely, elevated B12 levels are often due to increased transcobalamin I production in conditions like liver disease, renal disease, and myeloproliferative disorders.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0acf5ee4",
      "audio": ""
    },
    {
      "text": "A 28-year-old male with suspected dengue fever presents to the emergency department with thrombocytopenia. An intern collects a blood sample using an EDTA tube for a platelet count. The result shows 20,000 platelets/cumm and the peripheral blood smear is shown to have platelet clumping. What is the next best step in managing this patient?",
      "options": [
        {
          "label": "A",
          "text": "Send a sample again in EDTA tube",
          "correct": false
        },
        {
          "label": "B",
          "text": "Confirm thrombocytopenia and start treatment accordingly",
          "correct": false
        },
        {
          "label": "C",
          "text": "Send a sample again in sodium citrate tube",
          "correct": true
        },
        {
          "label": "D",
          "text": "Send a sample again in clot accelerator (red) tube",
          "correct": false
        }
      ],
      "correct_answer": "C. Send a sample again in sodium citrate tube",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Send a sample again in sodium citrate tube</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The presence of platelet clumping on the peripheral smear in a patient with thrombocytopenia suggests the possibility of pseudothrombocytopenia . This is an artifact that can occur when platelets agglutinate in EDTA (the anticoagulant used in the EDTA tube), which reduces calcium levels and leads to platelet aggregation . To confirm the platelet count and rule out pseudothrombocytopenia , a new sample should be collected in a sodium citrate tube (blue top), which is not as likely to cause platelet clumping.</li><li>\u2022 platelet clumping</li><li>\u2022 thrombocytopenia</li><li>\u2022 pseudothrombocytopenia</li><li>\u2022 platelets agglutinate in EDTA</li><li>\u2022 platelet aggregation</li><li>\u2022 pseudothrombocytopenia</li><li>\u2022 new sample</li><li>\u2022 sodium citrate tube</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Send a sample again in EDTA tube: Sending another sample in the EDTA tube would likely yield the same result due to the potential for pseudothrombocytopenia caused by platelet clumping. This is not the appropriate next step.</li><li>\u2022 Option A. Send a sample again in EDTA tube:</li><li>\u2022 EDTA tube</li><li>\u2022 pseudothrombocytopenia</li><li>\u2022 Option B. Confirm thrombocytopenia and start treatment accordingly: While thrombocytopenia is common in dengue fever , in this case, the result could be a false low due to platelet clumping in the EDTA tube. Treatment for dengue thrombocytopenia should only be initiated after confirming that the low platelet count is accurate.</li><li>\u2022 Option B. Confirm thrombocytopenia and start treatment accordingly:</li><li>\u2022 dengue fever</li><li>\u2022 false low</li><li>\u2022 platelet clumping</li><li>\u2022 dengue</li><li>\u2022 Option  D. Send a sample again in clot accelerator (red) tube: A clot accelerator (red) tube is used to collect serum for tests like serum chemistries or serological assays . It is not suitable for platelet counts, as it does not contain anticoagulant, and a clotted sample would not provide an accurate platelet count.</li><li>\u2022 Option  D. Send a sample again in clot accelerator (red) tube:</li><li>\u2022 clot accelerator (red) tube</li><li>\u2022 serum chemistries</li><li>\u2022 serological assays</li><li>\u2022 clotted sample</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 If pseudothrombocytopenia is suspected due to platelet clumping in an EDTA sample, the next best step is to send a new sample in a sodium citrate tube (blue top) or use a fresh unanticoagulated blood smear to confirm the true platelet count.</li><li>\u27a4 pseudothrombocytopenia</li><li>\u27a4 sodium citrate tube</li><li>\u27a4 fresh unanticoagulated blood smear</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d3e50646",
      "audio": ""
    },
    {
      "text": "A 30-year-old female is diagnosed with immune thrombocytopenic purpura (ITP) and is being evaluated for treatment options. Which of the following is not typically used in the treatment?",
      "options": [
        {
          "label": "A",
          "text": "Prednisone at 1 mg/kg",
          "correct": false
        },
        {
          "label": "B",
          "text": "4-day course of dexamethasone, 40 mg/d",
          "correct": false
        },
        {
          "label": "C",
          "text": "Rh0 (D) immune globulin in Rh-negative patients",
          "correct": true
        },
        {
          "label": "D",
          "text": "IVIgG at 1\u20132 g/kg total, given over 1\u20135 days",
          "correct": false
        }
      ],
      "correct_answer": "C. Rh0 (D) immune globulin in Rh-negative patients",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Rh0 (D) immune globulin in Rh-negative patients</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Rh0 (D) immune globulin (WinRho SDF) is used in the treatment of immune thrombocytopenic purpura (ITP) , but it is only given to Rh-positive patients, not Rh-negative patients. The mechanism of action involves antibody-coated cells \u201csaturating\u201d the Fc receptors on macrophages, thus inhibiting platelet destruction. In Rh-negative patients , administering Rh0 (D) immune globulin is not appropriate as it is not effective in this group.</li><li>\u2022 Rh0 (D) immune globulin</li><li>\u2022 immune thrombocytopenic purpura (ITP)</li><li>\u2022 Rh-positive</li><li>\u2022 Rh-negative</li><li>\u2022 Fc receptors</li><li>\u2022 Rh-negative patients</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Prednisone at 1 mg/kg: Prednisone is a first-line treatment for ITP. It is a corticosteroid used to suppress the immune response and increase platelet count. The standard dose is typically 1 mg/kg daily.</li><li>\u2022 Option A. Prednisone at 1 mg/kg: Prednisone</li><li>\u2022 1 mg/kg</li><li>\u2022 Option B. 4-day course of dexamethasone, 40 mg/d: A 4-day course of dexamethasone is also an effective treatment for ITP. It is used in higher doses, typically 40 mg/day for 4 days, and can provide rapid platelet count improvement in patients with ITP.</li><li>\u2022 Option B. 4-day course of dexamethasone, 40 mg/d:</li><li>\u2022 4-day course of dexamethasone</li><li>\u2022 40 mg/day</li><li>\u2022 Option D. IVIgG at 1\u20132 g/kg total, given over 1\u20135 days: IVIgG (intravenous immunoglobulin) is another treatment used in ITP. It works by blocking the Fc receptor system and increasing platelet survival. It is often given as 1-2 g/kg over 1-5 days, especially in cases that require urgent treatment or for postsplenectomy patients.</li><li>\u2022 Option D. IVIgG at 1\u20132 g/kg total, given over 1\u20135 days: IVIgG</li><li>\u2022 Fc receptor system</li><li>\u2022 1-2 g/kg</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Rh0 (D) immune globulin is used only in Rh-positive patients with ITP , not Rh-negative patients. Other treatments like prednisone , dexamethasone , and IVIgG are commonly used for ITP management.</li><li>\u27a4 Rh0 (D) immune globulin</li><li>\u27a4 Rh-positive</li><li>\u27a4 ITP</li><li>\u27a4 Rh-negative</li><li>\u27a4 prednisone</li><li>\u27a4 dexamethasone</li><li>\u27a4 IVIgG</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f7e8d47b",
      "audio": ""
    },
    {
      "text": "35-year-old female with thrombotic thrombocytopenic purpura (TTP) is being treated for an ADAMTS13 activity level <10% and is showing clinical symptoms such as microangiopathic hemolytic anemia and thrombocytopenia. Which of the following treatments, known for targeting von Willebrand factor (vWF), is most beneficial in reducing the mortality and burden of care in these patients?",
      "options": [
        {
          "label": "A",
          "text": "Ibritumomab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Caplacizumab",
          "correct": true
        },
        {
          "label": "C",
          "text": "Tiuxetan",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ofatumumab",
          "correct": false
        }
      ],
      "correct_answer": "B. Caplacizumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Caplacizumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Caplacizumab is an anti-von Willebrand factor (vWF) nanobody that has been shown to decrease mortality and the burden of care in patients with thrombotic thrombocytopenic purpura (TTP) . It works by preventing the interaction of vWF with platelets, thereby reducing platelet aggregation and microthrombus formation, which are central to the pathophysiology of TTP. Caplacizumab is used in combination with plasma exchange and steroids for patients with TTP who have ADAMTS13 activity <10% .</li><li>\u2022 Caplacizumab</li><li>\u2022 anti-von Willebrand factor (vWF) nanobody</li><li>\u2022 mortality</li><li>\u2022 burden of care</li><li>\u2022 thrombotic thrombocytopenic purpura (TTP)</li><li>\u2022 vWF</li><li>\u2022 plasma exchange</li><li>\u2022 steroids</li><li>\u2022 TTP</li><li>\u2022 ADAMTS13 activity <10%</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Ibritumomab: Ibritumomab is a monoclonal antibody used for radioimmunotherapy in certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia . It does not have a role in the treatment of TTP .</li><li>\u2022 Option A. Ibritumomab: Ibritumomab</li><li>\u2022 monoclonal antibody</li><li>\u2022 radioimmunotherapy</li><li>\u2022 non-Hodgkin lymphoma</li><li>\u2022 chronic lymphocytic leukemia</li><li>\u2022 TTP</li><li>\u2022 Option C. Tiuxetan: Tiuxetan is used as part of radioimmunotherapy for hematologic malignancies but does not target vWF or have any application in TTP treatment.</li><li>\u2022 Option C. Tiuxetan: Tiuxetan</li><li>\u2022 radioimmunotherapy</li><li>\u2022 hematologic malignancies</li><li>\u2022 vWF</li><li>\u2022 TTP</li><li>\u2022 Option D. Ofatumumab: Ofatumumab is another monoclonal antibody used in the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis but does not play a role in treating TTP .</li><li>\u2022 Option D. Ofatumumab: Ofatumumab</li><li>\u2022 monoclonal antibody</li><li>\u2022 chronic lymphocytic leukemia (CLL)</li><li>\u2022 multiple sclerosis</li><li>\u2022 TTP</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Caplacizumab , an anti-vWF nanobody , is an important therapeutic agent in TTP , helping to reduce platelet aggregation and improving patient outcomes, particularly in those with ADAMTS13 <10% .</li><li>\u27a4 Caplacizumab</li><li>\u27a4 anti-vWF nanobody</li><li>\u27a4 TTP</li><li>\u27a4 platelet aggregation</li><li>\u27a4 ADAMTS13 <10%</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "55926dad",
      "audio": ""
    },
    {
      "text": "A 68-year-old male presents with severe mucosal bleeding, including epistaxis and gum bleeding, without any previous history of bleeding disorders. He has a monoclonal gammopathy identified during workup for anemia. Which of the following is most commonly associated with this patient's condition?",
      "options": [
        {
          "label": "A",
          "text": "Congenital VWD",
          "correct": false
        },
        {
          "label": "B",
          "text": "Waldenstr\u00f6m\u2019s macroglobulinemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Monoclonal gammopathies of undetermined significance (MGUS)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Multiple myeloma",
          "correct": false
        }
      ],
      "correct_answer": "C. Monoclonal gammopathies of undetermined significance (MGUS)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Monoclonal gammopathies of undetermined significance (MGUS)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Von Willebrand disease (VWD) is an inherited bleeding disorder, but acquired von Willebrand syndrome (VWS) is commonly seen in monoclonal gammopathies of undetermined significance (MGUS) , multiple myeloma , and Waldenstr\u00f6m\u2019s macroglobulinemia . In patients with MGUS, acquired VWS typically manifests as severe mucosal bleeding , which may include symptoms like epistaxis and gingival bleeding . This bleeding tendency is due to the interference with von Willebrand factor (vWF) function caused by the underlying monoclonal protein. MGUS is the most common condition associated with acquired VWS, particularly in elderly patients .</li><li>\u2022 Von Willebrand disease (VWD)</li><li>\u2022 acquired von Willebrand syndrome (VWS)</li><li>\u2022 monoclonal gammopathies of undetermined significance (MGUS)</li><li>\u2022 multiple myeloma</li><li>\u2022 Waldenstr\u00f6m\u2019s macroglobulinemia</li><li>\u2022 acquired VWS</li><li>\u2022 severe mucosal bleeding</li><li>\u2022 epistaxis</li><li>\u2022 gingival bleeding</li><li>\u2022 MGUS</li><li>\u2022 elderly patients</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Congenital VWD: Congenital VWD is inherited and is characterized by a deficiency or dysfunction of von Willebrand factor (vWF). However, it is not typically associated with monoclonal gammopathies, which are the underlying cause of acquired VWS .</li><li>\u2022 Option A. Congenital VWD: Congenital VWD</li><li>\u2022 acquired VWS</li><li>\u2022 Option B. Waldenstr\u00f6m\u2019s macroglobulinemia: While Waldenstr\u00f6m\u2019s macroglobulinemia (a lymphoproliferative disorder) can be associated with acquired VWS , MGUS is more commonly linked to the development of acquired VWS, particularly in elderly patients. Waldenstr\u00f6m\u2019s may still be considered in this context but is less common than MGUS for causing acquired VWS.</li><li>\u2022 Option B. Waldenstr\u00f6m\u2019s macroglobulinemia:</li><li>\u2022 Waldenstr\u00f6m\u2019s macroglobulinemia</li><li>\u2022 acquired VWS</li><li>\u2022 MGUS</li><li>\u2022 Waldenstr\u00f6m\u2019s</li><li>\u2022 Option D. Multiple myeloma: Multiple myeloma is also associated with acquired VWS , but MGUS is more frequently seen as the underlying cause of this bleeding disorder.</li><li>\u2022 Option D. Multiple myeloma: Multiple myeloma</li><li>\u2022 acquired VWS</li><li>\u2022 MGUS</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Acquired von Willebrand syndrome is most commonly associated with monoclonal gammopathies of undetermined significance (MGUS) , particularly in elderly patients who present with new-onset mucosal bleeding .</li><li>\u27a4 Acquired von Willebrand syndrome</li><li>\u27a4 monoclonal gammopathies of undetermined significance (MGUS)</li><li>\u27a4 new-onset mucosal bleeding</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "99777466",
      "audio": ""
    },
    {
      "text": "A 3-year-old child with Down syndrome is diagnosed with acute myeloid leukemia (AML), specifically the acute megakaryocytic subtype. What is the most likely mutation associated with this form of leukemia?",
      "options": [
        {
          "label": "A",
          "text": "CEBPA",
          "correct": false
        },
        {
          "label": "B",
          "text": "ETV6",
          "correct": false
        },
        {
          "label": "C",
          "text": "GATA1",
          "correct": true
        },
        {
          "label": "D",
          "text": "GATA2",
          "correct": false
        }
      ],
      "correct_answer": "C. GATA1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) GATA1</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Down syndrome-associated AML in children, particularly those under 4 years old , is typically of the acute megakaryocytic subtype. This form of leukemia is most commonly associated with mutations in the GATA1 gene , which is involved in hematopoiesis , particularly megakaryocyte differentiation. The mutation in GATA1 leads to an increased risk of leukemia in children with Down syndrome , specifically in those with trisomy 21 .</li><li>\u2022 Down syndrome-associated AML</li><li>\u2022 4 years old</li><li>\u2022 acute megakaryocytic</li><li>\u2022 GATA1 gene</li><li>\u2022 hematopoiesis</li><li>\u2022 GATA1</li><li>\u2022 Down syndrome</li><li>\u2022 trisomy 21</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. CEBPA: CEBPA mutations are typically associated with AML in adults and are not commonly seen in Down syndrome-associated AML , which is more specifically linked to GATA1 mutations.</li><li>\u2022 Option A. CEBPA: CEBPA</li><li>\u2022 AML</li><li>\u2022 Down syndrome-associated AML</li><li>\u2022 GATA1</li><li>\u2022 Option B. ETV6: ETV6 mutations are associated with various forms of leukemia, including acute lymphoblastic leukemia (ALL) and AML in both adults and children, but they are not the hallmark of Down syndrome-associated AML .</li><li>\u2022 Option B. ETV6: ETV6</li><li>\u2022 acute lymphoblastic leukemia (ALL)</li><li>\u2022 AML</li><li>\u2022 Down syndrome-associated AML</li><li>\u2022 Option D. GATA2: While GATA2 mutations are associated with certain forms of leukemia, such as monosomy 7 -associated AML , they are not the primary mutation in Down syndrome-associated AML , which is more closely associated with GATA1 mutations.</li><li>\u2022 Option D. GATA2:</li><li>\u2022 GATA2</li><li>\u2022 monosomy 7</li><li>\u2022 AML</li><li>\u2022 Down syndrome-associated AML</li><li>\u2022 GATA1</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 GATA1 mutations are the hallmark of Down syndrome-associated AML , particularly in young children, and this mutation is strongly linked with the acute megakaryocytic subtype of the disease.</li><li>\u27a4 GATA1 mutations</li><li>\u27a4 Down syndrome-associated AML</li><li>\u27a4 acute megakaryocytic</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6e689725",
      "audio": ""
    },
    {
      "text": "A 50-year-old male is diagnosed with acute myeloid leukemia (AML) and is evaluated for cytogenetic abnormalities. Which of the following cytogenetic rearrangements is considered a poor prognostic factor in AML?",
      "options": [
        {
          "label": "A",
          "text": "t(15;17)",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(8;21)",
          "correct": false
        },
        {
          "label": "C",
          "text": "t(6;9)",
          "correct": true
        },
        {
          "label": "D",
          "text": "inv(16)",
          "correct": false
        }
      ],
      "correct_answer": "C. t(6;9)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) t(6;9)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The t(6;9) translocation is considered a poor prognostic factor in acute myeloid leukemia (AML) . This translocation is associated with a very poor prognosis in AML patients, with outcomes significantly worse than those with other more favorable cytogenetic abnormalities. Other genetic abnormalities associated with poor prognosis include TP53 mutations , complex karyotypes , and chromosomal abnormalities like inv(3) and -7 .</li><li>\u2022 t(6;9)</li><li>\u2022 poor prognostic factor</li><li>\u2022 acute myeloid leukemia (AML)</li><li>\u2022 very poor prognosis</li><li>\u2022 TP53 mutations</li><li>\u2022 complex karyotypes</li><li>\u2022 chromosomal abnormalities like inv(3)</li><li>\u2022 -7</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. t(15;17): The t(15;17) translocation, which leads to the formation of the PML-RARA fusion gene, is a hallmark of acute promyelocytic leukemia (APL) . This cytogenetic abnormality is associated with a very good prognosis , with high cure rates (approximately 85% cured) when treated with all-trans retinoic acid (ATRA) and chemotherapy .</li><li>\u2022 Option A. t(15;17):</li><li>\u2022 t(15;17)</li><li>\u2022 PML-RARA</li><li>\u2022 acute promyelocytic leukemia (APL)</li><li>\u2022 very good prognosis</li><li>\u2022 high cure rates</li><li>\u2022 85%</li><li>\u2022 all-trans retinoic acid (ATRA)</li><li>\u2022 chemotherapy</li><li>\u2022 Option B. t(8;21): The t(8;21) translocation is associated with a good prognosis in AML . Patients with this translocation tend to have a better outcome , with about 55% cured with appropriate treatment.</li><li>\u2022 Option B. t(8;21):</li><li>\u2022 t(8;21)</li><li>\u2022 AML</li><li>\u2022 better outcome</li><li>\u2022 55%</li><li>\u2022 Option D. inv (16): The inv (16) translocation is another favorable prognostic factor in AML. It is commonly seen in the core-binding factor AML subtype and is associated with a good prognosis , with around 55% of patients cured.</li><li>\u2022 Option D. inv (16):</li><li>\u2022 inv (16)</li><li>\u2022 core-binding factor AML</li><li>\u2022 good prognosis</li><li>\u2022 55%</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 t(6;9) is a poor prognostic factor in AML , associated with worse survival rates and a more aggressive disease course, whereas other cytogenetic abnormalities like t(15;17) , t(8;21) , and inv(16) generally predict better outcomes.</li><li>\u27a4 t(6;9)</li><li>\u27a4 poor prognostic factor</li><li>\u27a4 AML</li><li>\u27a4 t(15;17)</li><li>\u27a4 t(8;21)</li><li>\u27a4 inv(16)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "65c03331",
      "audio": ""
    },
    {
      "text": "A 60-year-old male presents with splenomegaly and recurrent infections. Laboratory tests reveal the presence of lymphoplasmacytic lymphoma and splenic marginal zone lymphoma. Which of the following viruses is most commonly associated with the development of these lymphomas?",
      "options": [
        {
          "label": "A",
          "text": "Hepatitis A virus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hepatitis B virus",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hepatitis C virus",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hepatitis E virus",
          "correct": false
        }
      ],
      "correct_answer": "C. Hepatitis C virus",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Hepatitis C virus</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Chronic hepatitis C virus (HCV) infection has been strongly associated with the development of both lymphoplasmacytic lymphoma and splenic marginal zone lymphoma (MZL). The chronic immune activation caused by HCV infection is believed to contribute to the pathogenesis of these B-cell lymphomas . The association between HCV and these lymphomas highlights the importance of early detection and management of HCV in patients at risk for lymphoproliferative disorders .</li><li>\u2022 Chronic hepatitis C virus (HCV)</li><li>\u2022 lymphoplasmacytic lymphoma</li><li>\u2022 splenic marginal zone lymphoma</li><li>\u2022 B-cell lymphomas</li><li>\u2022 lymphoproliferative disorders</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Hepatitis A virus: Hepatitis A virus (HAV) is an acute viral infection and is not typically associated with lymphoplasmacytic lymphoma or splenic marginal zone lymphoma . HAV does not have a known association with chronic immune stimulation leading to B-cell lymphomas.</li><li>\u2022 Option A. Hepatitis A virus: Hepatitis A virus (HAV)</li><li>\u2022 lymphoplasmacytic lymphoma</li><li>\u2022 splenic marginal zone lymphoma</li><li>\u2022 Option B. Hepatitis B virus: While hepatitis B virus (HBV) can lead to liver cirrhosis and increase the risk of hepatocellular carcinoma , it is not primarily associated with lymphoplasmacytic lymphoma or splenic marginal zone lymphoma . However, HBV may increase the risk of non-Hodgkin lymphoma more generally, but this is less specific than the association with HCV .</li><li>\u2022 Option B. Hepatitis B virus:</li><li>\u2022 hepatitis B virus (HBV)</li><li>\u2022 hepatocellular carcinoma</li><li>\u2022 not primarily associated</li><li>\u2022 lymphoplasmacytic lymphoma</li><li>\u2022 splenic marginal zone lymphoma</li><li>\u2022 HBV</li><li>\u2022 non-Hodgkin lymphoma</li><li>\u2022 HCV</li><li>\u2022 Option D. Hepatitis E virus: Hepatitis E virus (HEV) is generally associated with acute hepatitis , particularly in pregnant women, and does not have a known association with the development of lymphoplasmacytic lymphoma or splenic marginal zone lymphoma .</li><li>\u2022 Option D. Hepatitis E virus: Hepatitis E virus (HEV)</li><li>\u2022 acute hepatitis</li><li>\u2022 lymphoplasmacytic lymphoma</li><li>\u2022 splenic marginal zone lymphoma</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Chronic hepatitis C virus infection is associated with an increased risk of lymphoplasmacytic lymphoma and splenic marginal zone lymphoma , making HCV a critical factor in the pathogenesis of these B-cell lymphomas .</li><li>\u27a4 Chronic hepatitis C virus infection</li><li>\u27a4 lymphoplasmacytic lymphoma</li><li>\u27a4 splenic marginal zone lymphoma</li><li>\u27a4 B-cell lymphomas</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "83aa4a39",
      "audio": ""
    },
    {
      "text": "A 25-year-old male presents with painless lymphadenopathy. Biopsy is done and is shown. Which of the following markers is not typically expressed by these cells?",
      "options": [
        {
          "label": "A",
          "text": "BCL2",
          "correct": false
        },
        {
          "label": "B",
          "text": "CD20",
          "correct": false
        },
        {
          "label": "C",
          "text": "CD30",
          "correct": true
        },
        {
          "label": "D",
          "text": "CD45",
          "correct": false
        }
      ],
      "correct_answer": "C. CD30",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20155138.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) CD30</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The biopsy findings show popcorn-like Reed-Sternberg cells characteristic of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) . Unlike classical Hodgkin lymphoma (CHL), NLPHL expresses CD20 and CD45 , markers of B cells, and is negative for CD30 and CD15 . Additionally, BCL2 may be variably expressed in the reactive lymphocytes or tumor cells.</li><li>\u2022 popcorn-like Reed-Sternberg cells</li><li>\u2022 Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)</li><li>\u2022 CD20</li><li>\u2022 CD45</li><li>\u2022 CD30</li><li>\u2022 CD15</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. BCL2: This marker may be variably expressed, especially in the reactive lymphocytes surrounding the tumor cells, and is not a distinguishing feature.</li><li>\u2022 Option A.</li><li>\u2022 BCL2:</li><li>\u2022 Option B. CD20: CD20 is a key B-cell marker, strongly expressed by tumor cells in NLPHL.</li><li>\u2022 Option B.</li><li>\u2022 CD20:</li><li>\u2022 Option D. CD45: CD45 is a pan-leukocyte marker, typically expressed in NLPHL but absent in classical Hodgkin lymphoma.</li><li>\u2022 Option D.</li><li>\u2022 CD45:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Nodular Lymphocyte-Predominant Hodgkin Lymphoma is distinguished from classical Hodgkin lymphoma by its expression of CD20 and CD45 and lack of CD30 and CD15 , reflecting its B-cell lineage.</li><li>\u27a4 CD20 and CD45</li><li>\u27a4 CD30 and CD15</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3f157732",
      "audio": ""
    },
    {
      "text": "A 65-year-old male presents with hyperviscosity syndrome, anemia, and elevated IgM levels. Genetic testing reveals a MYD88 L265P mutation. In which of the following conditions is this mutation commonly found?",
      "options": [
        {
          "label": "A",
          "text": "Marginal zone lymphomas",
          "correct": false
        },
        {
          "label": "B",
          "text": "Multiple myeloma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Waldenstr\u00f6m\u2019s macroglobulinemia",
          "correct": true
        },
        {
          "label": "D",
          "text": "IgM-secreting myeloma",
          "correct": false
        }
      ],
      "correct_answer": "C. Waldenstr\u00f6m\u2019s macroglobulinemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Waldenstr\u00f6m\u2019s macroglobulinemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The MYD88 L265P mutation is a somatic mutation found in over 90% of patients with Waldenstr\u00f6m\u2019s macroglobulinemia (WM) , as well as the majority of IgM monoclonal gammopathy of undetermined significance (MGUS) . This mutation is considered a hallmark of WM and plays a significant role in distinguishing it from other IgM-secreting disorders . The presence of this mutation is useful in confirming the diagnosis of WM and helps differentiate it from conditions like marginal zone lymphoma (MZL) and IgM-secreting myeloma , which have overlapping clinical features.</li><li>\u2022 MYD88 L265P mutation</li><li>\u2022 somatic mutation</li><li>\u2022 over 90% of patients with Waldenstr\u00f6m\u2019s macroglobulinemia (WM)</li><li>\u2022 IgM monoclonal gammopathy of undetermined significance (MGUS)</li><li>\u2022 WM</li><li>\u2022 IgM-secreting disorders</li><li>\u2022 WM</li><li>\u2022 marginal zone lymphoma</li><li>\u2022 IgM-secreting myeloma</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Marginal zone lymphomas: MYD88 L265P is not a characteristic mutation for marginal zone lymphomas (MZLs) , though it can be found in a subset of these lymphomas. MYD88 mutations are more specific to Waldenstr\u00f6m\u2019s macroglobulinemia and IgM MGUS .</li><li>\u2022 Option A. Marginal zone lymphomas: MYD88 L265P</li><li>\u2022 marginal zone lymphomas (MZLs)</li><li>\u2022 MYD88 mutations</li><li>\u2022 Waldenstr\u00f6m\u2019s macroglobulinemia</li><li>\u2022 IgM MGUS</li><li>\u2022 Option B. Multiple myeloma: Multiple myeloma is not associated with MYD88 L265P mutations . It is more commonly associated with mutations affecting other genes, such as KRAS , TP53 , and IGH .</li><li>\u2022 Option B. Multiple myeloma: Multiple myeloma</li><li>\u2022 MYD88 L265P mutations</li><li>\u2022 KRAS</li><li>\u2022 TP53</li><li>\u2022 IGH</li><li>\u2022 Option D. IgM-secreting myeloma: While IgM-secreting myeloma may show overlap with Waldenstr\u00f6m\u2019s macroglobulinemia , MYD88 L265P mutations are not a prominent feature in IgM-secreting myeloma . This mutation is more characteristic of WM and IgM MGUS .</li><li>\u2022 Option D. IgM-secreting myeloma:</li><li>\u2022 IgM-secreting myeloma</li><li>\u2022 Waldenstr\u00f6m\u2019s macroglobulinemia</li><li>\u2022 MYD88 L265P mutations</li><li>\u2022 IgM-secreting myeloma</li><li>\u2022 WM</li><li>\u2022 IgM MGUS</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The MYD88 L265P mutation is found in >90% of patients with Waldenstr\u00f6m\u2019s macroglobulinemia (WM) and is an important diagnostic marker to differentiate WM from other IgM-producing disorders , such as marginal zone lymphomas and IgM-secreting myeloma .</li><li>\u27a4 MYD88 L265P mutation</li><li>\u27a4 >90% of patients with Waldenstr\u00f6m\u2019s macroglobulinemia (WM)</li><li>\u27a4 IgM-producing disorders</li><li>\u27a4 marginal zone lymphomas</li><li>\u27a4 IgM-secreting myeloma</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8303cac9",
      "audio": ""
    },
    {
      "text": "A 40-year-old male presents with jaundice, fatigue, and a history of chronic alcohol consumption. Which of the following is not a feature of alcoholic hepatitis?",
      "options": [
        {
          "label": "A",
          "text": "AST and ALT elevations often exceed 400 IU/L",
          "correct": true
        },
        {
          "label": "B",
          "text": "AST/ALT ratio of >2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Serum bilirubin >3 mg/dL",
          "correct": false
        },
        {
          "label": "D",
          "text": "Steatosis and inflammation in liver biopsy",
          "correct": false
        }
      ],
      "correct_answer": "A. AST and ALT elevations often exceed 400 IU/L",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) AST and ALT elevations often exceed 400 IU/L</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Alcoholic hepatitis typically presents with modest elevations in AST and ALT levels , generally not exceeding 300 IU/L . An AST/ALT ratio of >2 is a classic feature due to pyridoxine deficiency associated with chronic alcohol use. Severe cases often show elevated bilirubin levels (>3 mg/dL) , and liver biopsy confirms the presence of steatosis and inflammation , hallmark features of alcoholic hepatitis.</li><li>\u2022 modest elevations in AST and ALT levels</li><li>\u2022 300 IU/L</li><li>\u2022 AST/ALT ratio of >2</li><li>\u2022 elevated bilirubin levels (>3 mg/dL)</li><li>\u2022 steatosis and inflammation</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. AST/ALT ratio of >2: This is a diagnostic feature of alcoholic hepatitis.</li><li>\u2022 Option B.</li><li>\u2022 AST/ALT ratio of >2:</li><li>\u2022 Option C. Serum bilirubin >3 mg/dL: This indicates significant liver dysfunction in alcoholic hepatitis.</li><li>\u2022 Option C.</li><li>\u2022 Serum bilirubin >3 mg/dL:</li><li>\u2022 Option D. Steatosis and inflammation in liver biopsy: These are histological findings consistent with alcoholic hepatitis.</li><li>\u2022 Option D.</li><li>\u2022 Steatosis and inflammation in liver biopsy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Alcoholic hepatitis is characterized by modest elevations in AST and ALT levels , with an AST/ALT ratio >2 , hyperbilirubinemia, and characteristic histological findings such as steatosis and inflammation . AST and ALT levels exceeding 400 IU/L are more typical of other liver conditions, such as acute viral or ischemic hepatitis.</li><li>\u27a4 modest elevations in AST and ALT levels</li><li>\u27a4 AST/ALT ratio >2</li><li>\u27a4 steatosis and inflammation</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "73059811",
      "audio": ""
    },
    {
      "text": "A 30-year-old female presents to the emergency department after accidentally ingesting a drug. She is evaluated for liver toxicity. The Rumack-Matthew nomogram is used to assess the risk of hepatotoxicity. Which of the following is the nomogram specifically used for?",
      "options": [
        {
          "label": "A",
          "text": "Isoniazid",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amiodarone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Acetaminophen",
          "correct": true
        },
        {
          "label": "D",
          "text": "Alcoholic liver injury",
          "correct": false
        }
      ],
      "correct_answer": "C. Acetaminophen",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20155244.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Acetaminophen</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The Rumack-Matthew nomogram is used to assess the toxicity risk of acetaminophen overdose . It helps determine whether N-acetylcysteine (NAC) , the antidote, should be administered based on the time of ingestion and the serum acetaminophen level . The nomogram helps predict the likelihood of liver injury and can guide treatment decisions in patients with acetaminophen toxicity .</li><li>\u2022 Rumack-Matthew nomogram</li><li>\u2022 toxicity risk</li><li>\u2022 acetaminophen overdose</li><li>\u2022 N-acetylcysteine (NAC)</li><li>\u2022 time of ingestion</li><li>\u2022 serum acetaminophen level</li><li>\u2022 liver injury</li><li>\u2022 acetaminophen toxicity</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Isoniazid: While isoniazid overdose can cause liver toxicity , the Rumack-Matthew nomogram is specific to acetaminophen toxicity, not isoniazid. Isoniazid toxicity management involves other clinical measures and does not rely on this nomogram.</li><li>\u2022 Option A. Isoniazid:</li><li>\u2022 isoniazid</li><li>\u2022 liver toxicity</li><li>\u2022 Rumack-Matthew nomogram</li><li>\u2022 acetaminophen</li><li>\u2022 Option B. Amiodarone: Amiodarone toxicity, including liver injury , is a recognized concern but is not associated with the use of the Rumack-Matthew nomogram . This nomogram is not used in cases of amiodarone overdose .</li><li>\u2022 Option B. Amiodarone: Amiodarone</li><li>\u2022 liver injury</li><li>\u2022 Rumack-Matthew nomogram</li><li>\u2022 amiodarone overdose</li><li>\u2022 Option D. Alcoholic liver injury: Alcoholic liver injury results from chronic or acute alcohol consumption but is not related to the Rumack-Matthew nomogram , which is specific to acetaminophen toxicity.</li><li>\u2022 Option D. Alcoholic liver injury: Alcoholic liver injury</li><li>\u2022 Rumack-Matthew nomogram</li><li>\u2022 acetaminophen</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Rumack-Matthew nomogram is used to assess acetaminophen toxicity , guiding treatment decisions, particularly the use of N-acetylcysteine (NAC) for overdose management.</li><li>\u27a4 Rumack-Matthew nomogram</li><li>\u27a4 acetaminophen toxicity</li><li>\u27a4 N-acetylcysteine (NAC)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "57be276c",
      "audio": ""
    },
    {
      "text": "A 60-year-old male with cirrhosis presents with worsening fatigue, abdominal distension, and jaundice. His clinical and laboratory findings are as follows: Total bilirubin: 3.5 mg/dL Serum albumin: 2.5 g/dL INR: 1.8 Ascites: Controlled with diuretics Encephalopathy: Grade 1 Using the Child-Pugh scoring system, which of the following classifications does his score fall under?",
      "options": [
        {
          "label": "A",
          "text": "Child-Pugh class A",
          "correct": false
        },
        {
          "label": "B",
          "text": "Child-Pugh class B",
          "correct": true
        },
        {
          "label": "C",
          "text": "Child-Pugh class C",
          "correct": false
        },
        {
          "label": "D",
          "text": "Child-Pugh class D",
          "correct": false
        }
      ],
      "correct_answer": "B. Child-Pugh class B",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Child-Pugh class B</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The Child-Pugh score is calculated using five parameters: bilirubin, albumin, INR, ascites, and encephalopathy . Each parameter is scored from 1 to 3 points based on severity.</li><li>\u2022 bilirubin, albumin, INR, ascites, and encephalopathy</li><li>\u2022 For this patient:</li><li>\u2022 Bilirubin of 3.5 mg/dL: 3 points Albumin of 2.5 g/dL: 2 points INR of 1.8: 2 points Ascites (controlled with diuretics): 2 points Encephalopathy (Grade 1): 1 point</li><li>\u2022 Bilirubin of 3.5 mg/dL: 3 points</li><li>\u2022 3 points</li><li>\u2022 Albumin of 2.5 g/dL: 2 points</li><li>\u2022 2 points</li><li>\u2022 INR of 1.8: 2 points</li><li>\u2022 2 points</li><li>\u2022 Ascites (controlled with diuretics): 2 points</li><li>\u2022 2 points</li><li>\u2022 Encephalopathy (Grade 1): 1 point</li><li>\u2022 1 point</li><li>\u2022 Total score = 3 + 2 + 2 + 2 + 1 = 8 points</li><li>\u2022 8 points</li><li>\u2022 A score of 7\u20139 corresponds to Child-Pugh class B .</li><li>\u2022 7\u20139</li><li>\u2022 Child-Pugh class B</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Child-Pugh class A is for scores of 5\u20136 .</li><li>\u2022 Option A.</li><li>\u2022 Child-Pugh class A</li><li>\u2022 5\u20136</li><li>\u2022 Option C. Child-Pugh class C is for scores of 10\u201315 .</li><li>\u2022 Option C.</li><li>\u2022 Child-Pugh class C</li><li>\u2022 10\u201315</li><li>\u2022 Option D. Child-Pugh class D does not exist in the Child-Pugh classification system.</li><li>\u2022 Option D.</li><li>\u2022 Child-Pugh class D</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Child-Pugh score assesses liver function in cirrhotic patients and stratifies them into Class A, B, or C based on a total score from five clinical and laboratory parameters.</li><li>\u27a4 Child-Pugh score</li><li>\u27a4 Class A, B, or C</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f540a370",
      "audio": ""
    },
    {
      "text": "A 45-year-old male post-renal transplant is being treated with tacrolimus for immunosuppression. Which of the following statements is incorrect about tacrolimus?",
      "options": [
        {
          "label": "A",
          "text": "Tacrolimus is more potent than Cyclosporine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Neurotoxicity is more severe in Tacrolimus-treated patients",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tacrolimus frequently causes gingival hyperplasia",
          "correct": true
        },
        {
          "label": "D",
          "text": "Tacrolimus does not cause Hirsutism",
          "correct": false
        }
      ],
      "correct_answer": "C. Tacrolimus frequently causes gingival hyperplasia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Tacrolimus frequently causes gingival hyperplasia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Tacrolimus is a more potent immunosuppressive agent than cyclosporine , but it is associated with greater toxicity . One of the key differences between the two is that gingival hyperplasia is not a common side effect of tacrolimus . Gingival hyperplasia is more commonly seen with cyclosporine use. In contrast, tacrolimus can cause other adverse effects like neurotoxicity , nephrotoxicity , and diabetes mellitus , but gingival hyperplasia is not typically one of them.</li><li>\u2022 Tacrolimus</li><li>\u2022 cyclosporine</li><li>\u2022 greater toxicity</li><li>\u2022 gingival hyperplasia</li><li>\u2022 tacrolimus</li><li>\u2022 cyclosporine</li><li>\u2022 tacrolimus</li><li>\u2022 neurotoxicity</li><li>\u2022 nephrotoxicity</li><li>\u2022 diabetes mellitus</li><li>\u2022 gingival hyperplasia</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Tacrolimus is more potent than Cyclosporine: This is true. Tacrolimus is generally more potent than cyclosporine in terms of immunosuppressive effects, which allows for lower doses to be used.</li><li>\u2022 Option A. Tacrolimus is more potent than Cyclosporine:</li><li>\u2022 Tacrolimus</li><li>\u2022 cyclosporine</li><li>\u2022 Option B. Neurotoxicity is more severe in Tacrolimus-treated patients: This is true. Neurotoxicity (including symptoms like tremors , seizures , and psychosis ) is more pronounced in tacrolimus treatment, making it one of the more severe side effects associated with this drug.</li><li>\u2022 Option B. Neurotoxicity is more severe in Tacrolimus-treated patients:</li><li>\u2022 Neurotoxicity</li><li>\u2022 tremors</li><li>\u2022 seizures</li><li>\u2022 psychosis</li><li>\u2022 tacrolimus</li><li>\u2022 more severe side effects</li><li>\u2022 Option D. Tacrolimus does not cause Hirsutism: This is true. Hirsutism , or excessive hair growth, is a known side effect of cyclosporine , but it is not commonly associated with tacrolimus use.</li><li>\u2022 Option D. Tacrolimus does not cause Hirsutism:</li><li>\u2022 Hirsutism</li><li>\u2022 cyclosporine</li><li>\u2022 tacrolimus</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tacrolimus is more potent than cyclosporine and associated with greater neurotoxicity. However, it does not commonly cause gingival hyperplasia or hirsutism , which are more frequently seen with cyclosporine .</li><li>\u27a4 Tacrolimus</li><li>\u27a4 cyclosporine</li><li>\u27a4 gingival hyperplasia</li><li>\u27a4 hirsutism</li><li>\u27a4 cyclosporine</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6e7af33d",
      "audio": ""
    },
    {
      "text": "A 60-year-old male with cirrhosis presents with ascites that is not responding to initial diuretic therapy. After confirming compliance with low-sodium diet and medications, the physician considers escalating the diuretic dose. What is the maximum daily dose of spironolactone and furosemide that can be safely used in the management?",
      "options": [
        {
          "label": "A",
          "text": "Spironolactone 200 mg/d, furosemide 40 mg/d",
          "correct": false
        },
        {
          "label": "B",
          "text": "Spironolactone 300 mg/d, furosemide 80 mg/d",
          "correct": false
        },
        {
          "label": "C",
          "text": "Spironolactone 400 mg/d, furosemide 160 mg/d",
          "correct": true
        },
        {
          "label": "D",
          "text": "Spironolactone 500 mg/d, furosemide 200 mg/d",
          "correct": false
        }
      ],
      "correct_answer": "C. Spironolactone 400 mg/d, furosemide 160 mg/d",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Spironolactone 400 mg/d, furosemide 160 mg/d</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The maximum dose of diuretics for ascites in cirrhosis is spironolactone 400 mg/day and furosemide 160 mg/day . This combination is used to manage refractory ascites if compliance with a low-sodium diet is confirmed and if ascitic fluid is not being mobilized adequately. If ascites persists despite these maximum doses, it is considered refractory ascites , and alternative treatments, such as large volume paracentesis (LVP) or transjugular intrahepatic portosystemic shunt (TIPS) , should be considered.</li><li>\u2022 ascites</li><li>\u2022 cirrhosis</li><li>\u2022 spironolactone 400 mg/day</li><li>\u2022 furosemide 160 mg/day</li><li>\u2022 refractory ascites</li><li>\u2022 low-sodium diet</li><li>\u2022 refractory ascites</li><li>\u2022 large volume paracentesis (LVP)</li><li>\u2022 transjugular intrahepatic portosystemic shunt (TIPS)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Spironolactone 200 mg/d, furosemide 40 mg/d: These doses are lower than the maximum recommended doses . While they may be used for initial management, they are not sufficient for managing refractory ascites.</li><li>\u2022 Option A. Spironolactone 200 mg/d, furosemide 40 mg/d:</li><li>\u2022 maximum recommended doses</li><li>\u2022 Option B. Spironolactone 300 mg/d, furosemide 80 mg/d: These doses are still below the maximum daily doses and would not be considered appropriate for cases of refractory ascites , where higher doses are necessary for optimal fluid mobilization.</li><li>\u2022 Option B. Spironolactone 300 mg/d, furosemide 80 mg/d:</li><li>\u2022 maximum daily doses</li><li>\u2022 refractory ascites</li><li>\u2022 Option D. Spironolactone 500 mg/d, furosemide 200 mg/d: These doses exceed the recommended maximum doses . While doses above the recommended maximum may occasionally be used in very specific clinical settings, they increase the risk of adverse effects such as electrolyte imbalances , kidney dysfunction , and hepatorenal syndrome .</li><li>\u2022 Option D. Spironolactone 500 mg/d, furosemide 200 mg/d:</li><li>\u2022 recommended maximum doses</li><li>\u2022 electrolyte imbalances</li><li>\u2022 kidney dysfunction</li><li>\u2022 hepatorenal syndrome</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The maximum recommended doses for diuretics in the management of ascites are spironolactone 400 mg/day and furosemide 160 mg/day . If ascites remains refractory despite these doses, alternative treatments should be considered.</li><li>\u27a4 maximum recommended doses</li><li>\u27a4 ascites</li><li>\u27a4 spironolactone 400 mg/day</li><li>\u27a4 furosemide 160 mg/day</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0f5a8279",
      "audio": ""
    },
    {
      "text": "A 50-year-old asymptomatic individual undergoes colorectal cancer screening. Which of the following is the recommended screening interval for the multitargeted stool DNA test?",
      "options": [
        {
          "label": "A",
          "text": "Annually",
          "correct": false
        },
        {
          "label": "B",
          "text": "Every 3 years",
          "correct": true
        },
        {
          "label": "C",
          "text": "Every 5 years",
          "correct": false
        },
        {
          "label": "D",
          "text": "Every 10 years",
          "correct": false
        }
      ],
      "correct_answer": "B. Every 3 years",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Every 3 years</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 For asymptomatic individuals \u226545 years old, the multitargeted stool DNA test (which detects genetic changes and blood in the stool) is recommended to be performed every 3 years as part of colorectal cancer screening . This test is used as an alternative to other screening methods and is considered highly effective for early detection of colorectal cancer or advanced precancerous polyps.</li><li>\u2022 asymptomatic individuals \u226545 years</li><li>\u2022 multitargeted stool DNA test</li><li>\u2022 every 3 years</li><li>\u2022 colorectal cancer screening</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Annually: The multitargeted stool DNA test is not recommended to be performed annually . Screening intervals are set at every 3 years , not annually, for this test.</li><li>\u2022 Option A. Annually:</li><li>\u2022 multitargeted stool DNA test</li><li>\u2022 annually</li><li>\u2022 every 3 years</li><li>\u2022 Option C. Every 5 years: The screening interval for the multitargeted stool DNA test is every 3 years , not every 5 years.</li><li>\u2022 Option C. Every 5 years:</li><li>\u2022 multitargeted stool DNA test</li><li>\u2022 every 3 years</li><li>\u2022 Option D. Every 10 years: The multitargeted stool DNA test has a shorter interval of every 3 years . A colonoscopy , however, is recommended every 10 years for colorectal cancer screening.</li><li>\u2022 Option D. Every 10 years:</li><li>\u2022 multitargeted stool DNA test</li><li>\u2022 shorter interval</li><li>\u2022 every 3 years</li><li>\u2022 colonoscopy</li><li>\u2022 10 years</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 For asymptomatic individuals \u226545 years old , the multitargeted stool DNA test is done every 3 years as part of routine colorectal cancer screening .</li><li>\u27a4 asymptomatic individuals \u226545 years old</li><li>\u27a4 multitargeted stool DNA test</li><li>\u27a4 3 years</li><li>\u27a4 colorectal cancer screening</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b912a014",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents with dysphagia and diagnosed with Plummer Vinson Syndrome. What is the feature of the disorder?",
      "options": [
        {
          "label": "A",
          "text": "Proximal esophageal webs and iron-deficiency anemia",
          "correct": true
        },
        {
          "label": "B",
          "text": "Proximal esophageal webs and B12 deficiency anemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Distal esophageal webs and iron-deficiency anemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Distal esophageal webs and B12 deficiency anemia",
          "correct": false
        }
      ],
      "correct_answer": "A. Proximal esophageal webs and iron-deficiency anemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Proximal esophageal webs and iron-deficiency anemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The combination of proximal esophageal webs , dysphagia and iron-deficiency anemia is characteristic of Plummer-Vinson syndrome , also known as Paterson-Kelly Brown syndrome . This condition typically affects middle-aged women and presents with dysphagia due to the presence of esophageal webs, along with iron-deficiency anemia . This syndrome is associated with an increased risk of esophageal cancer , especially in the setting of chronic untreated iron deficiency.</li><li>\u2022 proximal esophageal webs</li><li>\u2022 dysphagia</li><li>\u2022 iron-deficiency anemia</li><li>\u2022 Plummer-Vinson syndrome</li><li>\u2022 Paterson-Kelly Brown syndrome</li><li>\u2022 middle-aged women</li><li>\u2022 dysphagia</li><li>\u2022 iron-deficiency anemia</li><li>\u2022 esophageal cancer</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Proximal esophageal webs and B12 deficiency anemia: While B12 deficiency anemia can cause symptoms such as fatigue and neurological deficits, it is not typically associated with proximal esophageal webs . This combination is not seen in Paterson-Kelly syndrome .</li><li>\u2022 Option B. Proximal esophageal webs and B12 deficiency anemia:</li><li>\u2022 B12 deficiency anemia</li><li>\u2022 proximal esophageal webs</li><li>\u2022 Paterson-Kelly syndrome</li><li>\u2022 Option C. Distal esophageal webs and iron-deficiency anemia: Distal esophageal webs are more commonly seen in ** Schatzki rings**, which are associated with gastroesophageal reflux disease (GERD) and not iron-deficiency anemia . The esophageal webs in Paterson-Kelly syndrome are typically proximal , not distal.</li><li>\u2022 Option C. Distal esophageal webs and iron-deficiency anemia: Distal esophageal webs</li><li>\u2022 gastroesophageal reflux disease (GERD)</li><li>\u2022 not iron-deficiency anemia</li><li>\u2022 Paterson-Kelly syndrome</li><li>\u2022 proximal</li><li>\u2022 Option D. Distal esophageal webs and B12 deficiency anemia: This combination is not typically associated with any specific syndrome and is not seen in Paterson-Kelly syndrome . B12 deficiency is more commonly associated with pernicious anemia or other conditions related to malabsorption .</li><li>\u2022 Option D. Distal esophageal webs and B12 deficiency anemia:</li><li>\u2022 Paterson-Kelly syndrome</li><li>\u2022 B12 deficiency</li><li>\u2022 pernicious anemia</li><li>\u2022 malabsorption</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Paterson-Kelly syndrome (Plummer-Vinson syndrome) is defined by the presence of proximal esophageal webs and iron-deficiency anemia , often in middle-aged women, and it increases the risk of esophageal cancer .</li><li>\u27a4 Paterson-Kelly syndrome (Plummer-Vinson syndrome)</li><li>\u27a4 proximal esophageal webs</li><li>\u27a4 iron-deficiency anemia</li><li>\u27a4 esophageal cancer</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "292e40a0",
      "audio": ""
    },
    {
      "text": "A 60-year-old male presents with unintentional weight loss and is concerned about his health. After a detailed assessment, he reveals a loss of 5% of his body weight over the past 8 months. How is this weight loss classified?",
      "options": [
        {
          "label": "A",
          "text": ">2% of one\u2019s body weight over a period of 6\u201312 months",
          "correct": false
        },
        {
          "label": "B",
          "text": ">3% of one\u2019s body weight over a period of 6\u201312 months",
          "correct": false
        },
        {
          "label": "C",
          "text": ">5% of one\u2019s body weight over a period of 6\u201312 months",
          "correct": true
        },
        {
          "label": "D",
          "text": ">10% of one\u2019s body weight over a period of 6\u201312 months",
          "correct": false
        }
      ],
      "correct_answer": "C. >5% of one\u2019s body weight over a period of 6\u201312 months",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) >5% of one\u2019s body weight over a period of 6\u201312 months</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Clinically important weight loss is typically defined as a loss of >5% of one\u2019s body weight over a period of 6\u201312 months . This level of weight loss is often considered significant and warrants further investigation to rule out underlying medical conditions, such as malignancies , endocrine disorders , or gastrointestinal diseases .</li><li>\u2022 loss of >5%</li><li>\u2022 body weight over a period of 6\u201312 months</li><li>\u2022 significant</li><li>\u2022 malignancies</li><li>\u2022 endocrine disorders</li><li>\u2022 gastrointestinal diseases</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. >2% of one\u2019s body weight over a period of 6\u201312 months: A 2% weight loss does not typically reach the threshold for clinically significant weight loss. It would be considered mild and usually not a cause for concern unless accompanied by other symptoms.</li><li>\u2022 Option A. >2% of one\u2019s body weight over a period of 6\u201312 months:</li><li>\u2022 2% weight loss</li><li>\u2022 mild</li><li>\u2022 Option B. >3% of one\u2019s body weight over a period of 6\u201312 months: While 3% weight loss can be noteworthy, it does not meet the commonly accepted definition for clinically significant weight loss, which is generally considered to be >5% .</li><li>\u2022 Option B. >3% of one\u2019s body weight over a period of 6\u201312 months:</li><li>\u2022 3% weight loss</li><li>\u2022 >5%</li><li>\u2022 Option D. >10% of one\u2019s body weight over a period of 6\u201312 months: A 10% weight loss is more extreme and may indicate severe malnutrition or a serious medical condition. Although important, the general clinical threshold for significant weight loss is >5% over 6\u201312 months , and >10% would be classified as severe, but not the general definition for clinical importance.</li><li>\u2022 Option D. >10% of one\u2019s body weight over a period of 6\u201312 months:</li><li>\u2022 10% weight loss</li><li>\u2022 malnutrition</li><li>\u2022 >5%</li><li>\u2022 6\u201312 months</li><li>\u2022 >10%</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Clinically significant weight loss is typically defined as a loss of >5% of one\u2019s body weight over a 6\u201312-month period , which requires further clinical evaluation to identify any underlying causes.</li><li>\u27a4 Clinically significant weight loss</li><li>\u27a4 loss of >5% of one\u2019s body weight</li><li>\u27a4 6\u201312-month period</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b73ed46a",
      "audio": ""
    },
    {
      "text": "A 50-year-old male presents with ascites. His serum albumin is 3.5 g/dL, and his ascitic fluid albumin is 1.8 g/dL. Based on these findings, which of the following is the most likely cause of his ascites?",
      "options": [
        {
          "label": "A",
          "text": "Peritoneal carcinomatosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Nephrotic syndrome",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cirrhosis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Tuberculosis",
          "correct": false
        }
      ],
      "correct_answer": "C. Cirrhosis",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-02-18%20162012.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Cirrhosis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The serum ascites albumin gradient (SAAG) is calculated by subtracting the ascitic fluid albumin from the serum albumin . The gradient is used to determine whether the ascites is due to portal hypertension or other causes.</li><li>\u2022 serum ascites albumin gradient (SAAG)</li><li>\u2022 ascitic fluid albumin</li><li>\u2022 serum albumin</li><li>\u2022 portal hypertension</li><li>\u2022 SAAG = Serum albumin \u2013 Ascitic fluid albumin In this case, SAAG = 3.5 g/dL \u2013 1.8 g/dL = 1.7 g/dL , which is >1.1 g/dL , indicating ascites due to portal hypertension . Cirrhosis is the most common cause of ascites due to portal hypertension , and this pattern is typically seen in cirrhosis-related ascites.</li><li>\u2022 SAAG = Serum albumin \u2013 Ascitic fluid albumin</li><li>\u2022 SAAG = Serum albumin \u2013 Ascitic fluid albumin</li><li>\u2022 In this case, SAAG = 3.5 g/dL \u2013 1.8 g/dL = 1.7 g/dL , which is >1.1 g/dL , indicating ascites due to portal hypertension .</li><li>\u2022 SAAG = 3.5 g/dL \u2013 1.8 g/dL = 1.7 g/dL</li><li>\u2022 >1.1 g/dL</li><li>\u2022 portal hypertension</li><li>\u2022 Cirrhosis is the most common cause of ascites due to portal hypertension , and this pattern is typically seen in cirrhosis-related ascites.</li><li>\u2022 Cirrhosis</li><li>\u2022 portal hypertension</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Peritoneal carcinomatosis: In cases of peritoneal carcinomatosis , the ascitic fluid albumin level is usually higher than in cirrhosis, and the SAAG is typically <1.1 g/dL (indicative of non-portal hypertension-related ascites).</li><li>\u2022 Option A. Peritoneal carcinomatosis:</li><li>\u2022 peritoneal carcinomatosis</li><li>\u2022 higher</li><li>\u2022 SAAG</li><li>\u2022 <1.1 g/dL</li><li>\u2022 Option B. Nephrotic syndrome: In nephrotic syndrome , ascites can occur due to hypoalbuminemia and fluid retention . However, the SAAG in nephrotic syndrome is typically <1.1 g/dL , and ascitic fluid albumin would be low , but not as low as seen in cirrhosis. The protein content of ascitic fluid would generally be low due to loss of protein in urine .</li><li>\u2022 Option B. Nephrotic syndrome:</li><li>\u2022 nephrotic syndrome</li><li>\u2022 hypoalbuminemia</li><li>\u2022 fluid retention</li><li>\u2022 SAAG</li><li>\u2022 <1.1 g/dL</li><li>\u2022 low</li><li>\u2022 protein content</li><li>\u2022 low</li><li>\u2022 loss of protein in urine</li><li>\u2022 Option D. Tuberculosis: Ascites due to tuberculosis generally has a low SAAG (<1.1 g/dL) , and the ascitic fluid albumin level would be lower than in cirrhosis, but it would be associated with other features of TB , such as fever, weight loss , and a positive culture or PCR for Mycobacterium tuberculosis .</li><li>\u2022 Option D. Tuberculosis: Ascites due to tuberculosis</li><li>\u2022 low SAAG (<1.1 g/dL)</li><li>\u2022 lower</li><li>\u2022 other features of TB</li><li>\u2022 fever, weight loss</li><li>\u2022 positive culture</li><li>\u2022 PCR</li><li>\u2022 Mycobacterium tuberculosis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A SAAG >1.1 g/dL , with low ascitic fluid albumin (as in this case), suggests portal hypertension , making cirrhosis the most likely cause of ascites.</li><li>\u27a4 SAAG >1.1 g/dL</li><li>\u27a4 low ascitic fluid albumin</li><li>\u27a4 portal hypertension</li><li>\u27a4 cirrhosis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9ac7c5e2",
      "audio": ""
    },
    {
      "text": "A child is diagnosed with inflammatory bowel disease (IBD). What is the definition of very early onset IBD (VEOIBD)?",
      "options": [
        {
          "label": "A",
          "text": "IBD in patients <2 years old",
          "correct": false
        },
        {
          "label": "B",
          "text": "IBD in patients <4 years old",
          "correct": false
        },
        {
          "label": "C",
          "text": "IBD in patients <6 years old",
          "correct": true
        },
        {
          "label": "D",
          "text": "IBD in patients <10 years old",
          "correct": false
        }
      ],
      "correct_answer": "C. IBD in patients <6 years old",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C)\u00a0 IBD in patients <6 years old</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Very-early-onset IBD (VEOIBD) is defined as IBD in patients <6 years old . This category of IBD typically affects children who have a strong family history of IBD and involves a more severe disease course. It mainly affects the colon and is often resistant to standard medications . In some cases, these patients may develop complications such as growth retardation or intestinal failure .</li><li>\u2022 Very-early-onset IBD (VEOIBD)</li><li>\u2022 IBD in patients <6 years old</li><li>\u2022 strong family history of IBD</li><li>\u2022 colon</li><li>\u2022 resistant to standard medications</li><li>\u2022 growth retardation</li><li>\u2022 intestinal failure</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. IBD in patients <2 years old: IBD in patients <2 years old is classified as infantile IBD , a more severe form that presents in early infancy and also affects the colon . It is even more resistant to standard treatments than VEOIBD.</li><li>\u2022 Option A. IBD in patients <2 years old: IBD in patients <2 years old</li><li>\u2022 infantile IBD</li><li>\u2022 colon</li><li>\u2022 Option B. IBD in patients <4 years old: While this answer seems close, the correct age range for very-early-onset IBD is <6 years old , not <4 years old .</li><li>\u2022 Option B. IBD in patients <4 years old:</li><li>\u2022 very-early-onset IBD</li><li>\u2022 <6 years old</li><li>\u2022 <4 years old</li><li>\u2022 Option D. IBD in patients <10 years old: IBD in patients <10 years old is categorized as early-onset IBD (EOIBD) , which includes patients with IBD before the age of 10 but after 6 years old . This category does not include the very-early-onset cases, which are specifically defined as <6 years old .</li><li>\u2022 Option D. IBD in patients <10 years old: IBD in patients <10 years old</li><li>\u2022 early-onset IBD (EOIBD)</li><li>\u2022 IBD</li><li>\u2022 6 years old</li><li>\u2022 very-early-onset</li><li>\u2022 <6 years old</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Very-early-onset IBD (VEOIBD) is defined as IBD in patients <6 years old and is associated with more severe disease, often affecting the colon and being resistant to standard treatment.</li><li>\u27a4 Very-early-onset IBD (VEOIBD)</li><li>\u27a4 IBD in patients <6 years old</li><li>\u27a4 colon</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9da8b74b",
      "audio": ""
    }
  ]
}